{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [],
   "source": [
    "import numpy as np # linear algebra\n",
    "import pandas as pd # data processing, CSV file I/O (e.g. pd.read_csv)\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "import os\n",
    "color = sns.color_palette()\n",
    "sns.set_style('darkgrid')\n",
    "sns.set_context('notebook')\n",
    "\n",
    "%matplotlib inline\n",
    "\n",
    "pd.options.mode.chained_assignment = None\n",
    "pd.options.display.max_columns = 999"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Start with some data exploration\n",
    "Import the files & start exploring them!"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Train and Test variants shape :  (3321, 4) (5668, 3)\n",
      "Train and Test text shape :  (3321, 2) (5668, 2)\n"
     ]
    }
   ],
   "source": [
    "train_variants_df = pd.read_csv(\"training_variants\")\n",
    "test_variants_df = pd.read_csv(\"test_variants\")\n",
    "train_text_df = pd.read_csv(\"training_text\", sep=\"\\|\\|\", engine='python', header=None, skiprows=1, names=[\"ID\",\"Text\"])\n",
    "test_text_df = pd.read_csv(\"test_text\", sep=\"\\|\\|\", engine='python', header=None, skiprows=1, names=[\"ID\",\"Text\"])\n",
    "\n",
    "print(\"Train and Test variants shape : \",train_variants_df.shape, test_variants_df.shape)\n",
    "print(\"Train and Test text shape : \",train_text_df.shape, test_text_df.shape)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ID</th>\n",
       "      <th>Gene</th>\n",
       "      <th>Variation</th>\n",
       "      <th>Class</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>FAM58A</td>\n",
       "      <td>Truncating Mutations</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>CBL</td>\n",
       "      <td>W802*</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>CBL</td>\n",
       "      <td>Q249E</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>CBL</td>\n",
       "      <td>N454D</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>CBL</td>\n",
       "      <td>L399V</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   ID    Gene             Variation  Class\n",
       "0   0  FAM58A  Truncating Mutations      1\n",
       "1   1     CBL                 W802*      2\n",
       "2   2     CBL                 Q249E      2\n",
       "3   3     CBL                 N454D      3\n",
       "4   4     CBL                 L399V      4"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train_variants_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ID</th>\n",
       "      <th>Text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>Cyclin-dependent kinases (CDKs) regulate a var...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>Abstract Background  Non-small cell lung canc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>Abstract Background  Non-small cell lung canc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>Recent evidence has demonstrated that acquired...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>Oncogenic mutations in the monomeric Casitas B...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   ID                                               Text\n",
       "0   0  Cyclin-dependent kinases (CDKs) regulate a var...\n",
       "1   1   Abstract Background  Non-small cell lung canc...\n",
       "2   2   Abstract Background  Non-small cell lung canc...\n",
       "3   3  Recent evidence has demonstrated that acquired...\n",
       "4   4  Oncogenic mutations in the monomeric Casitas B..."
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train_text_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"Cyclin-dependent kinases (CDKs) regulate a variety of fundamental cellular processes. CDK10 stands out as one of the last orphan CDKs for which no activating cyclin has been identified and no kinase activity revealed. Previous work has shown that CDK10 silencing increases ETS2 (v-ets erythroblastosis virus E26 oncogene homolog 2)-driven activation of the MAPK pathway, which confers tamoxifen resistance to breast cancer cells. The precise mechanisms by which CDK10 modulates ETS2 activity, and more generally the functions of CDK10, remain elusive. Here we demonstrate that CDK10 is a cyclin-dependent kinase by identifying cyclin M as an activating cyclin. Cyclin M, an orphan cyclin, is the product of FAM58A, whose mutations cause STAR syndrome, a human developmental anomaly whose features include toe syndactyly, telecanthus, and anogenital and renal malformations. We show that STAR syndrome-associated cyclin M mutants are unable to interact with CDK10. Cyclin M silencing phenocopies CDK10 silencing in increasing c-Raf and in conferring tamoxifen resistance to breast cancer cells. CDK10/cyclin M phosphorylates ETS2 in vitro, and in cells it positively controls ETS2 degradation by the proteasome. ETS2 protein levels are increased in cells derived from a STAR patient, and this increase is attributable to decreased cyclin M levels. Altogether, our results reveal an additional regulatory mechanism for ETS2, which plays key roles in cancer and development. They also shed light on the molecular mechanisms underlying STAR syndrome.Cyclin-dependent kinases (CDKs) play a pivotal role in the control of a number of fundamental cellular processes (1). The human genome contains 21 genes encoding proteins that can be considered as members of the CDK family owing to their sequence similarity with bona fide CDKs, those known to be activated by cyclins (2). Although discovered almost 20 y ago (3, 4), CDK10 remains one of the two CDKs without an identified cyclin partner. This knowledge gap has largely impeded the exploration of its biological functions. CDK10 can act as a positive cell cycle regulator in some cells (5, 6) or as a tumor suppressor in others (7, 8). CDK10 interacts with the ETS2 (v-ets erythroblastosis virus E26 oncogene homolog 2) transcription factor and inhibits its transcriptional activity through an unknown mechanism (9). CDK10 knockdown derepresses ETS2, which increases the expression of the c-Raf protein kinase, activates the MAPK pathway, and induces resistance of MCF7 cells to tamoxifen (6).Here, we deorphanize CDK10 by identifying cyclin M, the product of FAM58A, as a binding partner. Mutations in this gene that predict absence or truncation of cyclin M are associated with STAR syndrome, whose features include toe syndactyly, telecanthus, and anogenital and renal malformations in heterozygous females (10). However, both the functions of cyclin M and the pathogenesis of STAR syndrome remain unknown. We show that a recombinant CDK10/cyclin M heterodimer is an active protein kinase that phosphorylates ETS2 in vitro. Cyclin M silencing phenocopies CDK10 silencing in increasing c-Raf and phospho-ERK expression levels and in inducing tamoxifen resistance in estrogen receptor (ER)+ breast cancer cells. We show that CDK10/cyclin M positively controls ETS2 degradation by the proteasome, through the phosphorylation of two neighboring serines. Finally, we detect an increased ETS2 expression level in cells derived from a STAR patient, and we demonstrate that it is attributable to the decreased cyclin M expression level observed in these cells.Previous SectionNext SectionResultsA yeast two-hybrid (Y2H) screen unveiled an interaction signal between CDK10 and a mouse protein whose C-terminal half presents a strong sequence homology with the human FAM58A gene product [whose proposed name is cyclin M (11)]. We thus performed Y2H mating assays to determine whether human CDK10 interacts with human cyclin M (Fig. 1 Aâ€“C). The longest CDK10 isoform (P1) expressed as a bait protein produced a strong interaction phenotype with full-length cyclin M (expressed as a prey protein) but no detectable phenotype with cyclin D1, p21 (CIP1), and Cdi1 (KAP), which are known binding partners of other CDKs (Fig. 1B). CDK1 and CDK3 also produced Y2H signals with cyclin M, albeit notably weaker than that observed with CDK10 (Fig. 1B). An interaction phenotype was also observed between full-length cyclin M and CDK10 proteins expressed as bait and prey, respectively (Fig. S1A). We then tested different isoforms of CDK10 and cyclin M originating from alternative gene splicing, and two truncated cyclin M proteins corresponding to the hypothetical products of two mutated FAM58A genes found in STAR syndrome patients (10). None of these shorter isoforms produced interaction phenotypes (Fig. 1 A and C and Fig. S1A).Fig. 1.In a new window Download PPTFig. 1.CDK10 and cyclin M form an interaction complex. (A) Schematic representation of the different protein isoforms analyzed by Y2H assays. Amino acid numbers are indicated. Black boxes indicate internal deletions. The red box indicates a differing amino acid sequence compared with CDK10 P1. (B) Y2H assay between a set of CDK proteins expressed as baits (in fusion to the LexA DNA binding domain) and CDK interacting proteins expressed as preys (in fusion to the B42 transcriptional activator). pEG202 and pJG4-5 are the empty bait and prey plasmids expressing LexA and B42, respectively. lacZ was used as a reporter gene, and blue yeast are indicative of a Y2H interaction phenotype. (C) Y2H assay between the different CDK10 and cyclin M isoforms. The amino-terminal region of ETS2, known to interact with CDK10 (9), was also assayed. (D) Western blot analysis of Myc-CDK10 (wt or kd) and CycM-V5-6His expression levels in transfected HEK293 cells. (E) Western blot analysis of Myc-CDK10 (wt or kd) immunoprecipitates obtained using the anti-Myc antibody. â€œInputsâ€� correspond to 10 Î¼g total lysates obtained from HEK293 cells coexpressing Myc-CDK10 (wt or kd) and CycM-V5-6His. (F) Western blot analysis of immunoprecipitates obtained using the anti-CDK10 antibody or a control goat antibody, from human breast cancer MCF7 cells. â€œInputâ€� corresponds to 30 Î¼g MCF7 total cell lysates. The lower band of the doublet observed on the upper panel comigrates with the exogenously expressed untagged CDK10 and thus corresponds to endogenous CDK10. The upper band of the doublet corresponds to a nonspecific signal, as demonstrated by it insensitivity to either overexpression of CDK10 (as seen on the left lane) or silencing of CDK10 (Fig. S2B). Another experiment with a longer gel migration is shown in Fig. S1D.Next we examined the ability of CDK10 and cyclin M to interact when expressed in human cells (Fig. 1 D and E). We tested wild-type CDK10 (wt) and a kinase dead (kd) mutant bearing a D181A amino acid substitution that abolishes ATP binding (12). We expressed cyclin M-V5-6His and/or Myc-CDK10 (wt or kd) in a human embryonic kidney cell line (HEK293). The expression level of cyclin M-V5-6His was significantly increased upon coexpression with Myc-CDK10 (wt or kd) and, to a lesser extent, that of Myc-CDK10 (wt or kd) was increased upon coexpression with cyclin M-V5-6His (Fig. 1D). We then immunoprecipitated Myc-CDK10 proteins and detected the presence of cyclin M in the CDK10 (wt) and (kd) immunoprecipitates only when these proteins were coexpressed pair-wise (Fig. 1E). We confirmed these observations by detecting the presence of Myc-CDK10 in cyclin M-V5-6His immunoprecipitates (Fig. S1B). These experiments confirmed the lack of robust interaction between the CDK10.P2 isoform and cyclin M (Fig. S1C). To detect the interaction between endogenous proteins, we performed immunoprecipitations on nontransfected MCF7 cells derived from a human breast cancer. CDK10 and cyclin M antibodies detected their cognate endogenous proteins by Western blotting. We readily detected cyclin M in immunoprecipitates obtained with the CDK10 antibody but not with a control antibody (Fig. 1F). These results confirm the physical interaction between CDK10 and cyclin M in human cells.To unveil a hypothesized CDK10/cyclin M protein kinase activity, we produced GST-CDK10 and StrepII-cyclin M fusion proteins in insect cells, either individually or in combination. We observed that GST-CDK10 and StrepII-cyclin M copurified, thus confirming their interaction in yet another cellular model (Fig. 2A). We then performed in vitro kinase assays with purified proteins, using histone H1 as a generic substrate. Histone H1 phosphorylation was detected only from lysates of cells coexpressing GST-CDK10 and StrepII-cyclin M. No phosphorylation was detected when GST-CDK10 or StrepII-cyclin M were expressed alone, or when StrepII-cyclin M was coexpressed with GST-CDK10(kd) (Fig. 2A). Next we investigated whether ETS2, which is known to interact with CDK10 (9) (Fig. 1C), is a phosphorylation substrate of CDK10/cyclin M. We detected strong phosphorylation of ETS2 by the GST-CDK10/StrepII-cyclin M purified heterodimer, whereas no phosphorylation was detected using GST-CDK10 alone or GST-CDK10(kd)/StrepII-cyclin M heterodimer (Fig. 2B).Fig. 2.In a new window Download PPTFig. 2.CDK10 is a cyclin M-dependent protein kinase. (A) In vitro protein kinase assay on histone H1. Lysates from insect cells expressing different proteins were purified on a glutathione Sepharose matrix to capture GST-CDK10(wt or kd) fusion proteins alone, or in complex with STR-CycM fusion protein. Purified protein expression levels were analyzed by Western blots (Top and Upper Middle). The kinase activity was determined by autoradiography of histone H1, whose added amounts were visualized by Coomassie staining (Lower Middle and Bottom). (B) Same as in A, using purified recombinant 6His-ETS2 as a substrate.CDK10 silencing has been shown to increase ETS2-driven c-RAF transcription and to activate the MAPK pathway (6). We investigated whether cyclin M is also involved in this regulatory pathway. To aim at a highly specific silencing, we used siRNA pools (mix of four different siRNAs) at low final concentration (10 nM). Both CDK10 and cyclin M siRNA pools silenced the expression of their cognate targets (Fig. 3 A and C and Fig. S2) and, interestingly, the cyclin M siRNA pool also caused a marked decrease in CDK10 protein level (Fig. 3A and Fig. S2B). These results, and those shown in Fig. 1D, suggest that cyclin M binding stabilizes CDK10. Cyclin M silencing induced an increase in c-Raf protein and mRNA levels (Fig. 3 B and C) and in phosphorylated ERK1 and ERK2 protein levels (Fig. S3B), similarly to CDK10 silencing. As expected from these effects (6), CDK10 and cyclin M silencing both decreased the sensitivity of ER+ MCF7 cells to tamoxifen, to a similar extent. The combined silencing of both genes did not result in a higher resistance to the drug (Fig. S3C). Altogether, these observations demonstrate a functional interaction between cyclin M and CDK10, which negatively controls ETS2.Fig. 3.In a new window Download PPTFig. 3.Cyclin M silencing up-regulates c-Raf expression. (A) Western blot analysis of endogenous CDK10 and cyclin M expression levels in MCF7 cells, in response to siRNA-mediated gene silencing. (B) Western blot analysis of endogenous c-Raf expression levels in MCF7 cells, in response to CDK10 or cyclin M silencing. A quantification is shown in Fig. S3A. (C) Quantitative RT-PCR analysis of CDK10, cyclin M, and c-Raf mRNA levels, in response to CDK10 (Upper) or cyclin M (Lower) silencing. **P â‰¤ 0.01; ***P â‰¤ 0.001.We then wished to explore the mechanism by which CDK10/cyclin M controls ETS2. ETS2 is a short-lived protein degraded by the proteasome (13). A straightforward hypothesis is that CDK10/cyclin M positively controls ETS2 degradation. We thus examined the impact of CDK10 or cyclin M silencing on ETS2 expression levels. The silencing of CDK10 and that of cyclin M caused an increase in the expression levels of an exogenously expressed Flag-ETS2 protein (Fig. S4A), as well as of the endogenous ETS2 protein (Fig. 4A). This increase is not attributable to increased ETS2 mRNA levels, which marginally fluctuated in response to CDK10 or cyclin M silencing (Fig. S4B). We then examined the expression levels of the Flag-tagged ETS2 protein when expressed alone or in combination with Myc-CDK10 or -CDK10(kd), with or without cyclin M-V5-6His. Flag-ETS2 was readily detected when expressed alone or, to a lesser extent, when coexpressed with CDK10(kd). However, its expression level was dramatically decreased when coexpressed with CDK10 alone, or with CDK10 and cyclin M (Fig. 4B). These observations suggest that endogenous cyclin M levels are in excess compared with those of CDK10 in MCF7 cells, and they show that the major decrease in ETS2 levels observed upon CDK10 coexpression involves CDK10 kinase activity. Treatment of cells coexpressing Flag-ETS2, CDK10, and cyclin M with the proteasome inhibitor MG132 largely rescued Flag-ETS2 expression levels (Fig. 4B).Fig. 4.In a new window Download PPTFig. 4.CDK10/cyclin M controls ETS2 stability in human cancer derived cells. (A) Western blot analysis of endogenous ETS2 expression levels in MCF7 cells, in response to siRNA-mediated CDK10 and/or cyclin M silencing. A quantification is shown in Fig. S4B. (B) Western blot analysis of exogenously expressed Flag-ETS2 protein levels in MCF7 cells cotransfected with empty vectors or coexpressing Myc-CDK10 (wt or kd), or Myc-CDK10/CycM-V5-6His. The latter cells were treated for 16 h with the MG132 proteasome inhibitor. Proper expression of CDK10 and cyclin M tagged proteins was verified by Western blot analysis. (C and D) Western blot analysis of expression levels of exogenously expressed Flag-ETS2 wild-type or mutant proteins in MCF7 cells, in the absence of (C) or in response to (D) Myc-CDK10/CycM-V5-6His expression. Quantifications are shown in Fig. S4 C and D.A mass spectrometry analysis of recombinant ETS2 phosphorylated by CDK10/cyclin M in vitro revealed the existence of multiple phosphorylated residues, among which are two neighboring phospho-serines (at positions 220 and 225) that may form a phosphodegron (14) (Figs. S5â€“S8). To confirm this finding, we compared the phosphorylation level of recombinant ETS2wt with that of ETS2SASA protein, a mutant bearing alanine substitutions of these two serines. As expected from the existence of multiple phosphorylation sites, we detected a small but reproducible, significant decrease of phosphorylation level of ETS2SASA compared with ETS2wt (Fig. S9), thus confirming that Ser220/Ser225 are phosphorylated by CDK10/cyclin M. To establish a direct link between ETS2 phosphorylation by CDK10/cyclin M and degradation, we examined the expression levels of Flag-ETS2SASA. In the absence of CDK10/cyclin M coexpression, it did not differ significantly from that of Flag-ETS2. This is contrary to that of Flag-ETS2DBM, bearing a deletion of the N-terminal destruction (D-) box that was previously shown to be involved in APC-Cdh1â€“mediated degradation of ETS2 (13) (Fig. 4C). However, contrary to Flag-ETS2 wild type, the expression level of Flag-ETS2SASA remained insensitive to CDK10/cyclin M coexpression (Fig. 4D). Altogether, these results suggest that CDK10/cyclin M directly controls ETS2 degradation through the phosphorylation of these two serines.Finally, we studied a lymphoblastoid cell line derived from a patient with STAR syndrome, bearing FAM58A mutation c.555+1G>A, predicted to result in aberrant splicing (10). In accordance with incomplete skewing of X chromosome inactivation previously found in this patient, we detected a decreased expression level of cyclin M protein in the STAR cell line, compared with a control lymphoblastoid cell line. In line with our preceding observations, we detected an increased expression level of ETS2 protein in the STAR cell line compared with the control (Fig. 5A and Fig. S10A). We then examined by quantitative RT-PCR the mRNA expression levels of the corresponding genes. The STAR cell line showed a decreased expression level of cyclin M mRNA but an expression level of ETS2 mRNA similar to that of the control cell line (Fig. 5B). To demonstrate that the increase in ETS2 protein expression is indeed a result of the decreased cyclin M expression observed in the STAR patient-derived cell line, we expressed cyclin M-V5-6His in this cell line. This expression caused a decrease in ETS2 protein levels (Fig. 5C).Fig. 5.In a new window Download PPTFig. 5.Decreased cyclin M expression in STAR patient-derived cells results in increased ETS2 protein level. (A) Western blot analysis of cyclin M and ETS2 protein levels in a STAR patient-derived lymphoblastoid cell line and in a control lymphoblastoid cell line, derived from a healthy individual. A quantification is shown in Fig. S10A. (B) Quantitative RT-PCR analysis of cyclin M and ETS2 mRNA levels in the same cells. ***P â‰¤ 0.001. (C) Western blot analysis of ETS2 protein levels in the STAR patient-derived lymphoblastoid cell line transfected with an empty vector or a vector directing the expression of cyclin M-V5-6His. Another Western blot revealing endogenously and exogenously expressed cyclin M levels is shown in Fig. S10B. A quantification of ETS2 protein levels is shown in Fig. S10C.Previous SectionNext SectionDiscussionIn this work, we unveil the interaction between CDK10, the last orphan CDK discovered in the pregenomic era (2), and cyclin M, the only cyclin associated with a human genetic disease so far, and whose functions remain unknown (10). The closest paralogs of CDK10 within the CDK family are the CDK11 proteins, which interact with L-type cyclins (15). Interestingly, the closest paralog of these cyclins within the cyclin family is cyclin M (Fig. S11). The fact that none of the shorter CDK10 isoforms interact robustly with cyclin M suggests that alternative splicing of the CDK10 gene (16, 17) plays an important role in regulating CDK10 functions.The functional relevance of the interaction between CDK10 and cyclin M is supported by different observations. Both proteins seem to enhance each otherâ€™s stability, as judged from their increased expression levels when their partner is exogenously coexpressed (Fig. 1D) and from the much reduced endogenous CDK10 expression level observed in response to cyclin M silencing (Fig. 3A and Fig. S2B). CDK10 is subject to ubiquitin-mediated degradation (18). Our observations suggest that cyclin M protects CDK10 from such degradation and that it is the only cyclin partner of CDK10, at least in MCF7 cells. They also suggest that cyclin M stability is enhanced upon binding to CDK10, independently from its kinase activity, as seen for cyclin C and CDK8 (19). We uncover a cyclin M-dependent CDK10 protein kinase activity in vitro, thus demonstrating that this protein, which was named a CDK on the sole basis of its amino acid sequence, is indeed a genuine cyclin-dependent kinase. Our Y2H assays reveal that truncated cyclin M proteins corresponding to the hypothetical products of two STAR syndrome-associated FAM58A mutations do not produce an interaction phenotype with CDK10. Hence, regardless of whether these mutated mRNAs undergo nonsense-mediated decay (as suggested from the decreased cyclin M mRNA levels in STAR cells, shown in Fig. 5B) or give rise to truncated cyclin M proteins, females affected by the STAR syndrome must exhibit compromised CDK10/cyclin M kinase activity at least in some tissues and during specific developmental stages.We show that ETS2, a known interactor of CDK10, is a phosphorylation substrate of CDK10/cyclin M in vitro and that CDK10/cyclin M kinase activity positively controls ETS2 degradation by the proteasome. This control seems to be exerted through a very fine mechanism, as judged from the sensitivity of ETS2 levels to partially decreased CDK10 and cyclin M levels, achieved in MCF7 cells and observed in STAR cells, respectively. These findings offer a straightforward explanation for the already reported up-regulation of ETS2-driven transcription of c-RAF in response to CDK10 silencing (6). We bring evidence that CDK10/cyclin M directly controls ETS2 degradation through the phosphorylation of two neighboring serines, which may form a noncanonical Î²-TRCP phosphodegron (DSMCPAS) (14). Because none of these two serines precede a proline, they do not conform to usual CDK phosphorylation sites. However, multiple so-called transcriptional CDKs (CDK7, -8, -9, and -11) (to which CDK10 may belong; Fig. S11) have been shown to phosphorylate a variety of motifs in a nonâ€“proline-directed fashion, especially in the context of molecular docking with the substrate (20). Here, it can be hypothesized that the high-affinity interaction between CDK10 and the Pointed domain of ETS2 (6, 9) (Fig. 1C) would allow docking-mediated phosphorylation of atypical sites. The control of ETS2 degradation involves a number of players, including APC-Cdh1 (13) and the cullin-RING ligase CRL4 (21). The formal identification of the ubiquitin ligase involved in the CDK10/cyclin M pathway and the elucidation of its concerted action with the other ubiquitin ligases to regulate ETS2 degradation will require further studies.Our results present a number of significant biological and medical implications. First, they shed light on the regulation of ETS2, which plays an important role in development (22) and is frequently deregulated in many cancers (23). Second, our results contribute to the understanding of the molecular mechanisms causing tamoxifen resistance associated with reduced CDK10 expression levels, and they suggest that, like CDK10 (6), cyclin M could also be a predictive clinical marker of hormone therapy response of ERÎ±-positive breast cancer patients. Third, our findings offer an interesting hypothesis on the molecular mechanisms underlying STAR syndrome. Ets2 transgenic mice showing a less than twofold overexpression of Ets2 present severe cranial abnormalities (24), and those observed in STAR patients could thus be caused at least in part by increased ETS2 protein levels. Another expected consequence of enhanced ETS2 expression levels would be a decreased risk to develop certain types of cancers and an increased risk to develop others. Studies on various mouse models (including models of Down syndrome, in which three copies of ETS2 exist) have revealed that ETS2 dosage can repress or promote tumor growth and, hence, that ETS2 exerts noncell autonomous functions in cancer (25). Intringuingly, one of the very few STAR patients identified so far has been diagnosed with a nephroblastoma (26). Finally, our findings will facilitate the general exploration of the biological functions of CDK10 and, in particular, its role in the control of cell division. Previous studies have suggested either a positive role in cell cycle control (5, 6) or a tumor-suppressive activity in some cancers (7, 8). The severe growth retardation exhibited by STAR patients strongly suggests that CDK10/cyclin M plays an important role in the control of cell proliferation.Previous SectionNext SectionMaterials and MethodsCloning of CDK10 and cyclin M cDNAs, plasmid constructions, tamoxifen response analysis, quantitative RT-PCR, mass spectrometry experiments, and antibody production are detailed in SI Materials and Methods.Yeast Two-Hybrid Interaction Assays. We performed yeast interaction mating assays as previously described (27).Mammalian Cell Cultures and Transfections. We grew human HEK293 and MCF7 cells in DMEM supplemented with 10% (vol/vol) FBS (Invitrogen), and we grew lymphoblastoid cells in RPMI 1640 GlutaMAX supplemented with 15% (vol/vol) FBS. We transfected HEK293 and MCF7 cells using Lipofectamine 2000 (Invitrogen) for plasmids, Lipofectamine RNAiMAX (Invitrogen) for siRNAs, and Jetprime (Polyplus) for plasmids/siRNAs combinations according to the manufacturersâ€™ instructions. We transfected lymphoblastoid cells by electroporation (Neon, Invitrogen). For ETS2 stability studies we treated MCF7 cells 32 h after transfection with 10 Î¼M MG132 (Fisher Scientific) for 16 h.Coimmunoprecipitation and Western Blot Experiments. We collected cells by scraping in PBS (or centrifugation for lymphoblastoid cells) and lysed them by sonication in a lysis buffer containing 60 mM Î²-glycerophosphate, 15 mM p-nitrophenylphosphate, 25 mM 3-(N-morpholino)propanesulfonic acid (Mops) (pH 7.2), 15 mM EGTA, 15 mM MgCl2, 1 mM Na vanadate, 1 mM NaF, 1mM phenylphosphate, 0.1% Nonidet P-40, and a protease inhibitor mixture (Roche). We spun the lysates 15 min at 20,000 Ã— g at 4 Â°C, collected the supernatants, and determined the protein content using a Bradford assay. We performed the immunoprecipitation experiments on 500 Î¼g of total proteins, in lysis buffer. We precleared the lysates with 20 Î¼L of protein A or G-agarose beads, incubated 1 h 4 Â°C on a rotating wheel. We added 5 Î¼g of antibody to the supernatants, incubated 1 h 4 Â°C on a rotating wheel, added 20 Î¼L of protein A or G-agarose beads, and incubated 1 h 4 Â°C on a rotating wheel. We collected the beads by centrifugation 30 s at 18,000 Ã— g at 4 Â°C and washed three times in a bead buffer containing 50 mM Tris (pH 7.4), 5 mM NaF, 250 mM NaCl, 5 mM EDTA, 5 mM EGTA, 0.1% Nonidet P-40, and a protease inhibitor coktail (Roche). We directly added sample buffer to the washed pellets, heat-denatured the proteins, and ran the samples on 10% Bis-Tris SDS/PAGE. We transferred the proteins onto Hybond nitrocellulose membranes and processed the blots according to standard procedures. For Western blot experiments, we used the following primary antibodies: anti-Myc (Abcam ab9106, 1:2,000), anti-V5 (Invitrogen R960, 1:5,000), anti-tubulin (Santa Cruz Biotechnology B-7, 1:500), anti-CDK10 (Covalab pab0847p, 1:500 or Santa Cruz Biotechnology C-19, 1:500), anti-CycM (home-made, dilution 1:500 or Covalab pab0882-P, dilution 1:500), anti-Raf1 (Santa Cruz Biotechnology C-20, 1:1,000), anti-ETS2 (Santa Cruz Biotechnology C-20, 1:1,000), anti-Flag (Sigma F7425, 1:1,000), and anti-actin (Sigma A5060, 1:5,000). We used HRP-coupled anti-goat (Santa Cruz Biotechnology SC-2033, dilution 1:2,000), anti-mouse (Bio-Rad 170â€“6516, dilution 1:3,000) or anti-rabbit (Bio-Rad 172â€“1019, 1:5,000) as secondary antibodies. We revealed the blots by enhanced chemiluminescence (SuperSignal West Femto, Thermo Scientific).Production and Purification of Recombinant Proteins.GST-CDK10(kd)/StrepII-CycM. We generated recombinant bacmids in DH10Bac Escherichia coli and baculoviruses in Sf9 cells using the Bac-to-Bac system, as described by the provider (Invitrogen). We infected Sf9 cells with GST-CDK10- (or GST-CDK10kd)-producing viruses, or coinfected the cells with StrepII-CycMâ€“producing viruses, and we collected the cells 72 h after infection. To purify GST-fusion proteins, we spun 250 mL cells and resuspended the pellet in 40 mL lysis buffer (PBS, 250 mM NaCl, 0.5% Nonidet P-40, 50 mM NaF, 10 mM Î²-glycerophosphate, and 0.3 mM Na-vanadate) containing a protease inhibitor mixture (Roche). We lysed the cells by sonication, spun the lysate 30 min at 15,000 Ã— g, collected the soluble fraction, and added it to a 1-mL glutathione-Sepharose matrix. We incubated 1 h at 4 Â°C, washed four times with lysis buffer, one time with kinase buffer A (see below), and finally resuspended the beads in 100 Î¼L kinase buffer A containing 10% (vol/vol) glycerol for storage.6His-ETS2. We transformed Origami2 DE3 (Novagen) with the 6His-ETS2 expression vector. We induced expression with 0.2 mM isopropyl-Î²-d-1-thiogalactopyranoside for 3 h at 22 Â°C. To purify 6His-ETS2, we spun 50 mL cells and resuspended the pellet in 2 mL lysis buffer (PBS, 300 mM NaCl, 10 mM Imidazole, 1 mM DTT, and 0.1% Nonidet P-40) containing a protease inhibitor mixture without EDTA (Roche). We lysed the cells at 1.6 bar using a cell disruptor and spun the lysate 10 min at 20,000 Ã— g. We collected the soluble fraction and added it to 200 Î¼L Cobalt beads (Thermo Scientific). After 1 h incubation at 4 Â°C on a rotating wheel, we washed four times with lysis buffer. To elute, we incubated beads 30 min with elution buffer (PBS, 250 mM imidazole, pH 7.6) containing the protease inhibitor mixture, spun 30 s at 10,000 Ã— g, and collected the eluted protein.Protein Kinase Assays. We mixed glutathione-Sepharose beads (harboring GST-CDK10 wt or kd, either monomeric or complexed with StrepII-CycM), 22.7 Î¼M BSA, 15 mM DTT, 100 Î¼M ATP, 5 Î¼Ci ATP[Î³-32P], 7.75 Î¼M histone H1, or 1 Î¼M 6His-ETS2 and added kinase buffer A (25 mM TrisÂ·HCl, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT, and 3.7 Î¼M heparin, pH 7.5) up to a total volume of 30 Î¼L. We incubated the reactions 30 min at 30 Â°C, added Laemli sample buffer, heat-denatured the samples, and ran 10% Bis-Tris SDS/PAGE. We cut gel slices to detect GST-CDK10 and StrepII-CycM by Western blotting. We stained the gel slices containing the substrate with Coomassie (R-250, Bio-Rad), dried them, and detected the incorporated radioactivity by autoradiography. We identified four unrelated girls with anogenital and renal malformations, dysmorphic facial features, normal intellect and syndactyly of toes. A similar combination of features had been reported previously in a motherâ€“daughter pair1 (Table 1 and Supplementary Note online). These authors noted clinical overlap with Townes-Brocks syndrome but suggested that the phenotype represented a separate autosomal dominant entity (MIM601446). Here we define the cardinal features of this syndrome as a characteristic facial appearance with apparent telecanthus and broad tripartite nasal tip, variable syndactyly of toes 2â€“5, hypoplastic labia, anal atresia and urogenital malformations (Fig. 1aâ€“h). We also observed a variety of other features (Table 1).  Figure 1: Clinical and molecular characterization of STAR syndrome.  Figure 1 : Clinical and molecular characterization of STAR syndrome. (aâ€“f) Facial appearances of cases 1â€“3 (apparent telecanthus, dysplastic ears and thin upper lips; a,c,e), and toe syndactyly 2â€“5, 3â€“5 or 4â€“5 (b,d,f) in these cases illustrate recognizable features of STAR syndrome (specific parental consent has been obtained for publication of these photographs). Anal atresia and hypoplastic labia are not shown. (g,h) X-ray films of the feet of case 2 showing only four rays on the left and delta-shaped 4th and 5th metatarsals on the right (h; compare to clinical picture in d). (i) Array-CGH data. Log2 ratio represents copy number loss of six probes spanning between 37.9 and 50.7 kb, with one probe positioned within FAM58A. The deletion does not remove parts of other functional genes. (j) Schematic structure of FAM58A and position of the mutations. FAM58A has five coding exons (boxes). The cyclin domain (green) is encoded by exons 2â€“4. The horizontal arrow indicates the deletion extending 5' in case 1, which includes exons 1 and 2, whereas the horizontal line below exon 5 indicates the deletion found in case 3, which removes exon 5 and some 3' sequence. The pink horizontal bars above the boxes indicate the amplicons used for qPCR and sequencing (one alternative exon 5 amplicon is not indicated because of space constraints). The mutation 201dupT (case 4) results in an immediate stop codon, and the 555+1G>A and 555-1G>A splice mutations in cases 2, 5 and 6 are predicted to be deleterious because they alter the conserved splice donor and acceptor site of intron 4, respectively.  Full size image (97 KB)  Table 1: Clinical features in STAR syndrome cases  Table 1 - Clinical features in STAR syndrome cases  Full table  On the basis of the phenotypic overlap with Townes-Brocks, Okihiro and Feingold syndromes, we analyzed SALL1 (ref. 2), SALL4 (ref. 3) and MYCN4 but found no mutations in any of these genes (Supplementary Methods online). Next, we carried out genome-wide high-resolution oligonucleotide array comparative genomic hybridization (CGH)5 analysis (Supplementary Methods) of genomic DNA from the most severely affected individual (case 1, with lower lid coloboma, epilepsy and syringomyelia) and identified a heterozygous deletion of 37.9â€“50.7 kb on Xq28, which removed exons 1 and 2 of FAM58A (Fig. 1i,j). Using real-time PCR, we confirmed the deletion in the child and excluded it in her unaffected parents (Supplementary Fig. 1a online, Supplementary Methods and Supplementary Table 1 online). Through CGH with a customized oligonucleotide array enriched in probes for Xq28, followed by breakpoint cloning, we defined the exact deletion size as 40,068 bp (g.152,514,164_152,554,231del(chromosome X, NCBI Build 36.2); Fig. 1j and Supplementary Figs. 2,3 online). The deletion removes the coding regions of exons 1 and 2 as well as intron 1 (2,774 bp), 492 bp of intron 2, and 36,608 bp of 5' sequence, including the 5' UTR and the entire KRT18P48 pseudogene (NCBI gene ID 340598). Paternity was proven using routine methods. We did not find deletions overlapping FAM58A in the available copy number variation (CNV) databases.  Subsequently, we carried out qPCR analysis of the three other affected individuals (cases 2, 3 and 4) and the mother-daughter pair from the literature (cases 5 and 6). In case 3, we detected a de novo heterozygous deletion of 1.1â€“10.3 kb overlapping exon 5 (Supplementary Fig. 1b online). Using Xq28-targeted array CGH and breakpoint cloning, we identified a deletion of 4,249 bp (g.152,504,123_152,508,371del(chromosome X, NCBI Build 36.2); Fig. 1j and Supplementary Figs. 2,3), which removed 1,265 bp of intron 4, all of exon 5, including the 3' UTR, and 2,454 bp of 3' sequence.  We found heterozygous FAM58A point mutations in the remaining cases (Fig. 1j, Supplementary Fig. 2, Supplementary Methods and Supplementary Table 1). In case 2, we identified the mutation 555+1G>A, affecting the splice donor site of intron 4. In case 4, we identified the frameshift mutation 201dupT, which immediately results in a premature stop codon N68XfsX1. In cases 5 and 6, we detected the mutation 556-1G>A, which alters the splice acceptor site of intron 4. We validated the point mutations and deletions by independent rounds of PCR and sequencing or by qPCR. We confirmed paternity and de novo status of the point mutations and deletions in all sporadic cases. None of the mutations were seen in the DNA of 60 unaffected female controls, and no larger deletions involving FAM58A were found in 93 unrelated array-CGH investigations.  By analyzing X-chromosome inactivation (Supplementary Methods and Supplementary Fig. 4 online), we found complete skewing of X inactivation in cases 1 and 3â€“6 and almost complete skewing in case 2, suggesting that cells carrying the mutation on the active X chromosome have a growth disadvantage during fetal development. Using RT-PCR on RNA from lymphoblastoid cells of case 2 (Supplementary Fig. 2), we did not find any aberrant splice products as additional evidence that the mutated allele is inactivated. Furthermore, FAM58A is subjected to X inactivation6. In cases 1 and 3, the parental origin of the deletions could not be determined, as a result of lack of informative SNPs. Case 5, the mother of case 6, gave birth to two boys, both clinically unaffected (samples not available). We cannot exclude that the condition is lethal in males. No fetal losses were reported from any of the families.  The function of FAM58A is unknown. The gene consists of five coding exons, and the 642-bp coding region encodes a protein of 214 amino acids. GenBank lists a mRNA length of 1,257 bp for the reference sequence (NM_152274.2). Expression of the gene (by EST data) was found in 27 of 48 adult tissues including kidney, colon, cervix and uterus, but not heart (NCBI expression viewer, UniGene Hs.496943). Expression was also noted in 24 of 26 listed tumor tissues as well as in embryo and fetus. Genes homologous to FAM58A (NCBI HomoloGene: 13362) are found on the X chromosome in the chimpanzee and the dog. The zebrafish has a similar gene on chromosome 23. However, in the mouse and rat, there are no true homologs. These species have similar but intronless genes on chromosomes 11 (mouse) and 10 (rat), most likely arising from a retrotransposon insertion event. On the murine X chromosome, the flanking genes Atp2b3 and Dusp9 are conserved, but only remnants of the FAM58A sequence can be detected.  FAM58A contains a cyclin-box-fold domain, a protein-binding domain found in cyclins with a role in cell cycle and transcription control. No human phenotype resulting from a cyclin gene mutation has yet been reported. Homozygous knockout mice for Ccnd1 (encoding cyclin D1) are viable but small and have reduced lifespan. They also have dystrophic changes of the retina, likely as a result of decreased cell proliferation and degeneration of photoreceptor cells during embryogenesis7, 8.  Cyclin D1 colocalizes with SALL4 in the nucleus, and both proteins cooperatively mediate transcriptional repression9. As the phenotype of our cases overlaps considerably with that of Townes-Brocks syndrome caused by SALL1 mutations1, we carried out co-immunoprecipitation to find out if SALL1 or SALL4 would interact with FAM58A in a manner similar to that observed for SALL4 and cyclin D1. We found that FAM58A interacts with SALL1 but not with SALL4 (Supplementary Fig. 5 online), supporting the hypothesis that FAM58A and SALL1 participate in the same developmental pathway.  How do FAM58A mutations lead to STAR syndrome? Growth retardation (all cases; Table 1) and retinal abnormalities (three cases) are reminiscent of the reduced body size and retinal anomalies in cyclin D1 knockout mice7, 8. Therefore, a proliferation defect might be partly responsible for STAR syndrome. To address this question, we carried out a knockdown of FAM58A mRNA followed by a proliferation assay. Transfection of HEK293 cells with three different FAM58A-specific RNAi oligonucleotides resulted in a significant reduction of both FAM58A mRNA expression and proliferation of transfected cells (Supplementary Methods and Supplementary Fig. 6 online), supporting the link between FAM58A and cell proliferation.  We found that loss-of-function mutations of FAM58A result in a rather homogeneous clinical phenotype. The additional anomalies in case 1 are likely to result from an effect of the 40-kb deletion on expression of a neighboring gene, possibly ATP2B3 or DUSP9. However, we cannot exclude that the homogeneous phenotype results from an ascertainment bias and that FAM58A mutations, including missense changes, could result in a broader spectrum of malformations. The genes causing the overlapping phenotypes of STAR syndrome and Townes-Brocks syndrome seem to act in the same pathway. Of note, MYCN, a gene mutated in Feingold syndrome, is a direct regulator of cyclin D2 (refs. 10,11); thus, it is worth exploring whether the phenotypic similarities between Feingold and STAR syndrome might be explained by direct regulation of FAM58A by MYCN.  FAM58A is located approximately 0.56 Mb centromeric to MECP2 on Xq28. Duplications overlapping both MECP2 and FAM58A have been described and are not associated with a clinical phenotype in females12, but no deletions overlapping both MECP2 and FAM58A have been observed to date13. Although other genes between FAM58A and MECP2 have been implicated in brain development, FAM58A and MECP2 are the only genes in this region known to result in X-linked dominant phenotypes; thus, deletion of both genes on the same allele might be lethal in both males and females.\""
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train_text_df['Text'][0]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Seems like a paper or conference proceeding"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Distributions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x576 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(12,8))\n",
    "#sns.countplot(x=\"Class\", data=train_variants_df)\n",
    "train_variants_df.Class.value_counts().plot(kind='bar')\n",
    "plt.ylabel('Frequency', fontsize=12)\n",
    "plt.xlabel('Class number', fontsize=12)\n",
    "plt.xticks(rotation='vertical')\n",
    "plt.title(\"Frequency of Classes\", fontsize=15)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Some classes are much more rare than others"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x576 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(12,8))\n",
    "#sns.countplot(x=\"Class\", data=train_variants_df)\n",
    "train_variants_df.Gene.value_counts().plot(kind='bar')\n",
    "plt.ylabel('Frequency', fontsize=12)\n",
    "plt.xlabel('Gene name', fontsize=12)\n",
    "plt.xticks(rotation='vertical')\n",
    "plt.title(\"Frequency of Genes\", fontsize=15)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Seems like some genes are much more prone to mutation than others. Which genes are these?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "BRCA1     264\n",
       "TP53      163\n",
       "EGFR      141\n",
       "PTEN      126\n",
       "BRCA2     125\n",
       "KIT        99\n",
       "BRAF       93\n",
       "ALK        69\n",
       "ERBB2      69\n",
       "PDGFRA     60\n",
       "PIK3CA     56\n",
       "CDKN2A     52\n",
       "FGFR2      50\n",
       "FLT3       49\n",
       "TSC2       47\n",
       "MTOR       45\n",
       "KRAS       44\n",
       "MAP2K1     43\n",
       "VHL        41\n",
       "RET        40\n",
       "Name: Gene, dtype: int64"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "geneCounts = train_variants_df.Gene.value_counts()\n",
    "geneCounts.nlargest(20)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Are genes and classes correlated?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 720x720 with 4 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "f,axs = plt.subplots(2,2, figsize = (10,10))\n",
    "f.suptitle(\"Distribution of frequency occuring genes into various classes\", fontsize=15)\n",
    "\n",
    "train_variants_df.loc[train_variants_df['Gene'] =='BRCA1'].Class.value_counts().plot(kind='bar',ax=axs[0,0])\n",
    "axs[0,0].set_title('BRCA1')\n",
    "train_variants_df.loc[train_variants_df['Gene'] =='TP53'].Class.value_counts().plot(kind='bar',ax=axs[0,1])\n",
    "axs[0,1].set_title('TP53')\n",
    "train_variants_df.loc[train_variants_df['Gene'] =='EGFR'].Class.value_counts().plot(kind='bar',ax=axs[1,0])\n",
    "axs[1,0].set_title('EGFR')\n",
    "train_variants_df.loc[train_variants_df['Gene'] =='PTEN'].Class.value_counts().plot(kind='bar',ax=axs[1,1])\n",
    "axs[1,1].set_title('PTEN')\n",
    "plt.xlabel('Class', fontsize=12)\n",
    "plt.ylabel('Count', fontsize=12)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "It seems like the gene itself has some predictive power on the class in which it belongs. Now let's look at the variation types."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Truncating Mutations    93\n",
       "Deletion                74\n",
       "Amplification           71\n",
       "Fusions                 34\n",
       "Overexpression           6\n",
       "G12V                     4\n",
       "Q61H                     3\n",
       "E17K                     3\n",
       "Q61R                     3\n",
       "T58I                     3\n",
       "Q61L                     3\n",
       "R841K                    2\n",
       "I31M                     2\n",
       "K117N                    2\n",
       "F28L                     2\n",
       "R170W                    2\n",
       "C618R                    2\n",
       "Y64A                     2\n",
       "V321M                    2\n",
       "ETV6-NTRK3 Fusion        2\n",
       "Name: Variation, dtype: int64"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "variationCounts = train_variants_df.Variation.value_counts()\n",
    "variationCounts.nlargest(20)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Most mutations are protein-swaps. Does variation correlate wtih class?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# replace X123X variation types with \"protein swap\" and look at distribution of classes for each variation\n",
    "\n",
    "mutationTypes = {'Truncating Mutations','Deletion','Amplification','Fusions','Overexpression','ProteinSwap'}\n",
    "\n",
    "# copy the variation column\n",
    "train_variants_df['Variation_Alt'] = train_variants_df['Variation']\n",
    "\n",
    "# replace values\n",
    "train_variants_df['Variation_Alt'] = np.where(train_variants_df['Variation_Alt'].isin(mutationTypes), train_variants_df['Variation_Alt'], 'ProteinSwap')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0       Truncating Mutations\n",
       "1                ProteinSwap\n",
       "2                ProteinSwap\n",
       "3                ProteinSwap\n",
       "4                ProteinSwap\n",
       "                ...         \n",
       "3316             ProteinSwap\n",
       "3317             ProteinSwap\n",
       "3318                 Fusions\n",
       "3319             ProteinSwap\n",
       "3320             ProteinSwap\n",
       "Name: Variation_Alt, Length: 3321, dtype: object"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train_variants_df['Variation_Alt']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 2160x1440 with 6 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "g = sns.catplot(x='Class',data=train_variants_df[['Variation_Alt','Class']],col='Variation_Alt',kind='count',col_wrap=3,\n",
    "           height = 10,sharey=False,sharex=False)\n",
    "g.set_yticklabels(size = 18)\n",
    "g.set_xticklabels(size = 18)\n",
    "g.set_ylabels(size = 18)\n",
    "g.set_xlabels(size = 18)\n",
    "g.set_titles(size = 25)\n",
    "\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Seems like the variation type also has some predictive power!"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Interim Summary\n",
    "Based on their distributions, these variables seem to have some predictive power for the class which a mutation belongs:\n",
    "* Variation type\n",
    "* Gene that was mutated\n",
    "\n",
    "Some other interesting things we saw:\n",
    "* Seems like some genes are much more prone to mutation than others\n",
    "* Some classes occur more often than others\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Now let's take a look at the text data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [],
   "source": [
    "# add information about word count and character count\n",
    "train_text_df[\"num_words\"] = train_text_df[\"Text\"].apply(lambda x: len(str(x).split()) )\n",
    "train_text_df[\"num_chars\"] = train_text_df[\"Text\"].apply(lambda x: len(str(x)) )\n",
    "\n",
    "test_text_df[\"num_words\"] = test_text_df[\"Text\"].apply(lambda x: len(str(x).split()) )\n",
    "test_text_df[\"num_chars\"] = test_text_df[\"Text\"].apply(lambda x: len(str(x)) )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x576 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(12, 8))\n",
    "sns.distplot(train_text_df.num_words.values, bins=50, kde=False, color='red')\n",
    "plt.xlabel('Number of words in text', fontsize=12)\n",
    "plt.ylabel('Count', fontsize=12)\n",
    "plt.title(\"Frequency of number of words\", fontsize=15)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "count     3321.000000\n",
       "mean      9542.505872\n",
       "std       7845.251814\n",
       "min          1.000000\n",
       "25%       4733.000000\n",
       "50%       6871.000000\n",
       "75%      11996.000000\n",
       "max      76708.000000\n",
       "Name: num_words, dtype: float64"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train_text_df.num_words.describe()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "While it is interesting that some mutations have a longer text description than others, intuition tells me what it wouldn't make sense for the description length to have predictive power. Notice that the mean word count is 1; let's check if there are any entries with empty text descriptors."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ID</th>\n",
       "      <th>Text</th>\n",
       "      <th>num_words</th>\n",
       "      <th>num_chars</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1109</th>\n",
       "      <td>1109</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1277</th>\n",
       "      <td>1277</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1407</th>\n",
       "      <td>1407</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1639</th>\n",
       "      <td>1639</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2755</th>\n",
       "      <td>2755</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        ID Text  num_words  num_chars\n",
       "1109  1109  NaN          1          3\n",
       "1277  1277  NaN          1          3\n",
       "1407  1407  NaN          1          3\n",
       "1639  1639  NaN          1          3\n",
       "2755  2755  NaN          1          3"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train_text_df[train_text_df[\"num_words\"]<5]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "This will give us trouble -  let's remove these entries. But first, we should combine the text dataframe with the variants dataframe."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Combine text data w/ variation data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "metadata": {},
   "outputs": [],
   "source": [
    "# first merge dataframes\n",
    "train_df = train_variants_df.merge(train_text_df, how='inner', left_on='ID', right_on='ID')\n",
    "test_df = test_variants_df.merge(test_text_df, how='inner', left_on='ID', right_on='ID')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 280,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ID</th>\n",
       "      <th>Gene</th>\n",
       "      <th>Variation</th>\n",
       "      <th>Class</th>\n",
       "      <th>Variation_Alt</th>\n",
       "      <th>Text</th>\n",
       "      <th>num_words</th>\n",
       "      <th>num_chars</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>140</th>\n",
       "      <td>140</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>I491M</td>\n",
       "      <td>5</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>The accurate determination of perfluoroalkyl s...</td>\n",
       "      <td>430</td>\n",
       "      <td>2925</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>145</th>\n",
       "      <td>145</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>K467T</td>\n",
       "      <td>2</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>The accurate determination of perfluoroalkyl s...</td>\n",
       "      <td>430</td>\n",
       "      <td>2925</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>259</th>\n",
       "      <td>259</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>S464L</td>\n",
       "      <td>2</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>The accurate determination of perfluoroalkyl s...</td>\n",
       "      <td>430</td>\n",
       "      <td>2925</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>344</th>\n",
       "      <td>344</td>\n",
       "      <td>CDH1</td>\n",
       "      <td>A617T</td>\n",
       "      <td>4</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>E-cadherin is involved in the formation of cel...</td>\n",
       "      <td>187</td>\n",
       "      <td>1315</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>346</th>\n",
       "      <td>346</td>\n",
       "      <td>CDH1</td>\n",
       "      <td>A634V</td>\n",
       "      <td>4</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>E-cadherin is involved in the formation of cel...</td>\n",
       "      <td>187</td>\n",
       "      <td>1315</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>348</th>\n",
       "      <td>348</td>\n",
       "      <td>CDH1</td>\n",
       "      <td>T340A</td>\n",
       "      <td>4</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>E-cadherin is involved in the formation of cel...</td>\n",
       "      <td>187</td>\n",
       "      <td>1315</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>648</th>\n",
       "      <td>648</td>\n",
       "      <td>CDKN2A</td>\n",
       "      <td>Q50*</td>\n",
       "      <td>4</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>The p16 gene is located in chromosome 9p21, a ...</td>\n",
       "      <td>103</td>\n",
       "      <td>706</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>688</th>\n",
       "      <td>688</td>\n",
       "      <td>CDKN2A</td>\n",
       "      <td>R79P</td>\n",
       "      <td>4</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Cell division is controlled by a series of pos...</td>\n",
       "      <td>228</td>\n",
       "      <td>1540</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>692</th>\n",
       "      <td>692</td>\n",
       "      <td>CDKN2A</td>\n",
       "      <td>G93W</td>\n",
       "      <td>4</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Cell division is controlled by a series of pos...</td>\n",
       "      <td>228</td>\n",
       "      <td>1540</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>693</th>\n",
       "      <td>693</td>\n",
       "      <td>CDKN2A</td>\n",
       "      <td>V118D</td>\n",
       "      <td>4</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Cell division is controlled by a series of pos...</td>\n",
       "      <td>228</td>\n",
       "      <td>1540</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>868</th>\n",
       "      <td>868</td>\n",
       "      <td>HLA-A</td>\n",
       "      <td>596_619splice</td>\n",
       "      <td>1</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>A new variant of the HLA-A*010101 allele desig...</td>\n",
       "      <td>184</td>\n",
       "      <td>1219</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>941</th>\n",
       "      <td>941</td>\n",
       "      <td>PDGFRB</td>\n",
       "      <td>ATF7IP-PDGFRB Fusion</td>\n",
       "      <td>2</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Chronic myelomonocytic leukemia (CMML) is a my...</td>\n",
       "      <td>116</td>\n",
       "      <td>776</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1057</th>\n",
       "      <td>1057</td>\n",
       "      <td>EWSR1</td>\n",
       "      <td>EWSR1-FEV Fusion</td>\n",
       "      <td>2</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>As a result of chromosome translocations, the ...</td>\n",
       "      <td>207</td>\n",
       "      <td>1215</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1154</th>\n",
       "      <td>1154</td>\n",
       "      <td>KMT2C</td>\n",
       "      <td>S3660L</td>\n",
       "      <td>5</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Several studies indicated that the expression ...</td>\n",
       "      <td>341</td>\n",
       "      <td>2176</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1286</th>\n",
       "      <td>1286</td>\n",
       "      <td>HRAS</td>\n",
       "      <td>A146V</td>\n",
       "      <td>2</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Costello syndrome is a rare congenital disorde...</td>\n",
       "      <td>244</td>\n",
       "      <td>1692</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1290</th>\n",
       "      <td>1290</td>\n",
       "      <td>HRAS</td>\n",
       "      <td>T58I</td>\n",
       "      <td>2</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>We report a 10-year-old girl presenting with s...</td>\n",
       "      <td>231</td>\n",
       "      <td>1668</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1368</th>\n",
       "      <td>1368</td>\n",
       "      <td>AKT2</td>\n",
       "      <td>D32H</td>\n",
       "      <td>7</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>The activating E17K mutations recently discove...</td>\n",
       "      <td>448</td>\n",
       "      <td>2864</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1378</th>\n",
       "      <td>1378</td>\n",
       "      <td>AKT2</td>\n",
       "      <td>D399N</td>\n",
       "      <td>7</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>The activating E17K mutations recently discove...</td>\n",
       "      <td>448</td>\n",
       "      <td>2864</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1583</th>\n",
       "      <td>1583</td>\n",
       "      <td>PMS1</td>\n",
       "      <td>Q233*</td>\n",
       "      <td>4</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>HEREDITARY nonpolyposis colorectal cancer (HNP...</td>\n",
       "      <td>114</td>\n",
       "      <td>742</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1613</th>\n",
       "      <td>1613</td>\n",
       "      <td>VHL</td>\n",
       "      <td>L158Q</td>\n",
       "      <td>4</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>The case of a 40-year-old woman with severe ed...</td>\n",
       "      <td>53</td>\n",
       "      <td>337</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1620</th>\n",
       "      <td>1620</td>\n",
       "      <td>VHL</td>\n",
       "      <td>P25L</td>\n",
       "      <td>5</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Background: von Hippel-Lindau (VHL) disease is...</td>\n",
       "      <td>431</td>\n",
       "      <td>2643</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2146</th>\n",
       "      <td>2146</td>\n",
       "      <td>PTCH1</td>\n",
       "      <td>Truncating Mutations</td>\n",
       "      <td>1</td>\n",
       "      <td>Truncating Mutations</td>\n",
       "      <td>Basal cell carcinoma (BCC) is the most common ...</td>\n",
       "      <td>212</td>\n",
       "      <td>1407</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2504</th>\n",
       "      <td>2504</td>\n",
       "      <td>BRCA1</td>\n",
       "      <td>V11A</td>\n",
       "      <td>6</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Identification of protein-protein interaction...</td>\n",
       "      <td>230</td>\n",
       "      <td>1632</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2900</th>\n",
       "      <td>2900</td>\n",
       "      <td>NF2</td>\n",
       "      <td>E106G</td>\n",
       "      <td>1</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Neurofibromatosis 2 (NF2) is a tumor predispos...</td>\n",
       "      <td>183</td>\n",
       "      <td>1219</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2906</th>\n",
       "      <td>2906</td>\n",
       "      <td>NF2</td>\n",
       "      <td>Q538P</td>\n",
       "      <td>1</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Neurofibromatosis 2 (NF2) is a tumor predispos...</td>\n",
       "      <td>183</td>\n",
       "      <td>1219</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2908</th>\n",
       "      <td>2908</td>\n",
       "      <td>NF2</td>\n",
       "      <td>Q324L</td>\n",
       "      <td>5</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Neurofibromatosis 2 (NF2) is a tumor predispos...</td>\n",
       "      <td>183</td>\n",
       "      <td>1219</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2980</th>\n",
       "      <td>2980</td>\n",
       "      <td>KIT</td>\n",
       "      <td>N655K</td>\n",
       "      <td>2</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>TO THE EDITOR: I commend Drs. Freeman and Bank...</td>\n",
       "      <td>362</td>\n",
       "      <td>2689</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        ID    Gene             Variation  Class         Variation_Alt  \\\n",
       "140    140    EGFR                 I491M      5           ProteinSwap   \n",
       "145    145    EGFR                 K467T      2           ProteinSwap   \n",
       "259    259    EGFR                 S464L      2           ProteinSwap   \n",
       "344    344    CDH1                 A617T      4           ProteinSwap   \n",
       "346    346    CDH1                 A634V      4           ProteinSwap   \n",
       "348    348    CDH1                 T340A      4           ProteinSwap   \n",
       "648    648  CDKN2A                  Q50*      4           ProteinSwap   \n",
       "688    688  CDKN2A                  R79P      4           ProteinSwap   \n",
       "692    692  CDKN2A                  G93W      4           ProteinSwap   \n",
       "693    693  CDKN2A                 V118D      4           ProteinSwap   \n",
       "868    868   HLA-A         596_619splice      1           ProteinSwap   \n",
       "941    941  PDGFRB  ATF7IP-PDGFRB Fusion      2           ProteinSwap   \n",
       "1057  1057   EWSR1      EWSR1-FEV Fusion      2           ProteinSwap   \n",
       "1154  1154   KMT2C                S3660L      5           ProteinSwap   \n",
       "1286  1286    HRAS                 A146V      2           ProteinSwap   \n",
       "1290  1290    HRAS                  T58I      2           ProteinSwap   \n",
       "1368  1368    AKT2                  D32H      7           ProteinSwap   \n",
       "1378  1378    AKT2                 D399N      7           ProteinSwap   \n",
       "1583  1583    PMS1                 Q233*      4           ProteinSwap   \n",
       "1613  1613     VHL                 L158Q      4           ProteinSwap   \n",
       "1620  1620     VHL                  P25L      5           ProteinSwap   \n",
       "2146  2146   PTCH1  Truncating Mutations      1  Truncating Mutations   \n",
       "2504  2504   BRCA1                  V11A      6           ProteinSwap   \n",
       "2900  2900     NF2                 E106G      1           ProteinSwap   \n",
       "2906  2906     NF2                 Q538P      1           ProteinSwap   \n",
       "2908  2908     NF2                 Q324L      5           ProteinSwap   \n",
       "2980  2980     KIT                 N655K      2           ProteinSwap   \n",
       "\n",
       "                                                   Text  num_words  num_chars  \n",
       "140   The accurate determination of perfluoroalkyl s...        430       2925  \n",
       "145   The accurate determination of perfluoroalkyl s...        430       2925  \n",
       "259   The accurate determination of perfluoroalkyl s...        430       2925  \n",
       "344   E-cadherin is involved in the formation of cel...        187       1315  \n",
       "346   E-cadherin is involved in the formation of cel...        187       1315  \n",
       "348   E-cadherin is involved in the formation of cel...        187       1315  \n",
       "648   The p16 gene is located in chromosome 9p21, a ...        103        706  \n",
       "688   Cell division is controlled by a series of pos...        228       1540  \n",
       "692   Cell division is controlled by a series of pos...        228       1540  \n",
       "693   Cell division is controlled by a series of pos...        228       1540  \n",
       "868   A new variant of the HLA-A*010101 allele desig...        184       1219  \n",
       "941   Chronic myelomonocytic leukemia (CMML) is a my...        116        776  \n",
       "1057  As a result of chromosome translocations, the ...        207       1215  \n",
       "1154  Several studies indicated that the expression ...        341       2176  \n",
       "1286  Costello syndrome is a rare congenital disorde...        244       1692  \n",
       "1290  We report a 10-year-old girl presenting with s...        231       1668  \n",
       "1368  The activating E17K mutations recently discove...        448       2864  \n",
       "1378  The activating E17K mutations recently discove...        448       2864  \n",
       "1583  HEREDITARY nonpolyposis colorectal cancer (HNP...        114        742  \n",
       "1613  The case of a 40-year-old woman with severe ed...         53        337  \n",
       "1620  Background: von Hippel-Lindau (VHL) disease is...        431       2643  \n",
       "2146  Basal cell carcinoma (BCC) is the most common ...        212       1407  \n",
       "2504   Identification of protein-protein interaction...        230       1632  \n",
       "2900  Neurofibromatosis 2 (NF2) is a tumor predispos...        183       1219  \n",
       "2906  Neurofibromatosis 2 (NF2) is a tumor predispos...        183       1219  \n",
       "2908  Neurofibromatosis 2 (NF2) is a tumor predispos...        183       1219  \n",
       "2980  TO THE EDITOR: I commend Drs. Freeman and Bank...        362       2689  "
      ]
     },
     "execution_count": 280,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train_df[train_df[\"num_words\"]<500]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 276,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"Neurofibromatosis type 2 (NF2) is a multiple neoplasia syndrome and is caused by a mutation of the NF2 tumor suppressor gene that encodes for the tumor suppressor protein merlin. Biallelic NF2 gene inactivation results in the development of central nervous system tumors, including schwannomas, meningiomas, ependymomas, and astrocytomas. Although a wide variety of missense germline mutations in the coding sequences of the NF2 gene can cause loss of merlin function, the mechanism of this functional loss is unknown. To gain insight into the mechanisms underlying loss of merlin function in NF2, we investigated mutated merlin homeostasis and function in NF2-associated tumors and cell lines. Quantitative protein and RT-PCR analysis revealed that whereas merlin protein expression was significantly reduced in NF2-associated tumors, mRNA expression levels were unchanged. Transfection of genetic constructs of common NF2 missense mutations into NF2 gene-deficient meningioma cell lines revealed that merlin loss of function is due to a reduction in mutant protein half-life and increased protein degradation. Transfection analysis also demonstrated that recovery of tumor suppressor protein function is possible, indicating that these mutants maintain intrinsic functional capacity. Further, increased expression of mutant protein is possible after treatment with specific proteostasis regulators, implicating protein quality control systems in the degradative fate of mutant tumor suppressor proteins. These findings provide direct insight into protein function and tumorigenesis in NF2 and indicate a unique treatment paradigm for this disorder. Neurofibromatosis type 2 (NF2) is a multiple neoplasia syndrome with an incidence of 1 in 25,000 live births (1). It is the result of the mutation of the NF2 tumor suppressor gene that is on the long arm of chromosome 22 and can be inherited in an autosomal dominant manner. The NF2 gene encodes for the tumor suppressor protein merlin (69 kDa). Merlin indirectly regulates cellular pathways involved in tumorigenesis, including cell to cell adhesion, cytoskeletal architecture, and membrane protein organization (2â€“4). Decreased or absent merlin function in NF2 predisposes patients to develop a number of nervous system tumors, including bilateral vestibular schwannomas (over 90% of patients), other cranial nerve schwannomas (25â€“50%), meningiomas (50%), ependymomas (20â€“50%), and astrocytomas (5, 6). Missense mutations in the coding sequences of the NF2 gene occur in NF2. After biallelic inactivation, these and other types of NF2 gene mutations result in loss of merlin function, which underlies NF2-associated tumor development. Although a wide variety of missense mutations of the NF2 gene cause loss of merlin function, the cause of this functional loss remains unknown. Specifically, the ability of various different single nucleotide substitutions by missense mutations in the NF2 gene coding regions to give rise to similar manifestations of merlin function loss indicates that there may be a convergent effect of mutations on merlin protein. To gain insight into the mechanisms underlying loss of merlin function in NF2, we investigated mutated merlin homeostasis and function in NF2-associated tumors and cell lines. Results Quantitative Tumor Suppressor Protein Levels and mRNA Expression. To assess the levels of merlin expression in NF2 tumors, we quantitatively measured merlin expression in microdissected tumors from NF2 patients using Western blot analysis (Fig. 1A). Quantitative protein analysis revealed a significant reduction in merlin expression in NF2-associated meningiomas and schwannomas (95% reduction in merlin expression; seven tumors) compared with normal adjacent central nervous system tissue. Consistent with Western blot analysis of merlin expression in NF2- associated tumors, immunofluorescence in NF2-associated tumor specimens demonstrated an absence of merlin expression (Fig. 1B), with robust merlin expression in corresponding normal tissue in NF2 patients. Because NF2 mutations could affect associated merlin levels through either decreased mRNA and/or associated total protein levels, we measured mRNA transcript levels for merlin in multiple tumors from NF2 patients (five tumors from five patients). RT-PCR analysis revealed that NF2 mRNA encoding for merlin is expressed at the same levels in NF2-associated tumors compared with meningioma control cells without genetic mutations in the NF2 gene (Fig. 1C). The reduced merlin expression in the setting of normal mRNA expression levels in NF2-associated tumors suggests that inactivation of tumor suppressor function occurs as a result of an absolute decrease in merlin levels rather than a decrease in NF2 gene-encoded mRNA. Half-Life Reduction of Merlin in NF2 Tumor-Derived Mutants. Because NF2-associated functional loss of merlin appeared to occur at the protein level, we hypothesized that increased protein degradation underlies the net loss of function seen in NF2-associated tumors. To test this hypothesis, we investigated the stability of mutant and wild-type merlin. Because missense mutations occur and are well-characterized in NF2, we identified hotspot missense mutations (L46R, L141P, A211D, K413E, Q324L, and L535P) from patients with NF2 and inserted these coding sequences into pCMV6-Entry vectors. After transfection of these vectors into meningioma cell lines deficient in NF2 gene expression, we investigated protein stability using the [35S]-methionine mediated pulse chase assay to quantitatively identify half-life changes in newly synthesized mutant merlin (Fig. 2A). Consistent with effective mutant and wild-type protein translation, pulse chase analysis revealed that newly synthesized mutant and wild-type merlin exist in their full length immediately after pulse labeling and that there was no difference between mutant and wild-type merlin expression levels after initial transAuthor contributions: C.Y., A.R.A., Z.Z., and R.R.L. designed research; C.Y., R.R.I., D.S.X., and A.K. performed research; C.Y., A.R.A., R.R.I., J.L., R.O.B., Z.Z., and R.R.L. analyzed data; and C.Y., R.R.I., R.O.B., Z.Z., and R.R.L. wrote the paper. The authors declare no conflict of interest. 1 To whom correspondence may be addressed. E-mail: lonserr@ninds.nih.gov, zhuangp@ ninds.nih.gov, or bradyr@ninds.nih.gov. 4980â€“4985 | PNAS | March 22, 2011 | vol. 108 | no. 12 www.pnas.org/cgi/doi/10.1073/pnas.1102198108 lation. Over time, there was a marked reduction in labeled merlin expression compared with wild type, consistent with increased mutant merlin turnover and a reduced mutant merlin half-life compared with wild type (Fig. 2 B and C). Autoradiography and 35S liquid scintillation revealed that there was minimal reduction in wild-type merlin expression 6 h after labeling, but 24 h after labeling, the majority of the wild-type merlin was degraded, indicative of merlin turnover under normal conditions. Pulse chase analysis of mutant merlin revealed rapid degradation and a significantly decreased half-life compared with wild-type merlin. For example, in merlin mutant K413E, [35S]-merlin expression was found to be <50% of wild-type merlin 4 h after labeling. Kinetics of Merlin Degradation. To precisely determine differences between mutant and wild-type merlin half-life, we assessed the rate of degradation of wild-type and mutant merlin. Using an established exponential decay regression (7), merlin mutant halflives were significantly shorter (L46R t1/2, 1.8 h; L141P t1/2, 7.8 h; A211D t1/2, 2.2 h; Q324L t1/2, 3.3 h; K413E t1/2, 4.3 h) than that of wild-type merlin (t1/2, 14.6 h). Mutant Merlin Protein Maintains Intrinsic Functional Capacity. To determine if reduced merlin function in NF2 also results from impaired merlin functional capacity, we investigated whether mutant merlin maintains its functional capacity by reintroducing it into CH157 NM meningioma cells lacking analogous NF2 gene expression (8). Specifically, we measured the effects of mutant merlin transfection on cytoskeletal reorganization and growth control. Although merlin does not control cellular proliferation and differentiation directly, it affects these processes indirectly through interactions with cell membrane and cytoskeletal components. In particular, inactivation of NF2 protein causes abnormalities in intracellular filamentous actin (F-actin) organization and stress fiber formation, both of which are characteristics of meningiomas and schwannomas in NF2 patients, as well as the CH157 NM cell line (9, 10). Based on the well-described effects of merlin on cytoskeletal function, we initially tested mutant merlin function through its effects on F-actin. Consistent with previous findings (11), strong, bundle-like F-actin stress fiber formation occurred in tumor cells deficient in merlin protein. With the introduction of wild-type merlin into these cells, cytoskeletal abnormalities were eliminated. The bundle-like F-actin was eliminated from the cytoplasm and became localized adjacent to the plasma membrane. Similarly, the introduction of merlin mutants significantly reduced F-actin stress fiber formation. With this intervention, bundle-like F-actin also decreased and accumulated in the cytoplasm and on the plasma membrane. In particular, merlin mutant K413E was found at ruffled areas of cell membrane, suggesting its role in the regulation of membrane dynamics and motility (Fig. 3A). Next, we examined the effect of introducing mutant or wildtype merlin on cell to cell contact inhibition in NF2-deficient cells. Functional loss of merlin is also known to affect cellular contact inhibition, which may occur through Î²-catenin-mediated signaling pathways (12). Specifically, loss of merlin function results in down-regulation of Î²-catenin expression via cyclin D1- Fig. 1. Quantification of merlin protein and RNA expression. (A) Western blot of merlin proteins from various microdissected NF2-associated tumor samples. (B) Immunofluorescence staining for merlin (red) in tumor specimens and normal tissue derived from patients with NF2. The nuclei of cells are counterstained with Hoechst (blue). (C) RT-PCR for NF2 mRNA expression from various NF2-associated tumors. Fig. 2. Half-life kinetic analysis of reduction of mutant merlin proteins. (A) Radioactive 35S pulse chase assay of wild-type merlin and different merlin missense mutants at 0, 6, and 24 h demonstrating increased turnover and degradation of mutant merlin compared with wild-type control. (B) Radioactive 35S pulse chase assay at several time points (in hours) demonstrating the degradation kinetics of merlin mutant K413E compared with wild-type control. (C) Liquid scintillation measurement of 35S-labeled merlin demonstrating an increased degradation rate of K413E merlin mutant compared with wild-type control. Yang et al. PNAS | March 22, 2011 | vol. 108 | no. 12 | 4981 MEDICAL SCIENCES regulated pathways, which occurs in NF2-associated meningiomas and schwannomas (11, 13). To determine if wild-type or mutant merlin can maintain normal Î²-catenin regulation, we tested whether Î²-catenin and cyclin D1 expression were changed in CH157 NM cells after reintroduction of wild-type and mutant merlin. We found that with such intervention, both mutant and wild-type merlin up-regulated catenin expression and cyclin D1 expression. Further, this effect appears to be specific, because expression of upstream cadherins, including N- and VE-cadherin, remained unaffected with the introduction of mutant and wildtype merlin (Fig. 3B). Effect of Mutant Merlin on Tumor Growth. To determine whether transfected mutant merlin can regulate growth of meningioma cells, we performed an MTT proliferation assay on CH157 NM meningioma cell lines transfected with various merlin missense mutations (14). In cell lines transfected with wild-type merlin, cell growth was reduced by 31.4% compared with cell lines transfected with an empty control vector. Although not as effective as wild-type merlin, introduction of merlin mutants reduced cell growth from 14.6 to 24.9%, a significant effect compared with control (Fig. 3C). The effect of mutant merlin on cell growth was further assessed by cell cycle analysis using a BrdU incorporation assay. A reduction of 22.5% was found in the S-phase population of cells when wild-type merlin was introduced. When a similar analysis was performed using merlin mutants, L46R and A211D mutants reduced the S-phase population by 18.5 and 13.4%, respectively (Fig. 3D). These results indicate that merlin mutants maintain intrinsic tumor suppressor function. Mechanism of Merlin Degradation. It has previously been shown that truncated merlin protein products are degraded through ubiquitin-mediated proteasomal pathways (15). However, it remains unclear whether missense mutations in merlin result in accelerated degradation by similar mechanisms. To investigate the mechanism of degradation of merlin mutants, immunoprecipitated mutant merlin was probed with an antibody for ubiquitin. Based on Western blot analysis, there was a 42% increase in ubiquitylated merlin mutants compared with wild-type merlin protein (Fig. 3B). This finding suggests that missense merlin mutants are degraded by a ubiquitin-mediated proteasomal pathway, similar to the known mechanism of wild-type merlin turnover under normal conditions. Thus, deficiency of mutant merlin function in NF2 patients may be due to protein maturation effects resulting from changes in protein structure and conformation, with minimal effects due to changes in intrinsic protein function (16). Increased Merlin Expression after Treatment with Proteostasis Regulators.After determining that mutant merlin retains intrinsic tumor suppressor function and that NF2-related loss of merlin function is due to rapid degradation, we sought to investigate a potential treatment strategy that could reduce mutant protein degradation and minimize the effects of decreased tumor suppressor protein function. Specifically, we screened small molecule compounds known to modulate protein degradation and proteostasis. Among these compounds, two flavanoid compounds, celastrol and quercetin, were found to be effective in delaying merlin degradation. Pulse chase analysis demonstrated that celastrol and quercetin treatments both result in increased mutant merlin half-life (Fig. 4A). This result was confirmed by liquid scintillation analysis of radiolabeled merlin, which revealed an increase in proteasomal mutant merlin from 79.7 to 108.7 and 136.9 cpm (*P < 0.05, **P < 0.01) after treatment with celastrol and quercetin, respectively (Fig. 4B). Because celastrol had a potent effect on prolonging mutant merlin half-life at lower doses compared with quercetin, we further quantified the effect of celastrol treatment on mutant merlin degradation. Using nonlinear regression, the half-life of merlin mutant Fig. 3. Mutant merlin protein maintains intrinsic functional capacity. (A) Immunofluorescence staining for F-actin (green) and merlin mutants (red) in CH157 NM cells transfected with wild-type merlin, merlin mutants, as well as empty vector (blank). The nuclei of cells were counterstained with Hoechst (blue). Arrows point to F-actin stress fibers and arrowheads point to mutant merlin. (B) Western blot of lysates from CH157 NM cells transfected with either wild-type or K413E mutant merlin protein. K413E-transfected cells demonstrate increased merlin ubiquitylation and up-regulation of Î²-catenin and cyclin D1 cytoplasmic expression. (C) MTT proliferation assay demonstrating suppression of CH157 NM cell growth with mutant merlin transfection compared with empty vector (blank). (D) Flow cytometric BrdU-PI cell cycle analysis demonstrating reduced proliferation in CH157 NM cells transfected with L46R and A211D merlin mutants compared with wild type and empty vector (blank). 4982 | www.pnas.org/cgi/doi/10.1073/pnas.1102198108 Yang et al. Fig. 4. Increased cellular expression levels of mutant merlin protein after treatment with proteostasis regulators. (A) Radioactive 35S pulse chase assay demonstrating prolonged K413E merlin mutant protein half-life with celastrol and quercetin treatment. (B) 35S liquid scintillation measurement demonstrating a quantitative decrease in K413E mutant merlin degradation rate with celastrol and high dose quercetin treatment. (C) Radioactive 35S pulse chase assay at several time points (in hours) demonstrating the degradation kinetics of merlin mutant K413E before and after treatment with celastrol compared with wild type. (D) 35S liquid scintillation measurement at several time points (in hours) demonstrating the degradation kinetics of mutant merlin K413E before and after treatment with celastrol compared with wild-type control. (E) Western blot of lysates from CH157 NM cells transfected with merlin mutant K413E before and after celastrol treatment, demonstrating decreased ubiquitin binding, increased Hsp70 and TCP1 binding to immunoprecipitated merlin protein, as well as decreased Î²-catenin expression after celastrol treatment. (F) Flow cytometric analysis of CH157 NM cells transfected with K413 mutant merlin demonstrating decreased cell proliferation after treatment with celastrol. (G) Immunofluorescence staining for F-actin (green) and merlin K413E mutant protein (red) in CH157 NM cells before and after celastrol treatment. The nuclei of cells are counterstained with Hoechst (blue). Yang et al. PNAS | March 22, 2011 | vol. 108 | no. 12 | 4983 MEDICAL SCIENCES K413E was found to increase from 3.7 to 5.5 h after celastrol treatment. These results indicate that modulation of proteostasis and proteosomal degradation pathways can increase mutant merlin half-life and decrease its degradation (Fig. 4 C and D). Posttranslational interactions of nascent proteins include those with important mediators of the protein folding and maturation process. To better define the molecular interactions of mutant merlin in the posttranslational period and to further elucidate pathways of merlin degradation, we assessed the levels of known mediators of such processes before and after celastrol treatment. Immunoprecipitated mutant merlin protein treated with celastrol was found to have decreased binding to ubiquitin and increased binding to heat shock protein 70 (Hsp70) and Tcomplex protein 1 (TCP1) (Fig. 4E), two well-accepted mediators of protein folding and maturation (17, 18). The effect of celastrol on tumor suppressor protein functional recovery is evidenced by an increase in mutant merlin expression levels and reduced cell proliferation, Î²-catenin expression, and F-actin stress fiber formation (Fig. 4 F and G). These results indicate that celastrol prolongs merlin mutant half-life, likely through its effects on mutant protein binding with important mediators of the protein folding and maturation process. Discussion Although Knudsenâ€™s two-hit model of tumorigenesis describes the genetic mechanism that underlies inherited neoplastic syndromes (19, 20), the specific pathogenic mechanisms underlying functional loss of gene-specific translated proteins are not known. Despite variable mutations in the NF2 tumor suppressor gene, biallelic loss of this gene results in the loss of merlin function (tumor suppressor protein encoded by the NF2 gene). The loss of merlin function in NF2 results in dysregulation of cellular growth control pathways and uncontrolled cellular proliferation, which gives rise to tumors of the nervous system. To gain insight into mechanisms of merlin functional loss in NF2, we investigated pathways that mediate mutant merlin function, quality control, and degradation. After determining that accelerated protein degradation underlies the loss of mutant merlin function, we identified potential modifiers of merlin degradation pathways that could serve as putative therapeutics in NF2. To assess whether reduced merlin underlies its functional loss in NF2, we analyzed merlin expression levels in tumors (meningiomas and schwannomas) from NF2 patients. Western blot analysis revealed that there was a significant decrease (95% reduction in meningiomas and schwannomas) in the quantity of merlin across all samples compared with controls. Immunofluorescence underscored these quantitative results and demonstrated the absence of merlin in NF2-associated tumors. These findings are consistent with results from previous work examining the qualitative expression pattern of merlin in tumors from NF2 patients (21). Although these data indicate that reduced expression or increased degradation could underlie tumor formation in NF2, the potential mechanisms that underlie quantitative loss of merlin in NF2 were unknown. To determine the cause of underlying quantitative decreases in expression and function of mutant merlin in NF2, we investigated possible mechanisms, including altered gene transcription, abnormal protein translation, and reduced stability of mutant merlin products. Consistent with intact NF2 gene transcription, RT-PCR analysis of NF2-associated tumors demonstrated that NF2 gene mRNA expression levels were similar to those in control cells. Evidence of effective translation was established by pulse chase analysis, which revealed that successful translation of both mutant and wild-type merlin occurs. Whereas evidence of effective transcription and translation of mutant merlin was demonstrated, pulse chase analysis revealed a reduction in mutant merlin half-life across all mutations, which was found to be 2â€“4 times shorter than that of wild-type merlin. Additionally, increased ubiquitylation of mutant merlin occurred, which suggests that reduced merlin expression in NF2-associated tumors is the result of enhanced degradation through previously described ubiquitin-mediated merlin degradation pathways (7). To determine whether reduced total mutant merlin function results from impaired intrinsic function in addition to enhanced degradation, we introduced plasmid vectors containing common NF2 missense mutations (22, 23) into a meningioma cell line lacking the NF2 gene. Reintroduction of wild-type or mutant merlin genes in this cell line reversed previously described effects of NF2 deficiency (i.e., abnormalities in intracellular F-actin organization, stress fiber formation, reduced cell to cell contact inhibition, and increased cell proliferation). Specifically, introduction of mutant or wild-type NF2 genes resulted in normalization of the cytoskeleton, including reduction of F-actin stress-fiber formation (11) and restoration of cell to cell contact inhibition. Moreover, incorporation of mutant or wild-type NF2 genes led to a reduction in the S-phase population of cells, indicating a reduction in the proliferative and mitotic capacity. These changes in cell cycle were validated by a reduction in the proliferation of meningioma cells transduced with mutant and wild-type merlin vectors compared with empty vector controls. Taken together, the preceding results suggest that missense mutations in the NF2 gene encode for mutant merlin that is functionally competent and that intrinsic mutant merlin functional loss does not underlie the pathogenesis of NF2 tumor formation. Rather, enhanced degradation of mutant forms of merlin may in fact underlie the pathogenesis of NF2. These findings provide potential insight into the clinical findings associated with NF2. Specifically, variations in missense mutations resulting in a spectrum of mutant merlin proteins with different degradation rates (as demonstrated by pulse chase and scintillation analyses) may underlie the variable severity of NF2 clinical manifestations and/or the variability of growth patterns associated with NF2-associated tumors. A similar mechanism of protein loss underlies the pathogenesis and disease severity described in Gaucher disease patients in which enzyme quantity, rather than function, was decreased in patients with this heritable neurological disorder (17). The finding that amino acid substitutions in mutant merlin result in quantitative reductions in protein expression, rather than intrinsic functional changes, suggests that NF2 missense mutations result in altered protein stability and implicates a protein quality control pathway through which such mutant merlin is detected and degraded within cells. Acceleration of these degradative pathways with missense merlin mutants may occur as a result of protein misfolding, a concept supported by previous work examining the crystal structure of merlin; results from this study demonstrated accelerated degradation of missense merlin mutants, such as L64P, that have altered secondary and tertiary protein structure and may thus lead to improper protein folding (24). Also consistent with the idea of increased degradation of mutant merlin by protein quality control pathways, the application of proteostasis regulators (celastrol and quercetin) signifi- cantly increased merlin half-life. The results of this study have implications for both diagnostics and therapeutics for NF2 and, potentially, other heritable tumor suppressor syndromes. Current molecular diagnostics are aimed at detecting gene mutations and loss of heterozygosity in tumor suppressor genes, which largely rely on the comparison of singlenucleotide polymorphisms of different alleles using a relatively large quantity of tumor sample as well as patient-matched normal control tissue. The current results suggest that a tumor suppressor protein quantification assay might be of greater utility in the diagnosis of the disease and in the prediction of disease severity. Further, because manipulation of protein quality control pathways using proteostasis regulators results in increased expression of functional mutant tumor suppressor protein, spe- 4984 | www.pnas.org/cgi/doi/10.1073/pnas.1102198108 Yang et al. cific molecular mediators involved in these pathways may provide a unique treatment paradigm for NF2 and other similar disorders.  Current models imply that the FERM domain protein Merlin, encoded by the tumor suppressor NF2, inhibits mitogenic signaling at or near the plasma membrane. Here, we show that the closed, growth-inhibitory form of Merlin accumulates in the nucleus, binds to the E3 ubiquitin ligase CRL4DCAF1, and suppresses its activity. Depletion of DCAF1 blocks the promitogenic effect of inactivation of Merlin. Conversely, enforced expression of a Merlin-insensitive mutant of DCAF1 counteracts the antimitogenic effect of Merlin. Re-expression of Merlin and silencing of DCAF1 implement a similar, tumor-suppressive program of gene expression. Tumor-derived mutations invariably disrupt Merlin's ability to interact with or inhibit CRL4DCAF1. Finally, depletion of DCAF1 inhibits the hyperproliferation of Schwannoma cells from NF2 patients and suppresses the oncogenic potential of Merlin-deficient tumor cell lines. We propose that Merlin suppresses tumorigenesis by translocating to the nucleus to inhibit CRL4DCAF1.  Graphical Abstract  Image for unlabelled figure Figure options Highlights  â–º The tumor suppressor Merlin inhibits the E3 ligase CRL4DCAF1 in the nucleus â–º CRL4DCAF1 induces an oncogenic program of gene expression â–º Tumor-derived mutations disrupt Merlin's ability to bind and/or suppress CRL4DCAF1 â–º DCAF1 silencing suppresses the oncogenic potential of Merlin-deficient cells  Author Keywords SIGNALING; HUMDISEASE Introduction The tumor suppressor NF2, which is inactivated in the familial cancer syndrome Neurofibromatosis type 2, encodes for Merlin, a member of the Ezrin/Radixin/Moesin (ERM) family of proteins. The prevalence of NF2 mutations in sporadic tumors, especially Schwannomas, meningiomas, and malignant mesotheliomas, and the predisposition of heterozygous Nf2 mutant mice to develop multiple malignant tumor types suggest that Merlin has a relatively broad tumor-suppressor function ( McClatchey and Giovannini, 2005 ;  Okada et al., 2007). Despite extensive research on Merlin's role as a tumor suppressor, its biological function remains poorly understood.  Classical ERM proteins, which consist of an N-terminal FERM domain, a coiled-coil domain, and a C-terminal segment containing an actin-binding motif, switch between a closed conformation, presumed dormant, and an open conformation, which mediates linkage of certain cell adhesion receptors to the actin cytoskeleton (Bretscher et al., 2002). The sequence homology of Merlin to ERM proteins and its apparently prevalent localization to the cortical cytoskeleton have led to the hypothesis that Merlin functions at or near the plasma membrane to inhibit the transmission of promitogenic signals (McClatchey and Fehon, 2009). However, Merlin does not contain a canonical actin-binding motif. In addition, it is the closed form of Merlin that suppresses tumorigenesis and is thereby considered â€œactive.â€� In fact, many tumor-derived missense mutations are predicted to disrupt the closed conformation (Okada et al., 2007).  The interconversion between the closed and the open form of Merlin is promoted by the p21-activated kinase PAK, which phosphorylates Merlin at S518, disrupting the intramolecular C-terminal tail-FERM interaction, which maintains the protein in the closed conformation (Kissil et al., 2002 ;  Xiao et al., 2002). Cadherin-mediated adhesion inhibits PAK, causing an accumulation of the dephosphorylated, growth-inhibitory form of Merlin. Conversely, integrin-dependent adhesion to the matrix activates PAK, causing inactivation of Merlin and, thereby, presumably removing a block to cell-cycle progression (Okada et al., 2005). Accordingly, inactivation of Merlin induces exit from contact inhibition (Lallemand et al., 2003; Lallemand et al., 2009 ;  Okada et al., 2005) and accelerates progression through the G1 phase of the cell cycle (LÃ³pez-Lago et al., 2009). These results suggest that Merlin integrates antithetic signals from cadherins and integrins to regulate cell-cycle progression.  Merlin exerts inhibitory effects on multiple mitogenic signaling pathways. The closed form of Merlin suppresses the recruitment of Rac to the plasma membrane and the activation of PAK (Kaempchen et al., 2003; Kissil et al., 2003 ;  Okada et al., 2005) and inhibits the activation of mTORC1 independently of Akt (James et al., 2009 ;  LÃ³pez-Lago et al., 2009). Furthermore, Merlin inhibits the Ras-ERK and PI-3K-Akt pathways and focal adhesion kinase (FAK)-Src signaling (Ammoun et al., 2008; Jin et al., 2006a; Poulikakos et al., 2006 ;  Rong et al., 2004). Finally, Merlin cooperates with the related ERM protein Expanded to activate the Hippo tumor-suppressor pathway in Drosophila ( Cho et al., 2006 ;  Hamaratoglu et al., 2006). However, the contribution of each of the identified pathways to NF2-dependent tumorigenesis has not been defined.  Although yeast two-hybrid screens and other approaches have led to the identification of several Merlin-binding proteins, the biochemical function of Merlin and, hence, the mechanism through which it suppresses tumorigenesis have remained elusive. This study shows that the closed form of Merlin enters the nucleus, binds to the E3 ubiquitin ligase CRL4DCAF1, and inhibits its activity. Genetic evidence indicates that this inhibitory interaction is essential for tumor suppression.  Results The Closed Form of Merlin Binds to DCAF1, the Substrate Receptor of the E3 Ubiquitin Ligase CRL4DCAF1  Tandem affinity purification (TAP) revealed that Merlin, tagged at either its N or its C terminus, associates with proteins displaying an apparent molecular weight of 169 kD and 127 kD (Figure 1A). The two proteins were recovered in similar amounts, each at an apparent ratio of âˆ¼1:5 to Merlin. Importantly, the tumor-derived mutant L64P, which lacks tumor-suppressor activity (Gutmann et al., 2001), did not associate with these proteins (Figure 1A). MALDI-reTOF-MS followed by peptide mass fingerprinting and mass spectrometric sequencing unequivocally identified the 127kD protein as DDB1 (DNA Damage-Binding protein 1) and the 169 kD protein as DCAF1 (DDB1-and Cul4-Associated Factor 1) ( Figure 1A). NanoLC-MS/MS indicated that wild-type Merlin, but not Merlin-L64P, interacts also with Cul4B, albeit at a lower apparent stoichiometry (Table S1 available online).  Merlin Associates with CRL4DCAF1 in the Nucleus(A) Cos7 cells were transfected ... Figure 1.  Merlin Associates with CRL4DCAF1 in the Nucleus (A) Cos7 cells were transfected with the indicated FH-tagged (FH; FLAG-HA) forms of Merlin, lysed in RIPA, and subjected to TAP. Proteins were separated by SDS-PAGE and stained with Colloidal Blue. Dots point to the FH-tagged baits and asterisks to the 169 and 127 kD bands identified by mass spectrometry as DCAF1 and DDB1, respectively. (B) 293T cells were transfected with FH-DCAF1 or empty vector. Total lysates and Flag immunoprecipitates (M2) were subjected to immunoblotting with antibodies to the indicated proteins. (C) As in (B), with transfection of the indicated constructs and immunoprecipitation with anti-FLAG (M2) or control (C) antibodies. (D) As in (B), with cotransfection of Myc-Merlin or empty vector and immunoprecipitation with anti-FLAG (M2) or control (C). To control for the specificity of the anti-P-Merlin antibodies, the indicated sample was treated with calf intestinal alkaline phosphatase (CIP) prior to SDS-PAGE. Endogenous Merlin was detected upon longer exposure. (E) Meso-33 cells were transiently transfected with the indicated constructs and subjected to double-immunofluorescent staining with anti-HA and anti-Myc followed by DAPI. (F) HeLa cells were infected with lentiviral vectors encoding a shRNA targeting Merlin or a control shRNA and subjected to immunoblotting (left) or staining with affinity-purified antibodies to the N-terminal segment of Merlin followed by DAPI (right). (G) The indicated cells were stained as in (F). (H) MCF-10A cells were subjected to subcellular fractionation. Equal amounts of proteins from the nuclear (NF) and nonnuclear (CM; cytosol + crude membranes) fraction were subjected to immunoblotting with antibodies to the indicated proteins. (I) Equal amounts of proteins from the nonnuclear (CM) and nuclear-soluble (NS) fraction of HeLa cells and Merlin immunoprecipitates were immunoblotted as indicated. Anti-Cul4 recognizes Cul4-A as well as a higher molecular weight band, possibly corresponding to neddylated Cul4-A or Cul4-B (asterisk). See also Figure S1. Figure options Prior studies have established that DDB1 functions as a SKP1-like adaptor to recruit WD40 domain-containing substrate receptors, such as DDB2, CSA (the Cockayne syndrome protein A), and Det1-COP1 to the E3 ligase Cul4-Roc1 (Lee and Zhou, 2007, and references therein; O'Connell and Harper, 2007, and references therein). DCAF1, which was originally identified as the cellular receptor for the HIV protein Vpr and designated VprBP, is one of several additional WD40 domain substrate receptors able to combine with DDB1 to mediate assembly of distinct Cul4 (CRL4) ligases (Lee and Zhou, 2007). In agreement with the mass spectrometric analysis, immunoblotting indicated that FH-Merlin combines with DCAF1, DDB1, and Cul4, but not DYRK2 or EDD (Figure 1B), components of the alternative EDD-DYRK2-DDB1-VprBP E3 ligase complex (Maddika and Chen, 2009). These observations indicate that Merlin interacts selectively with the E3 ligase CRL4DCAF1.  Since Merlin formed a stoichiometric complex with DCAF1 but not DDB1 upon cotransfection in Cos7 cells (Figure S1A), we hypothesized that Merlin binds directly to DCAF1 but indirectly to DDB1. To test this hypothesis, we examined the ability of GST-fusion proteins comprising either the FERM or the helical and C-terminal domain of Merlin to bind to in vitro translated DCAF1 or DDB1. As shown in Figure S1B, the FERM domain of Merlin bound directly to DCAF1 but not DDB1, whereas the helical and C-terminal segments did not (Figure S1B). Thus, Merlin binds directly, through its FERM domain, to DCAF1.  Related to Figure 1(A) Cos7 cells were transfected with HA-Merlin in combination ... Figure S1.  Related to Figure 1 (A) Cos7 cells were transfected with HA-Merlin in combination with FH-DCAF1 or FH-DDB1, immunoprecipitated with anti-Flag (M2) or control (nMIgG) antibodies, and immunoblotted with anti-HA. Total lysates were also subjected to immunoblotting. (B) TNT-translated and biotinylated DCAF1 was subjected to pull down with GST fusion proteins comprising the Î±-helical and C-terminal domain (GST-CTerm) or the FERM domain of Merlin (GST-FERM). An aliquot of TNT-DCAF1 was run as a control (left). TNT-translated and biotinylated DDB1 and DCAF1 were subjected to pull down with a GST fusion protein comprising the FERM domain of Merlin (GST-FERM) or with GST alone. Aliquots of TNT-DDB1 and TNT-DCAF1 were run as controls (right). Blots were stained with Ponceau and reacted with peroxidase-conjugated Streptavidin. (C) Meso-33 cells were transiently transfected with moderate amounts of HA-Merlin and subjected to subcellular fractionation. Equal amounts of proteins from the nuclear (NF) and non-nuclear (CM; cytosol + crude membranes) fractions were subjected to immunoblotting with antibodies to the indicated proteins. (D) MCF-10A cells were infected with lentiviral vectors encoding a shRNA targeting Merlin or a control shRNA and stained with affinity-purified antibodies to the C terminus of Merlin. Nuclei were labeled by DAPI. The efficiency of silencing was verified by immunoblotting (lower right panel). (E) The indicated cells were subjected to staining with anti-Merlin as above and counterstained with DAPI. (F) The indicated cells were subjected to subcellular fractionation as described above. Figure options To examine whether the conformational transition between the open and the closed form regulates Merlin's binding to CRL4DCAF1, we tested the behavior of two well-characterized phosphorylation mutants. Merlin-S518A, which cannot be phosphorylated at S518 and is stabilized in the closed conformation, associated efficiently with DCAF1 and DDB1 in transfected 293T cells. In contrast, the phosphorylation site mimetic mutant Merlin-S518D, which is thought to maintain an open conformation, displayed dramatically diminished binding to DCAF1 and DDB1 (Figure 1C). As anticipated, Ezrin and Merlin-L64P exhibited essentially no binding in this assay. In agreement with the model that the closed form of Merlin selectively interacts with CRL4DCAF1, immunoblotting with anti-P-Merlin antibodies indicated that the fraction of recombinant Merlin bound to FH-DCAF1 is not detectably phosphorylated at S518 (Figure 1D). Thus, the unphosphorylated, closed form of Merlin interacts specifically with CRL4DCAF1, whereas the open form and a well-characterized tumor-derived mutant do not, raising the possibility that Merlin suppresses cell proliferation and tumorigenesis by binding to CRL4DCAF1.  Merlin Associates with CRL4DCAF1 in the Nucleus  To identify the cellular compartment where Merlin interacts with CRL4DCAF1, we cotransfected Myc-tagged DCAF1 and HA-tagged Merlin into Merlin-deficient Meso-33 mesothelioma cells. These cells undergo growth arrest following re-expression of Merlin and therefore represent an excellent model to study the tumor-suppressor function of Merlin (see below). Immunofluorescent staining indicated that Myc-DCAF1 localizes in the nucleus in Meso-33 cells (Figure 1E), suggesting that CRL4DCAF1 functions in this compartment like other CRL4 ligases (Lee and Zhou, 2007 ;  O'Connell and Harper, 2007). Interestingly, in addition to localizing underneath the plasma membrane, HA-Merlin also accumulated in the nucleus (Figure 1E). Subcellular fractionation confirmed these results (Figure S1C).  We reasoned that poor permeabilization of the nuclear membrane or epitope masking may have hampered detection of Merlin in the nucleus in previous immunofluorescence studies (with the exception of Muranen et al., 2005). To study the localization of endogenous Merlin, we designed a fixation and permeabilization protocol able to circumvent these potential problems (see the Experimental Procedures). Using this protocol, we found that a monospecific antibody to the N-terminal segment of Merlin generates prominent nuclear staining in multiple cell types, including HeLa squamous carcinoma cells and nonneoplastic HEI286 Schwann cells, LP9 mesothelial cells, and MCF-10A mammary epithelial cells (Figures 1F and 1G). This pattern of staining was specific because it was suppressed by silencing of Merlin (Figure 1F) and could be reproduced by using an antibody to a C-terminal epitope (Figures S1D and S1E). Finally, biochemical fractionation confirmed that Merlin and DCAF1 accumulate in the nucleus in multiple cell types (Figure 1H and Figure S1F). Thus, Merlin can enter the nucleus and bind to DCAF1.  Many CRL4 ligases associate with DNA or chromatin during the cell cycle or in response to DNA damage (O'Connell and Harper, 2007). However, subnuclear fractionation indicated that both DCAF1 and Merlin accumulate in the soluble nuclear fraction and do not move into the chromatin fraction during cell-cycle progression or in response to UV-induced DNA damage (W.L. and F.G.G., unpublished data), consistent with the hypothesis that CRL4DCAF1 performs a function distinct from that of other known CRL4 ligases. Interestingly, coimmunoprecipitation analysis showed that Merlin combines with DCAF1, DDB1, and Cul4 in the soluble nuclear fraction, but not in the nonnuclear fraction, despite the presence of abundant amounts of these components (Figure 1I). This suggests that association with a cofactor, dissociation of an inhibitor, or a posttranslational modification occurring in the nucleus promote the association of Merlin with CRL4DCAF1. Taken together, these results indicate that the closed, growth-inhibitory form of Merlin binds to CRL4DCAF1 in the nucleus.  Merlin Is Not a Substrate of CRL4DCAF1  Constitutively activated Akt can promote phosphorylation and proteasome-mediated degradation of Merlin (Tang et al., 2007), and overexpression studies have suggested that CRL4DCAF1 mediates this process (Huang and Chen, 2008). However, experiments with Cycloheximide indicated that Merlin exhibits a half-life far exceeding 24 hr in several cell types (Figure S2A). In addition, treatment with the proteasome inhibitor MG132 did not stabilize recombinant Merlin in Cos7 cells, and Merlin-S518D and Merlin-L64P, which do not interact with CRL4DCAF1, did not display increased stability in this assay (Figure S2B). Finally, knockdown of DCAF1 did not cause increased accumulation of Merlin in multiple cell types under standard culture conditions, or in HeLa cells acutely exposed to mitogens (Figures S2C and S2D). In fact, depletion of DCAF1 decreased the levels of Merlin, especially shortly after mitogenic stimulation, suggesting that binding to DCAF1 stabilizes Merlin (Figure S2D). These results argue that Merlin is not targeted for degradation by CRL4DCAF1 and suggest that Merlin functions upstream, not downstream, of CRL4DCAF1.  Related to Figure 2(A) Cells were treated with 75 Î¼g/ml Cycloheximide for the ... Figure S2.  Related to Figure 2 (A) Cells were treated with 75 Î¼g/ml Cycloheximide for the indicated times and subjected to immunoblotting as indicated. (B) Cos7 cells transiently transfected with HA-Merlin or the indicated mutants were treated for 6 hr with 25 Î¼M MG132 and subjected to immunoblotting with the indicated antibodies. (C) Cells were infected with a shRNA targeting DCAF1 or a control shRNA and subjected to immunoblotting. (D) HeLa cells infected with lentiviruses encoding a control shRNA (sh-Contr.) or a shRNA targeting DCAF1 (sh-DCAF1) were starved for 48 hr, restimulated with 10% serum for the indicated times, and subjected to immunoblotting. (E) Total lysates from the samples of Figure 2A (left), 2C (middle), and 2D (right) were blotted to verify expression levels. (F) TNT-translated and biotinylated DCAF1 and the indicated mutants were subjected to pull down with GST-FERM. Aliquots of input TNT-proteins and the GST-FERM bound fractions were blotted with peroxidase-conjugated Streptavidin. Staining with Ponceau was used to verify levels of GST-FERM in each sample. (G) Cos7 cells were transfected with FH-DCAF1 or the indicated mutants in combination with Myc-DDB1 and HA-Merlin. Anti-Flag (M2) or control Mab (C) precipitates and total lysates were immunoblotted as indicated. (H) Cos7 cells were infected with lentiviruses encoding a control shRNA (Co.) or a shRNA targeting Merlin (Mer.) and then transfected with FH-DCAF1 and Myc-Ubiquitin plus HA-Merlin (HA-Mer.), HA-Ezrin (HA-Ezr.), or empty vector (V). Lysates were immunoblotted to verify knock down and expression levels. (I) Samples from H were immunoprecipitated with anti-Flag and immunoblotted as indicated. Figure options Merlin Inhibits CRL4DCAF1  To examine the effect of Merlin on the ubiquitylating activity of CRL4DCAF1, we set up an in vivo ubiquitylation assay. Cos7 cells were transfected with FH-DCAF1 and Myc-ubiquitin, treated with MG132 to stabilize ubiquitylated products, and immunoprecipitated with anti-Flag to isolate CRL4DCAF1 and associated ubiquitylated products. Immunoblotting with anti-Myc antibody revealed that FH-DCAF1 isolated from MG132-treated cells coprecipitates with ubiquitylated species of apparent molecular weight ranging from 55 to 300 kD, suggesting that CRL4DCAF1 ubiquitylates in vivo one or more substrates and that these remain associated with the enzyme throughout immunoprecipitation (Figure 2A, left). In contrast, FH-DCAF1 isolated from untreated cells contained a modest amount of ubiquitylated species of apparent molecular weight ranging from 180 to 250 kD. Cotransfection of increasing concentrations of HA-Merlin caused a dose-dependent suppression of the accumulation of ubiquitylated products, suggesting that Merlin suppresses the ubiquitylating activity of CRL4DCAF1 (Figure 2A left). Immunoblotting with anti-HA antibody indicated that Merlin does not become ubiquitylated upon association with DCAF1, consistent with the notion that Merlin is a regulator and not a substrate of the ligase (Figure 2A right). Immunoblotting of total lysates provided a control for the expression levels of recombinant proteins and indicated that treatment with MG132 partially stabilizes DCAF1 (Figure S2E). These observations suggest that Merlin binds to CRL4DCAF1 and suppresses its ability to mediate ubiquitylation of target proteins.  Merlin Inhibits CRL4DCAF1-Dependent Ubiquitylation(A) Cos7 cells were ... Figure 2.  Merlin Inhibits CRL4DCAF1-Dependent Ubiquitylation (A) Cos7 cells were transfected with 3 Î¼g FH-DCAF1 and 2 Î¼g Myc-Ubiquitin in combination with the indicated amounts of HA-Merlin and treated with MG132 or left untreated. Flag or control immunoprecipitates (M2 and C, respectively) were subjected to immunoblotting with anti-Myc to visualize ubiquitylated proteins (left) or anti-HA to visualize DCAF1 and Merlin (right). Upper arrow points to DCAF1 and lower arrow to Merlin. (B) Cos7 cells were transfected with FH-DCAF1 or FH-DCAF1 (1â€“1417) in combination with HA-Merlin (top panel) or HA-Vpr (bottom panel). Flag or control immunoprecipitates were subjected to immunoblotting. Levels of expression of DCAF1, DDB1, and Merlin or Vpr were verified by immunoblotting aliquots of total lysates. (C) As in (B), with cotransfection of Myc-Ubiquitin and treatment or not with MG132. Flag or control immunoprecipitates were immunoblotted with anti-Myc (left) or anti-HA (right). (D) Cos7 cells stably infected with lentiviral vectors encoding a control shRNA or a shRNA targeting Merlin were subjected to immunoblotting (left) or transfected with FH-DCAF1 and Myc-Ubiquitin followed by immunoblotting of Flag or control immunoprecipitates with anti-Myc (middle) or anti-HA (right). (E) Hypothetical model of Merlin-mediated inhibition of CRL4DCAF1. Merlin is proposed to function as a competitive inhibitor of CRL4DCAF1. Blue hexagons, three Î² propeller folds of DDB1, which contact Cul4 (B) and DCAF1 (A and C); yellow hexagon, WD40 domain of DCAF1; yellow sticks, double DxR box implicated in binding to DDB1; S, substrate; Ub, ubiquitin; Mer, closed Merlin. See also Figure S2. Figure options To confirm this hypothesis, we examined whether a mutant form of DCAF1 unable to bind to Merlin mediates enhanced CRL4DCAF1 ligase activity in cells expressing endogenous Merlin. Deletion mapping indicated that the GST-FERM domain of Merlin binds directly to a 90 aa C-terminal segment of DCAF1 in vitro (Figure S2F). Immunoprecipitation experiments confirmed that DCAF1 (1â€“1417) lacking this C-terminal segment combines with endogenous DDB1 but not with HA-Merlin in Cos7 cells (Figure 2B). Interestingly, this mutant retained the ability to interact with the HIV protein Vpr (Figure 2B), suggesting that it is not grossly misfolded and indicating that Merlin and Vpr bind to distinct sites on DCAF1. In addition, mutation of the double DxR box on the bottom surface of the WD40 propeller fold of DCAF1 (R1247/1283A) disrupted the association of DCAF1 with DDB1, as previously reported (Jin et al., 2006b), but not with Merlin (Figure S2G), indicating that distinct segments of DCAF1 mediate interaction with DDB1 and with Merlin. Notably, in vivo ubiquitylation assays revealed that ligase complexes containing DCAF1 (1â€“1417) exhibit higher apparent enzymatic activity than those containing wild-type DCAF1 in Cos7 cells (Figure 2C). Pretreatment with MG132 caused a large increase in the activity of CRL4 containing wild-type DCAF1 but had only a small effect on CRL4 containing DCAF1 (1â€“1417) (Figure 2C and Figure S2E), suggesting that the latter is a more potent E3 ligase. These results suggest that deletion of the Merlin binding segment of DCAF1 leads to constitutive activation of CRL4DCAF1, consistent with the notion that Merlin inhibits the E3 ligase activity.  Finally, we tested the effect of depletion of Merlin on CRL4DCAF1 activity. Cos7 cells were infected with lentiviruses encoding a control short hairpin RNA (shRNA) or a shRNA targeting Merlin and then subjected to in vivo ubiquitylation assay. The results indicated that depletion of Merlin causes a significant increase in CRL4DCAF1 ligase activity (Figure 2D). The effect of the shRNA targeting Merlin was specific, because it was suppressed by overexpression of HA-Merlin but not of HA-Ezrin, which does not associate with FH-DCAF1 (Figures S2H and S2I). Together, the results of positive expression, mutational activation, and depletion provide compelling evidence that Merlin functions as a negative regulator of CRL4DCAF1 (see Figure 2E for a hypothetical model).  CRL4DCAF1 Mediates the Hyperproliferation Caused by Inactivation of Merlin  Recent studies have implicated CRL4DCAF1 in DNA replication and progression through the G2 phase of the cell cycle (Hrecka et al., 2007 ;  McCall et al., 2008). To examine whether Merlin suppresses cell proliferation by inhibiting CRL4DCAF1, we silenced DCAF1 in NF2 mutant Meso-33 mesothelioma cells using a smart pool of small interfering RNAs (siRNAs) ( Figure S3A). Since loss of Merlin promotes progression through G1 (LÃ³pez-Lago et al., 2009), we examined whether loss of DCAF1 affects this specific phase of the cell cycle. BrdU incorporation experiments revealed that depletion of DCAF1 inhibits the ability of G0 synchronized Meso-33 cells to progress through G1 and enter S phase in response to mitogens (Figure 3A). Deconstruction of the smartpool indicated that each individual siRNA in the pool was able to inhibit expression of DCAF1 and cell proliferation, as expected from specific inhibition (Figures S3B and S3C). In contrast, silencing of DCAF1 exerted a moderate growth inhibitory effect in normal mesothelial Met-5A cells (Figure 3B and Figure S3D), suggesting that Merlin-deficient cells are more sensitive to inactivation of DCAF1 than their normal counterpart.  Related to Figure 3(A) Meso-33 were transfected with a SMARTpool of siRNAs ... Figure S3.  Related to Figure 3 (A) Meso-33 were transfected with a SMARTpool of siRNAs targeting the adaptor protein AP3Î², DCAF1, or a control non-targeting pool and subjected to Q-PCR to verify knock down of DCAF1. (B) Meso-33 cells were transfected with 75 pmol of a control siRNA or each of four siRNAs targeting DCAF1 and subjected to Q-PCR as above. (C) Meso-33 cells treated as above were deprived of growth factors, incubated with BrdU in the presence of mitogens for 24 hr, and subjected to anti-BrdU staining. The graph indicates the percentage (+ SEM) of BrdU-positive cells. (D) Met-5A cells were transfected with a SMARTpool of siRNAs targeting the adaptor protein AP3Î², DCAF1, or a control non-targeting pool and subjected to Q-PCR to verify knock down of DCAF1. (E) Meso-33 cells were infected with lentiviral constructs encoding a control shRNA (sh-control) or a shRNA targeting DCAF1 (sh-DCAF1). Meso-33 cells expressing sh-DCAF1 were also infected with a CMV-based lentiviral vector encoding a shRNA-resistant form of DCAF1 (CMV-DCAF1) or a LTR-based retroviral vector encoding a shRNA-resistant form of DCAF1 (LTR-DCAF1). Cells were lysed and equal amounts of total proteins were subjected to immunoblotting with antibodies reacting with DCAF1, phospho-RB and Î²-actin (left) or they were deprived of growth factors, detached, plated on fibronectin-coated coverslips in complete medium with BrdU for 24 hr, and stained with anti-BrdU. The graph indicates the percentage (+ SEM) of BrdU-positive cells. (F) FH-912 and FC-1801 cells were infected with lentiviruses encoding a control shRNA (sh-control) or a shRNA targeting DCAF1 (sh-DCAF1). Cell were lysed and subjected to immunoblotting with antibodies reacting with DCAF1, Merlin and Î²-actin (left) or they were starved, plated on fibronectin-coated coverslips in complete medium with BrdU for 24 hr, and stained with anti-BrdU. The graph indicates the percentage (+ SEM) of BrdU-positive cells. (G) Lysates containing 0.3 mg of total proteins from Meso-33 cells transfected with FH-DCAF1 WT and HA-Merlin(as in Figure 3E) were immunoprecipitated with anti-Flag Mab (M2) or a control Mab (C) followed by immunoblotting with anti-HA (right). Note that DCAF1 is not saturated by Merlin under these experimental conditions. Figure options DCAF1 Mediates Hyperproliferation and Loss of Contact Inhibition in ... Figure 3.  DCAF1 Mediates Hyperproliferation and Loss of Contact Inhibition in Merlin-Deficient Cells (A and B) Meso-33 cells (A) and Met-5a cells (B) were transfected with a SMARTpool of siRNAs targeting the adaptor protein AP3Î², DCAF1, or a control nontargeting pool, deprived of growth factors for 24 hr, incubated with BrdU in the presence of mitogens for 24 hr, and subjected to anti-BrdU staining followed by counterstaining with DAPI. The graph shows the percentage (Â± standard error of the mean [SEM]) of BrdU+ cells and the pictures show representative fields. (C and D) HUVECs (C) and HEI 286 human Schwann cells (D) were transfected with a control si-RNA or two distinct si-RNAs targeting DCAF1, alone or in combination with a previously validated si-RNA targeting Merlin (Okada et al., 2005). Cells were deprived of growth factors for 24 hr, plated under confluent (C) or sparse (D) conditions on fibronectin, and subjected to BrdU incorporation in the presence of mitogens for 24 hr followed by anti-BrdU staining. The graphs show the percentage (Â±SEM) of BrdU+ cells. Immunoblotting was used to verify the efficiency of knockdown. (E) Meso-33 cells were transiently transfected with the indicated Î¼g of vectors encoding HA-Merlin, alone or in combination with FH-DCAF1 or FH-DCAF1 (1â€“1417), and subjected to immunoblotting (left) and BrdU incorporation assay (right). The anti-HA blots including FH-DCAF1 and HA-Merlin were exposed for the same time. The graph shows the percentage (Â±SEM) of BrdU+ cells. See also Figure S3. Figure options To further explore the role of CRL4DCAF1 in the proliferation of Merlin-deficient tumor cells, we designed a shRNA able to target both human and mouse DCAF1. Silencing of DCAF1 with this shRNA inhibited phosphorylation of Rb and entry into the S phase in Meso-33 cells (Figure S3E). FACS analysis of unsynchronized Meso-33 cells confirmed that depletion of DCAF1 predominantly inhibits progression through G1 (control Meso-33: 23% G1, 68% S, 9% G2/M; DCAF1-depleted Meso-33: 59% G1, 35% S, 6% G2/M). Re-expression of DCAF1 from either a moderate or a strong promoter rescued phosphorylation of Rb and cell-cycle progression, confirming the specificity of the shRNA targeting DCAF1 (Figure S3E). We therefore used this shRNA to silence DCAF1 in FC-1801 Schwannoma cells, which were derived from NF2 conditional knockout mice, and their normal counterpart, the FH-912 cells. Notably, inactivation of DCAF1 caused a more profound growth inhibition in Merlin null FC-1801 cells as compared to Merlin-positive FH-912 cells ( Figure S3F), confirming that CRL4DCAF1 is required for the proliferation of Merlin-deficient tumor cells but to a lesser degree for that of normal cells. These observations suggest that CRL4DCAF1 is a key component of the oncogenic signaling pathway activated by loss of Merlin.  To examine whether CRL4DCAF1 is required for exit from contact inhibition after inactivation of Merlin, we silenced Merlin in confluent human umbilical vein endothelial cells (HUVECs). As anticipated, this manipulation induced a significant fraction of confluent HUVECs to enter into S phase (Figure 3C). Notably, depletion of DCAF1 with each of two distinct siRNAs suppressed this unscheduled event (Figure 3C), suggesting that Merlin induces contact inhibition through inhibition of CRL4DCAF1.  To confirm that CRL4DCAF1 functions downstream of Merlin, we conducted an additional genetic epistasis experiment in HEI-286 Schwann cells, which are immortalized but not neoplastic. Silencing of Merlin caused these cells to undergo accelerated progression through G1 and entry into S phase in response to growth factors (Figure 3D), in agreement with the observation that Merlin contributes to restraining G1 progression (LÃ³pez-Lago et al., 2009). Inactivation of DCAF1 reverted the hyperproliferation caused by depletion of Merlin but did not affect the rate of growth of control cells expressing Merlin (Figure 3D), providing additional evidence that CRL4DCAF1 mediates the growth inhibitory effect of Merlin.  If Merlin suppresses cell proliferation by inhibiting CRL4DCAF1, expression of a mutant form of DCAF1 unable to interact with Merlin should counteract the antimitogenic effect of Merlin. To test this prediction, we transfected Meso-33 cells with FH-Merlin, alone or in combination with wild-type DCAF1 or DCAF1 (1â€“1417), and subjected them to BrdU incorporation assay. Interestingly, expression of DCAF1 (1â€“1417) fully rescued Meso-33 cells from undergoing growth arrest upon introduction of Merlin, whereas wild-type DCAF1 had only a moderate effect (Figure 3E). We note that, in spite of its higher level of expression, Merlin did not bind stoichiometrically to wild-type DCAF1 under these experimental conditions (Figure S3G). Presumably, transient transfection saturates the cellular machinery that modifies Merlin to enable it to bind to CRL4DCAF1 in Meso-33 cells. Taken together, these results provide strong evidence that Merlin suppresses cell proliferation by inhibiting CRL4DCAF1.  Merlin-Mediated Inhibition of CRL4DCAF1 Activates a Growth-Inhibitory Gene Expression Program  CRL4 ligases can regulate gene expression by promoting ubiquitylation of histones and recruitment of enzymes involved in chromatin remodeling or histone methylation or by inducing proteasome-mediated degradation of transcription factors (O'Connell and Harper, 2007). To examine whether Merlin controls gene expression through inhibition of CRL4DCAF1, we compared the gene expression program activated by expression of Merlin or depletion of DCAF1 in Nf2âˆ’/âˆ’ FC-1801 mouse Schwannoma cells. Unsupervised clustering of 1566 probe sets differentially expressed upon expression of wild-type but not L64P mutant Merlin or upon specific depletion of DCAF1 revealed largely overlapping changes in gene expression (Figure 4A). In fact, expression of Merlin and depletion of DCAF1 induced a concordant upregulation or downregulation of 855 probe sets (54%) (Figure 4B and Figure S4A). In spite of this considerable functional overlap, expression of Merlin and knock down of DCAF1 also induced specific effects on gene expression (Figure 4B). These results indicate that Merlin regulates gene expression largely through inhibition of CRL4DCAF1 but also suggest that Merlin has CRL4DCAF1-independent functions.  Expression of Merlin and Depletion of DCAF1 Induce a Largely Overlapping Gene ... Figure 4.  Expression of Merlin and Depletion of DCAF1 Induce a Largely Overlapping Gene Expression Program (A) FC-1801 cells were infected with lentiviral vectors encoding a shRNA targeting DCAF1 (sh-DCAF1), a control shRNA (sh-Control), wild-type Merlin, Merlin-L64P, or sh-DCAF1 in combination with wild-type Merlin and subjected to DNA microarray analysis. Unsupervised clustering of 1566 probe sets differentially expressed â‰¥2 fold in at least one of the two major comparisons (sh-DCAF1 versus sh-Control and Merlin-WT versus Merlin-L64P). Values were normalized to parental uninfected cells. (B) Venn diagram shows the overlap between the list of genes differentially expressed upon expression of Merlin-WT or silencing of DCAF1 (â‰¥2-fold change). Coregulated genes (885) are identified as differentially expressed â‰¥2-fold in one of the two comparisons and displaying a consensual significant change in the other comparison (p â‰¤ 0.01 by the ANOVA test). (C) Six hundred and sixty-seven genes coregulated upon expression of Merlin-WT or silencing of DCAF1 (â‰¥2-fold change in both comparisons) were subjected to ingenuity pathway analysis. Both downregulated (353) and upregulated (314) genes are included in the category of biological functions. Representative downregulated genes are shown in blue, and representative upregulated genes in red in order of decreasing average fold change. See also Figure S4. Figure options Related to Figure 4(A) FC-1801 cells expressing a control shRNA (1), a shRNA ... Figure S4.  Related to Figure 4 (A) FC-1801 cells expressing a control shRNA (1), a shRNA targeting DCAF1 (2), no insert (3), or Merlin (4) were subjected to Q-PCR analysis to confirm that the indicated genes are coregulated by knock down of DCAF1 and expression of Merlin. (B) Ingenuity Pathway analysis of 667 coregulated genes. Downregulated and upregulated genes are visualized separately in the category of Canonical Pathways. Representative downregulated genes are shown in blue and upregulated genes in red in order of decreasing average fold change. (C) Coregulated genes implicated in cell adhesion and tyrosine kinase signaling (56), intracellular traffic (30) and Hippo targets (25) were subjected to hierarchical clustering. Downregulated genes are shown in blue and upregulated genes in red. Figure options Ingenuity pathway analysis revealed that expression of Merlin and inactivation of CRL4DCAF1 cause a concordant downregulation of genes promoting cell-cycle progression and upregulation of genes involved in growth arrest and apoptosis (Figure 4C). In addition, these two manipulations downregulated several cell adhesion genes, such as the integrin Î± subunits Itga6 and Itga7, the integrin counter-receptor Vcam1, and the integrin-linked kinase Ilk, and upregulated the Rho effectors Rock1 and Limk1. Ingenuity analysis of canonical pathways indicated that expression of Merlin and loss of DCAF1 inhibit integrin and PDGF signaling as well as the signaling pathways jointly regulated by integrins and receptor tyrosine kinases ( Figure S4B). Interestingly, these two manipulations also led to downregulation of the integrin signaling component Bcar3, which has been implicated in recruitment of p130CAS to lamellipodia and in activation of Rac (Schrecengost et al., 2007). A survey of the genes coordinately regulated by expression of Merlin or loss of DCAF1 revealed additional features of the gene expression program activated by Merlin through inhibition of CRL4DCAF1. In addition to expanding the category of genes involved in cell adhesion and receptor tyrosine kinase signaling, this analysis revealed that Merlin regulates, through CRL4DCAF1, several genes involved in intracellular trafficking and a fraction of the known Hippo pathway target genes (Figure S4C). These observations suggest that Merlin's inhibition of CRL4DCAF1 activates a broad tumor-suppressive gene expression program.  Intramolecular Association of the FERM Domain with the C-Terminal Tail Promotes Nuclear Accumulation of Merlin  In order to obtain insight into the regulation of the association of Merlin with CRL4DCAF1, we studied the mechanism that enables Merlin to accumulate in the nucleus. Preliminary experiments indicated that Merlin's translocation in the nucleus does not require DCAF1 (W.L. and F.G.G., unpublished data). Since Merlin does not contain a canonical nuclear import sequence, we examined the ability of the FERM domain and of the Î±-helical and C-terminal domain of the protein to localize to the nucleus. The FERM domain of Merlin (1â€“341) accumulated in the nucleus of Meso-33 cells to a significantly larger degree as compared to wild-type Merlin. In contrast, the Î±-helical and C-terminal domain of the protein (341â€“595) failed to localize to the nucleus under the same conditions (Figures S5A and S5B). These results indicate that the FERM domain of Merlin is sufficient for nuclear translocation and suggest that the C-terminal portion of the protein may exert an inhibitory role. Since this portion of Merlin contains a nuclear export signal (Kressel and Schmucker, 2002), it is possible that this signal is masked in the closed conformer.  Related to Figure 5(A) Meso-33 cells were transiently transfected with moderate ... Figure S5.  Related to Figure 5 (A) Meso-33 cells were transiently transfected with moderate amounts of constructs encoding HA-Merlin or the indicated truncation mutants and subjected to immunofluorescent staining with anti-HA and DAPI. (B) Meso-33 cells transfected as indicated above were subjected to subcellular fractionation. Equal amounts of total proteins from the non-nuclear (CM; cytosol + crude membranes) and nuclear (NF) fraction were subjected to immunoblotting with antibodies against the indicated proteins. (C) HUVECs were deprived of growth factors, detached, replated on fibronectin (Fn)-coated plates under sparse or confluent conditions, and then treated or not with mitogens (bFGF + Hep, EGF,and ITS) for 2 hr. Equal amounts of total proteins from the non-nuclear (CM) and nuclear (NF) fraction were subjected to SDS-PAGE on a gel containing a decreased Acrylamide/Bis-Acrylamide ratio (16:1) to separate the phosphorylated and unphosphorylated form of Merlin (top 2 blots) or on a regular gel (other blots). Samples were subjected to immunoblotting with antibodies against the indicated proteins. The slower migrating form of merlin present in the nucleus may be phosphorylated at a site distinct from S518, as it is not recognized by anti-P-Merlin (S518) antibodies. (D) Data were quantified by densitometry. The graph illustrates the ratio of unphosphorylated Merlin or Merlin phosphorylated at S518 present in the nuclear over the non-nuclear fraction. (E) Meso-33 cells were transiently transfected with moderate amounts of HA-Merlin, HA-Merlin-S518A, or HA-Merlin-S518D and subjected to subcellular fractionation. Equal amounts of total proteins from the non-nuclear (CM) and nuclear (NF) fraction were subjected to immunoblotting as indicated. Lower arrow points to a band, which we have detected only after high-resolution SDS-PAGE. This band is recognized by anti-Merlin but not anti-HA antibodies and thus may represent an N-terminally cleaved form of Merlin. The amount of Merlin in each fraction was estimated by densitometry. The graph illustrates the ratio between the nuclear and non-nuclear fraction for the wild-type and each of the two mutant forms of Merlin. Figure options To examine whether antimitogenic signals, such as cell-to-cell adhesion and growth factor deprivation, regulate the accumulation of Merlin in the nucleus, we monitored the subcellular localization of the unphosphorylated and phosphorylated form of Merlin under various growth conditions. Mobility shift assay and immunoblotting with anti-P-Merlin (S518) indicated that the dephosphorylated form of Merlin, which was prevalent in confluent cells especially if they were not exposed to mitogens, accumulated predominantly in the nucleus, whereas Merlin phosphorylated at S518 remained largely confined to the non-nuclear fraction under all conditions (Figures S5C and S5D). To confirm that the closed, growth-inhibitory form of Merlin accumulates preferentially in the nucleus, we examined the subcellular distribution of Merlin-S518A, which cannot be phosphorylated by PAK, and Merlin-S518D, which mimics the phosphorylated form of the protein. Notably, Merlin-S518A accumulated in the nucleus to a significantly higher extent than did wild-type Merlin (Figure S5E). In contrast, Merlin-S518D displayed defective nuclear accumulation, suggesting that PAK-mediated phosphorylation inhibits nuclear localization of Merlin. In agreement with this hypothesis, a dominant negative form of PAK enhanced nuclear accumulation of Merlin (W.L. and F.G.G., unpublished data). Thus, intramolecular association of the FERM domain with the C-terminal tail promotes nuclear accumulation of Merlin, whereas phosphorylation of S518 inhibits this process.  Tumor-Derived Mutations Prevent Merlin's Ability to Interact with or to Inhibit CRL4DCAF1  Most NF2 missense mutations map to the FERM domain ( Ahronowitz et al., 2007). To further study the relevance of Merlin's interaction with CRL4DCAF1 for tumor suppression, we examined several of these mutations. L46R, F62S, L64P, L141P, A211D, and E270G have been found in two or more unrelated NF2 patients or are known to track with disease in individual families and are therefore bona fide pathogenic mutations. In contrast, G197C, which was identified in a single patient affected by mild bilateral Schwannoma, may represent a polymorphism or a passenger mutation (Ahronowitz et al., 2007). Structural considerations suggest that L46R, F62S, L64P, L141P, and A211D disrupt the hydrophobic core of subdomain A or B, whereas E270G simply removes a surface charge from subdomain C (Figures 5Aâ€“5C). In contrast, G197C can be accommodated by a slight adjustment of the surface loop in which it resides, without overt effects on the overall structure of subdomain B, and does not introduce or delete a charge (Figure 5C).  Several Pathogenic Missense Mutations Disrupt Binding of Merlin to CRL4DCAF1 In ... Figure 5.  Several Pathogenic Missense Mutations Disrupt Binding of Merlin to CRL4DCAF1 In Vivo (A) Tumor-derived mutants (red sticks) are shown in the context of the overall structure of the FERM domain of human Merlin (colored ribbons; PDB 1ISN). The Î±-helical coiled-coil domain from the crystal structure of the closed form of Spodoptera frugiperda Moesin (thin gray Î±-carbon trace; PDB 2I1K), which is highly homologous to human Merlin, is shown for reference. The coiled-coil domain was positioned by superimposing the FERM domains from the structures of Merlin and Moesin, which have a root mean square deviation for Î±-carbon atoms of 1.3 Ã… and share 62% sequence identity. (B) Close-up view of tumor-derived mutations (red sticks) located in subdomain A (green ribbon) in the crystal structure of human Merlin. Residues in contact with mutated residues are drawn as sticks and colored according to atom type (carbon, yellow; sulfur, green). (C) Subdomain B represented as in (B), with oxygen as magenta sticks. Red sphere, G197. (D) Meso-33 cells were transiently transfected with empty vector or vectors encoding wild-type Merlin or indicated mutants. Asynchronized cells growing in 10% fetal calf serum were subjected to BrdU incorporation assay. The graph indicates the percentage (Â±SEM) of BrdU-positive cells. Pictures show representative fields of cells transfected with indicated vectors and stained with anti-BrdU (red) and DAPI (blue). (E) Cos7 cells were transfected with FH-tagged versions of wild-type Merlin or indicated mutants. Flag or control immunoprecipitates (M2 and C, respectively) and total lysates were immunoblotted as indicated. See also Figure S5. Figure options To evaluate their growth-suppressive function, we introduced Merlin and mutants thereof into Meso-33 cells. As anticipated, wild-type Merlin and Merlin-S518A suppressed progression through G1 and entry in S phase in these cells, whereas Merlin-S518D inhibited proliferation to a much smaller degree (Figure 5D). Notably, all the bona fide pathogenic mutants were found to be devoid of growth inhibitory activity in Meso-33 cells. In contrast, Merlin G197C suppressed proliferation as effectively as wild-type Merlin, suggesting that this is not a pathogenic mutation (Figure 5D). To examine the ability of tumor-derived mutants of Merlin to interact with CRL4DCAF1 in cells, we subjected Cos7 cells expressing FH-Merlin and mutants thereof to coimmunoprecipitation. Remarkably, all the bona fide tumor-derived mutant forms of Merlin did not interact with CRL4DCAF1 in vivo, whereas the control mutant G197C associated with the ligase as efficiently as wild-type Merlin under the same conditions (Figure 5E, see Figure 1C for L64P), providing evidence that Merlin needs to combine with CRL4DCAF1 to suppress tumorigenesis.  To obtain insight into the mechanism through which each of these pathogenic missense mutations impairs association of Merlin with CRL4DCAF1 in vivo, we first assessed their effect on nuclear accumulation of the protein. Biochemical fractionation indicated that L46R, L64P, L141P, and A211D accumulate in the nucleus to a much smaller degree than wild-type Merlin or G197C (Figures 6A and 6B). Defective nuclear translocation and decreased level of expression, presumably arising from deficient protein stability, contributed to varying degrees to inhibit accumulation of each of these mutants into the nucleus. At the two opposite ends of the spectrum, L46R and L141 did not accumulate in the nucleus in spite of near wild-type levels of expression, suggesting that these two mutations affect predominantly nuclear translocation, whereas A211D nuclear levels were low largely as a consequence of reduced expression (Figures 6A and 6B). In contrast, F62S and E270 translocated into the nucleus as efficiently as wild-type Merlin, although the amounts of the latter in the nucleus appeared to be reduced. These results suggest that defective stability and nuclear translocation contribute to impair the interaction of certain tumor-derived mutant forms of Merlin with CRL4DCAF1.  Pathogenic Mutations Disrupt the Ability of Merlin to Accumulate in the Nucleus, ... Figure 6.  Pathogenic Mutations Disrupt the Ability of Merlin to Accumulate in the Nucleus, to Bind to DCAF1, or to Inhibit CRL4DCAF1 (A) Meso-33 cells were transiently transfected with FH-tagged versions of wild-type Merlin or the indicated mutants and subjected to subcellular fractionation. Equal amounts of proteins from the nonnuclear (CM) and nuclear (NF) fractions were subjected to immunoblotting. (B) The amount of Merlin or indicated mutants present in nuclear and nonnuclear fractions was estimated by densitometry of the blot in (A). Top: ratio of Merlin or indicated mutants present in nuclear versus nonnuclear fractions. Bottom: amount of each Merlin mutant present in the nucleus as a percentage over the wild-type value. (C) In vitro-translated and TNT-labeled DCAF1 was incubated with 0.5, 1, and 2 Î¼g GST fusion proteins comprising the FERM domain of wild-type Merlin or indicated mutants. GST-bound DCAF1 was detected by blotting with HRP-streptavidin. (D) Densitometric analysis of (C). The graph shows the binding values in arbitrary units. (E) Cos7 cells were transfected with the indicated FH-tagged forms of Merlin and subjected to immunoprecipitation with control (C) or anti-Flag Mab (M2) followed by immunoblotting. (F) Cos7 cells were transfected with FH-DCAF1 and HA-Ubiquitin in combination with the indicated Myc-tagged constructs or empty vector and treated with MG132. Flag or control immunoprecipitates were immunoblotted with anti-HA (left). Total lysates were immunoblotted with anti-Myc (right). Figure options To examine the ability of tumor-derived missense mutants to interact with CRL4DCAF1 in vitro, we engineered each mutation into a fusion protein comprising the isolated FERM domain of Merlin, which we had shown binds efficiently to in vitro translated DCAF1. As shown in Figures 6C and 6D, GST-FERM-A211D bound to DCAF1 in vitro almost as efficiently as wild-type GST-FERM or GST-FERM-G197C, suggesting that the A211D mutant does not interact in vivo with CRL4DCAF1 because it does not accumulate in the nucleus to sufficient levels (Figures 6A and 6B). All the other mutant FERM domains displayed decreased ability to bind to recombinant DCAF1: L46R, L64P, and E270G did not bind at all under our experimental conditions, whereas F62S and L141P displayed defective binding (Figures 6C and 6D). Since F62S and E270G were able to accumulate in the nucleus to normal or near-normal levels (Figures 6A and 6B), we infer that they do not combine in vivo with CRL4DCAF1 because they are unable to interact directly with DCAF1 with sufficient affinity. Notably, the E270G mutation simply removes a charge from a surface exposed loop on subdomain C (Figure 5A), implicating this loop in interaction with DCAF1 and confirming the high specificity of the interaction of Merlin with DCAF1. In contrast, both defective nuclear accumulation and deficient binding to DCAF1 contribute to the inability of L46R, L64P, and L141P to interact with CRL4DCAF1 in vivo. Together, these experiments indicate that the six tumor-derived missense mutants that we have tested do not combine with CRL4DCAF1 in vivo, owing to defective accumulation in the nucleus, deficient binding to DCAF1, or a combination of the two mechanisms.  While mutations that introduce stop codons within the FERM domain are likely to give rise to misfolded and unstable protein products, certain nonsense mutations delete only the C-terminal domainâ€”a structural perturbation that may affect the ability of Merlin to maintain a closed conformation. To examine whether tumor-derived nonsense mutations affect the ability of Merlin to interact with or to suppress CRL4DCAF1, we examined two prevalent truncation mutants: Merlin 466X, which lacks the C-terminal portion of the Î±-helical domain as well as the C-terminal domain, and Merlin 341X, which retains the FERM domain but lacks both the Î±-helical and the C-terminal domains (Ahronowitz et al., 2007). Coimmunoprecipitation indicated that these two Merlin mutants retain the ability to interact with CRL4DCAF1 in vivo (Figure 6E). In fact, progressive deletion from the C terminus resulted in increased, as opposed to decreased, binding of Merlin to the ligase. Since the isolated FERM domain of Merlin accumulates in the nucleus to a larger extent than the wild-type protein, whereas the C-terminal portion of Merlin including the Î±-helical and C-terminal domain remains in the cytoplasm (Figure S5B), it is possible that increased nuclear accumulation facilitates the interaction of tumor-derived truncations mutants with CRL4DCAF1. Interestingly, in spite of its increased ability to bind to CRL4DCAF1 in vivo, the FERM domain of Merlin did not suppress CRL4DCAF1 ligase activity in vivo as efficiently as wild-type Merlin (Figure 6F), indicating that the Î±-helical and C-terminal domains contribute to Merlin's inhibitory activity. These results suggest that the tumor-derived truncation mutants of Merlin that retain the FERM domain are able to interact with CRL4DCAF1 but fail to suppress its activity. The observation that several distinct tumor-derived mutations impair Merlin's ability to translocate into the nucleus, to bind to DCAF1, or to inhibit CRL4DCAF1 activity provides strong genetic evidence that Merlin suppresses tumorigenesis by inhibiting CRL4DCAF1.  Inactivation of DCAF1 Suppresses the Tumorigenic Potential of Mesothelioma and Schwannoma Cells  To test whether CRL4DCAF1 is required for NF2-dependent tumorigenesis, we silenced DCAF1 in Meso-33 and FC-1801 cells ( Figures 7A and 7B). Knockdown of DCAF1 inhibited the ability of both mesothelioma and Schwannoma cells to grow in soft agar (Figure 7C and Figure S6A). In contrast, depletion of DCAF1 did not affect the ability of Ras-V12 or v-Src transformed cells to express elevated levels of Cyclin D1 and p-Rb and to proliferate under adherent conditions or in soft agar (Figures S6B and S6C), suggesting that inactivation of CRL4DCAF1 specifically inhibits the malignant properties of Merlin-deficient tumor cells.  Silencing of DCAF1 Suppresses the Tumorigenic Potential of Merlin-Deficient ... Figure 7.  Silencing of DCAF1 Suppresses the Tumorigenic Potential of Merlin-Deficient Cells (A) Meso-33 cells were infected with lentiviral vectors encoding two distinct shRNAs targeting DCAF1 (sh-1 and sh-2) or a control shRNA (sh-Contr.) and subjected to immunoblotting. (B) FC-1801 cells treated as in (A). Cells infected with sh-1 were also infected with a retroviral vector encoding a shRNA-resistant version of DCAF1 or with empty vector. Immunoblotting was as indicated. (C) Meso-33 cells infected with the indicated lentiviral vectors were subjected to soft agar assay. The graph illustrates the total number (Â±SEM) of colonies present in each well after 2 weeks of culture. Representative images are shown. (D and E) Two million FC-1801 cells infected with the indicated lentiviral vectors were injected subcutaneously in nude mice. (D) shows the increase in volume (Â±SEM) over time of tumors generated by cells infected with lentiviruses encoding a control shRNA (sh-Control) or two distinct shRNAs targeting DCAF1 (sh-1 and sh-2). (E) shows the increase in volume (Â±SEM) over time of tumors generated by cells infected with sh-1 and either a retroviral vector encoding a shRNA-resistant version of DCAF1 or empty vector. Data were obtained from the same experiment. Note the different scale of the y axes of the two graphs. (F) Primary Schwann cells from two normal individuals (NF2+/+) and Schwannoma cells from two NF2 patients (NF2âˆ’/âˆ’) were infected with lentiviruses encoding a shRNA targeting DCAF1 (sh-2) or a control shRNA (sh-Co.), deprived of growth factors, restimulated with mitogens in the presence of BrdU, and subjected to anti-BrdU staining. The graph shows the percentage (Â±SEM) of BrdU+ cells. See also Figure S6. Figure options Related to Figure 7(A) FC-1801 cells infected with lentiviral vectors encoding ... Figure S6.  Related to Figure 7 (A) FC-1801 cells infected with lentiviral vectors encoding two distinct shRNAs targeting DCAF1 (sh-1 and sh-2) or a control shRNA (sh-Co.) were subjected to soft agar assay. The graph shows the total number (+ SEM) of colonies present in each well after 2 weeks of culture. The pictures show representative images. (B) Ras-V12-transformed 3T3 cells were infected with lentiviral vectors encoding a control shRNA (sh-Co.) or a shRNA targeting DCAF1 (sh-2) and subjected to immunoblotting with antibodies against the indicated proteins (left), BrdU incorporation assay (middle), and soft agar assay (right). The graph on the right shows the total number (+ SEM) of colonies present in each well after 2 weeks of culture. (C) v-Src-transformed 3T3 cells were infected with lentiviral vectors encoding a control shRNA (sh-Co.) or a shRNA targeting DCAF1 (sh-2) and subjected to immunoblotting with antibodies against the indicated proteins (left), BrdU incorporation assay (middle), and soft agar assay. The graph on the right shows the total number (+ SEM) of colonies present in each well after 3 weeks of culture. Figure options Meso-33 cells as well as other Merlin-deficient mesothelioma cell lines did not give rise to tumors upon subcutaneous or intrapleural injection in mice. In contrast, the FC-1801 cells, which express robust levels of DCAF1, gave rise to sizeable tumors in less than 4 weeks upon subcutaneous injection in nude mice (Figure 7D). Silencing of DCAF1 with two distinct shRNAs inhibited tumor growth in vivo by approximately 75% at day 24. This effect was highly specific, as moderate overexpression of a shRNA-resistant form of DCAF1 rescued the ability of FC-1801 cells expressing one of the two shRNAs targeting DCAF1 to give rise to subcutaneous tumors (Figure 7E). In fact, the tumors generated by these cells grew at a much faster pace as compared to those generated by parental FC-1801 cells (by approximately 2-fold, compare Figures 7D and 7E, data are from the same experiment), suggesting that elevated levels of DCAF1 can promote tumorigenesis.  To explore the relevance of our findings to the pathogenesis of NF2, we examined whether DCAF1 affects the ability of primary human Schwannoma cells derived from NF2 patients to proliferate in vitro. Silencing of DCAF1 suppressed the ability of these cells to progress through G1 and enter into S phase in response to mitogens. In contrast, knockdown of DCAF1 did not significantly affect the proliferation of control human Schwann cells (Figure 7F). Together, these results indicate that CRL4DCAF1 is necessary for NF2-dependent hyperproliferation, anchorage-independent growth, and tumorigenesis.  Discussion The mechanism by which Merlin suppresses tumorigenesis has remained elusive since the discovery of the NF2 gene. This study reveals that the closed, growth-inhibitory form of Merlin translocates to the nucleus, binds to the E3 ubiquitin ligase CRL4DCAF1, and suppresses its ability to ubiquitylate target proteins. Multiple converging lines of evidence indicate that Merlin's inhibition of CRL4DCAF1 activity is required to induce growth arrest and suppress tumorigenesis. Notably, analysis of several tumor-derived mutants indicates that some display impaired nuclear translocation, others fail to interact with DCAF1, and still others bind to DCAF1 but do not suppress CRL4DCAF1 E3 ligase activity. Furthermore, silencing of DCAF1 reverses the consequences of Merlin inactivation in normal cells and suppresses the ability of Merlin-deficient tumor cells to grow in soft agar and in nude mice. These findings indicate that entry into the nucleus and inhibition of CRL4DCAF1 are integral components of the mechanism by which Merlin suppresses tumorigenesis.  The mechanisms through which antimitogenic signals induce Merlin to inhibit CRL4DCAF1 are likely to be complex. Our results suggest that these signals promote, largely through inhibition of PAK, accumulation of the closed form of Merlin, which translocates into the nucleus. Merlin does not contain a classical importin-Î± nuclear localization sequence but has a C-terminal CRM1-dependent nuclear export signal (Kressel and Schmucker, 2002). Mutational analysis suggests that the FERM domain is necessary and sufficient for nuclear entry, whereas the C-terminal coiled-coil domain inhibits this process unless it is folded back and interacts with the FERM domain. In addition or instead, unfolding of the C-terminal helical domain may expose the nuclear export signal and thereby facilitate Merlin's exit from the nucleus. Interestingly, other FERM domain proteins, such as the isoforms H and R of band 4.1 and FAK, appear to shuttle in and out of the nucleus through similar conformational transitions (Gascard et al., 1999; Lim et al., 2008 ;  Luque et al., 1998).  Upon entering the nucleus, the closed form of Merlin binds to the C-terminal segment of DCAF1. Our results indicate that Merlin is not a substrate of CRL4DCAF1 but exerts its antimitogenic function by blocking DCAF1-dependent recruitment or ubiquitylation of CRL4DCAF1 substrates. Since subdomain A of the FERM domain of Merlin consists of an ubiquitin-like fold (Shimizu et al., 2002), Merlin may function as an inhibitory pseudosubstrate for CRL4DCAF1. Reconstitution of CRL4DCAF1 ligase activity in vitro will be necessary to directly test this model. Irrespective of the specific mechanism by which Merlin inhibits CRL4DCAF1, several lines of evidence support the conclusion that this inhibitory interaction restrains cell proliferation. First, inactivation of Merlin enables normal cells to exit from contact inhibition and to undergo cell cycle progression, while depletion of DCAF1 suppresses both effects. Second, enforced expression of a Merlin-insensitive mutant of DCAF1 counteracts the antimitogenic effect of Merlin. Third, depletion of DCAF1 suppresses hyperproliferation in Merlin-deficient Schwannoma and mesothelioma cells but inhibits their normal counterpart to a lesser extent, consistent with the hypothesis that loss of Merlin activates oncogenic signaling through CRL4DCAF1. Finally, silencing of DCAF1 suppresses the ability of primary human Schwannoma cells from NF2 patients to proliferate in vitro, suggesting that deregulated CRL4DCAF1 activity contributes to the pathogenesis of NF2.  CRL4 ligases have been implicated in chromatin remodeling, DNA replication, and the response to DNA damage (Lee and Zhou, 2007 ;  O'Connell and Harper, 2007). For example, CRL4DDB2 promotes the ubiquitylation of several histones and the DNA repair components DDB2 and XPC, restricting the threshold of DNA damage response and inhibiting UV-induced skin carcinogenesis, CRL4CSA mediates ubiquitylation of CSB, a SWI2/SNF2 ATP-dependent chromatin remodeling enzyme, and CRL4DET1-Cop1 promotes ubiquitylation and proteasome-mediated degradation of the transcription factor c-Jun (reviewed in Lee and Zhou, 2007 and O'Connell and Harper, 2007 ;  Liu et al., 2009). Although the physiological substrates of CRL4DCAF1 have not been identified, our results suggest that CRL4DCAF1 broadly regulates gene expression. In fact, expression of Merlin and depletion of DCAF1 cause similar changes in the expression of several hundred genes, suggesting that Merlin controls a wide gene expression program through inhibition of CRL4DCAF1. Notably, this program includes the inhibition of genes involved in promoting progression through each phase of the cell cycle as well as the upregulation of genes involved in growth arrest and apoptosis. Parenthetically, we speculate that knockdown of DCAF1 may cause an accumulation of Merlin-deficient cells in G1 because loss of Merlin specifically deregulates this phase of the cell cycle. In addition, we have observed that Merlin controls, through CRL4DCAF1, the expression of genes involved in receptor tyrosine kinase and adhesion signaling, intracellular trafficking, and a subset of Hippo pathway target genes. The ability of CRL4DCAF1 to regulate these genes may explain some of the effects that Merlin has been reported to exert on receptor tyrosine kinase and adhesion signaling (Ammoun et al., 2008; Curto et al., 2007; Kissil et al., 2003; Lallemand et al., 2009; Okada et al., 2005; Poulikakos et al., 2006 ;  Shaw et al., 2001). The observation that re-expression of Merlin and depletion of DCAF1 induce a gene expression program of similar breadth, specificity, and scope reinforces the model that Merlin suppresses tumorigenesis through inhibition of CRL4DCAF1.  The analysis of tumor-derived mutations, in particular missense mutations, has provided considerable insight into the function of important tumor suppressors, such as P53, RB, PTEN, and APC. We have studied six pathogenic missense mutations mapping to the FERM domain of Merlin and found that each of them impairs the ability of Merlin to accumulate in the nucleus and/or bind to DCAF1. Both types of defects disrupt the association of Merlin with CRL4DCAF1. In contrast, severe truncation mutants, such as 341X, display increased accumulation in the nucleus and interaction with CRL4DCAF1 in vivo but fail to suppress ligase activity. Among the missense mutations, L64R, F62S, and L64P, located in subdomain A, disrupt binding to DCAF1 in vitro, whereas L141P and A211D, mapping to subdomain B, do not. Furthermore, E270G, which removes a single charge from the surface of subdomain C, drastically reduces binding to DCAF1 in vitro. These results implicate subdomains A and C in interaction with DCAF1 and suggest that mutations in other portions of the protein, such as subdomain B and the helical segment, may affect nuclear localization determinants or disrupt the closed conformation that is required for nuclear accumulation. The observation that many pathogenic NF2 mutations disrupt, and several others are predicted to disrupt, the ability of Merlin to interact with or to suppress CRL4DCAF1 provides strong genetic evidence that Merlin suppresses tumorigenesis by inhibiting this E3 ligase.  In conclusion, our results indicate that NF2-dependent tumorigenesis arises from the inability of mutant Merlin to enter into the nucleus and to suppress CRL4DCAF1-dependent gene expression. This delineated tumor-suppressor pathway bears antithetic resemblance to the Wnt/Î²-catenin pathway, where an intercellular signal hijacks the cytoskeletal component Î²-catenin to promote oncogenic gene expression in the nucleus (Clevers, 2006). Identification of the substrate(s) of CRL4DCAF1 and elucidation of the mechanism through which this ligase exerts its pro-proliferative and anti-apoptotic role should help to generate targeted therapies for NF2 mutant tumors.  Despite intense study of the neurofibromatosis type 2 (NF2) tumor-suppressor protein merlin, the biological properties and tumor-suppressor functions of merlin are still largely unknown. In this study, we examined the molecular activities of NF2-causing mutant merlin proteins in transfected mammalian cells, to elucidate the merlin properties that are critical for tumor-suppressor function. Most important, we found that 80% of the merlin mutants studied significantly altered cell adhesion, causing cells to detach from the substratum. This finding implies a function for merlin in regulating cell-matrix attachment, and changes in cell adhesion caused by mutant protein expression may be an initial step in the pathogenesis of NF2. In addition, five different mutations in merlin caused a significant increase in detergent solubility of merlin compared to wild type, indicating a decreased ability to interact with the cytoskeleton. Although not correlated to the cell-adhesion phenotype, four missense mutations decreased the binding of merlin to the ERM-interacting protein EBP-50, implicating this interaction in merlin inhibition of cell growth. Last, we found that some NF2 point mutations in merlin most closely resembled gain-of-function alleles in their cellular phenotype, which suggests that mutant NF2 alleles may not always act in a loss-of-function manner, as had been assumed, but may include a spectrum of allelic types with different phenotypic effects on the function of the protein. In aggregate, these cellular phenotypes provide a useful assay for identifying the functional domains and molecular partners necessary for merlin tumor-suppressor activity.  Go to: Introduction Neurofibromatosis type 2 (NF2) (MIM 101000) is an autosomal disorder characterized by the formation of nervous system tumorsâ€”specifically, bilateral schwannomas of the eighth cranial nerve and, to a lesser extent, schwannomas of other cranial and peripheral nerves and spinal nerve roots, meningiomas, ependymonas, and gliomas, as well as posterior lens-capsule opacities and retinal abnormalities (Martuza and Eldridge 1988; Kaiser-Kupfer et al. 1989; Evans et al. 1992). Mutational analysis of the NF2 gene in inherited and sporadic schwannomas, meningiomas, and ependymonas has shown that both copies of NF2 are often mutated and/or deleted in >50% of tumors, which suggests that the NF2 protein has a tumor-suppressor activity (Rouleau et al. 1993; Trofatter et al. 1993; Bourn et al. 1994; Jacoby et al. 1994; MacCollin et al. 1994). In support of the NF2 proteinâ€™s proposed role as negative regulator of cell growth, overexpression of the wild-type NF2 gene inhibits cell growth both in vitro and in vivo (Lutchman and Rouleau 1995; Sherman et al. 1997) and reverses the Ras-induced phenotype of anchorage-independent growth in v-Has-Ras transformed fibroblasts (Tikoo et al. 1994).  The NF2 protein, nicknamed â€œmerlin,â€� shares 45% sequence identity with the family proteins ezrin, radixin, and moesin (ERM) (MIM 309845), which link the actin cytoskeleton to plasma membrane proteins at specialized, dynamic regions (Lamb et al. 1997; Martin et al. 1997). Like the ERM proteins, merlin localizes to the plasma membrane at regions rich in filamentous actin, both in cultured cells and endogenous tissues (den Bakker et al. 1995a; Gonzalez-Agosti et al. 1996; Stemmer-Rachamimov et al. 1997). Depletion of merlin protein by antisense oligonucleotide treatment (Huynh and Pulst 1996), as well as overexpression of merlin in cultured cells, causes cellular changes associated with alterations in cell-matrix interactions, such as cell morphology, cell motility, and cell-substrate attachment (den Bakker et al. 1995b; Koga et al. 1998; Gutmann et al. 1999). Furthermore, studies in cultured NIH3T3 cells demonstrate that endogenous levels of merlin expression and phosphorylation are responsive to changes in cell adhesion, cell confluency, and growth factor stimuli (Shaw et al. 1998), which suggests that merlin may function as part of a signal transduction pathway regulating cell-cell and cell-matrix interactions. Several studies investigating merlin function have focused on identifying cellular interacting proteins. Merlin can bind actin filaments in vitro (Xu and Gutmann 1998), and immunoprecipitation studies have identified the actin-binding protein Î²II-spectrin, the Na+-H+ exchanger regulatory cofactor EBP50, and the matrix receptor Î²1-integrin as interactors of merlin (Murthy et al. 1998; Obremski et al. 1998; Scoles et al. 1998). However, the importance of these interactions to merlin tumor-suppressor activity and NF2 pathogenesis has not been clarified.  To elucidate the molecular mechanisms of NF2 tumor-suppressor function, we analyzed the effect of NF2 missense and deletion mutations on merlin cellular and molecular properties in cultured mammalian cells, hypothesizing that these changes would produce stable proteins that are functionally defective. In this report, we demonstrate that the majority of single amino acid (aa) mutations in merlin produce proteins that significantly inhibit cell adhesion and show increased detergent solubility compared to wild-type merlin, which suggests that merlin tumor-suppressor activity involves cell-adhesion signaling. In addition, we provide evidence that missense mutations can act as dominant alleles, which suggests the possibility that a subset of NF2 mutant alleles in patients may act in a dominant manner to promote tumorigenesis.  Go to: Material and Methods Protein Expression Constructs  To create the untagged mammalian expression constructs, all cDNAs were cloned into the mammalian expression vector pcDNA3 (Invitrogen). The green fluorescent protein (GFP) tag was fused N-terminal to all cDNAs by means of the expression vector pEGFP-C1 (Clontech). All cDNAs were cloned into the pGEX-5X-2 bacterial expression vector (Pharmacia Biotech), to fuse glutathione-S-transferase (GST) to the amino terminus of the protein of interest. The full-length merlin cDNA clone for isoform 1 was isolated from a human testes library in the vector pBK-CMV (Stratagene) and was designated M7. All missense merlin constructs were generated from the plasmid M7 by means of the oligonucleotide-mediated mutagenesis protocol of Kunkel et al. (1987), with primers engineered to contain the exact nucleotide change reported in the literature as the disease-associated mutation. The C-terminal coding sequence for isoform 2 was PCR amplified from human lymphocyte cDNA and was subcloned into M7, to generate the full-length isoform 2 cDNA. For Î”Cterm, a unique internal Xho1 site and the Xho1 multiple cloning site were used to â€œpop outâ€� the carboxyl terminus of M7, to produce a construct encoding aa 1â€“341 of merlin. Î”Nterm (aa 342â€“595) was generated by PCR amplification of the C-terminal half of merlin. Mer559 was engineered by PCR amplification by means of internal merlin primers. Î”BB was engineered essentially as described elsewhere (LaJeunesse et al. 1998) for the Drosophila â€œBlue Boxâ€� deletion. The entire EBP50 coding sequence was isolated by HindIII/Not1 digestion, from I.M.A.G.E. clone 33147 (Lennon et al. 1996). The full-length human moesin cDNA was isolated by PCR from I.M.A.G.E. clone 645267. The sequence of all constructs was confirmed by restriction digestion and by direct DNA sequencing with the use of the Sequenase 2.0 DNA Sequencing Kit (United States Biochemical) or the automated fluorescent sequencing machine ABI 377 (PE Biosystems).  Cell Culture and Transient Expression of Merlin Proteins in Culture Cells  COS-7, Hela, and 293 cells (ATCC) were cultured in Dulbeccoâ€™s modified Eagleâ€™s minimum essential medium, supplemented with 10% fetal bovine serum and antibiotics (Gibco), at 37Â°C in a 5% CO2 humidified incubator. Exponentially growing COS-7, Hela, and 293 cells were seeded 24 h before transfection. At 50% cell confluency, DNA transfer was performed by liposome-mediated gene transfer, with the use of either Effectene reagent or Superfect reagent (Qiagen). Cells were incubated for 3 h (Superfect) or overnight (Effectene) in the presence of the DNA-liposome reagent and were washed with PBS; fresh medium was then added. Cells were assayed for protein production 24â€“72 h after transfection. Overnight exposure to Effectene did not show differences in cell death, morphology, or protein expression compared to a 3-h exposure to lipofect reagent Superfect (Qiagen).  Antibodies  The merlin polyclonal antibodies N50 and C53 were generated by injecting female New Zealand white rabbits with synthetic peptides conjugated to keyhole limpet hemocyanin: N50 (YAEHRGRARDEAEMEYLK-C; residues 192â€“209, including a carboxyl-terminal cysteine residue) and C53 (C-LHNENSDRGGSSKHNTIK; residues 561â€“578, including an amino-terminal cysteine residue). N50 antibody was affinity-purified on peptide columns by means of the HiTrap NHSâ€“activated reagent (Pharmacia Biotech). All other antibodies were commercially available: rabbit polyclonal antimerlin antibody A-19 (Santa Cruz Biotechnology), mouse monoclonal anti-GFP antibody (Clontech, Boehringer-Mannheim), rhodamine- and Texas Redâ€“coupled goat antirabbit antibodies, Oregon Green 488â€“coupled goat antimouse antibody, Texas Redâ€“conjugated X phalloidin, and anti-Î²-tubulin mouse monoclonal antibody (Molecular Probes).  Immunofluorescence and Microscopy  Transfected cells grown on untreated or poly-D lysine-coated coverslips (Sigma) were fixed in 4% paraformaldehyde and permeabilized with 0.05% saponin (Sigma). Fixed cells were incubated with 0.4â€“2.0 Î¼g/ml primary antibody. When staining for actin, we also added a 1:40 dilution of Texas Redâ€“conjugated anti-X phalloidin. Cells were rinsed in PBS containing 1% Triton X-100; incubated with 1:500 dilution of the appropriate secondary fluorescent antibody; conjugated to either rhodamine, Texas Red, or Oregon Green 488; and then mounted in Prolong medium and DAPI (Molecular Probes). Cells were visualized with a Zeiss epifluorescence microscope or with a Molecular Dynamics confocal laser-scanning microscope 2010. For analysis of GFP expression and viability in cells, GFP-transfected cells were incubated with propidium iodide (Molecular Probes), washed with PBS, resuspended in culture media without phenol red (Gibco), and visualized with the epifluorescence microscope.  Preparation of Cell Extracts  Suspended COS-7 cells were collected 48â€“72 h after transfection, washed with PBS, and resuspended in lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.1% sodium deoxycholate, 0.1% sodium dodecyl sulfate) containing proteinase inhibitors (1 mM Pefabloc [Boehringer-Mannheim], 10 Î¼g/ml aprotinin, 10 Î¼g/ml leupeptin, and 10 Î¼g/ml pepstatin). These were used as the detached fractions. Attached cells were incubated with lysis buffer for 30 min at 4Â°C and were used as the attached fractions. Protein concentrations were determined by means of the BioRad DC Protein Assay Kit.  Detergent Extraction  COS-7 transfected cells were extracted for 40â€“50 s with 30-Î¼l extraction buffer (50 mM MES, pH 6.4, 3 mM EGTA, 5 mM MgCl2, 0.5% Triton X-100). The detergent-soluble material was precipitated with 85% acetone overnight at âˆ’20Â°C, and the pellet was recovered after centrifugation at 14,000 g for 15 min at 4Â°C. Detergent-insoluble material was scraped in PBS containing proteinase inhibitors and was centrifuged at 14,000 g for 15 min at 4Â°C. All pellets were resuspended in the same volume of Laemmli sample buffer.  Immunoblotting  Cell lysates were boiled in 1X Laemmli sample buffer (2% SDS, 10% glycerol, 5% Î²-mercaptoethanol, 0.002% bromophenol blue, and 62.5 mM Tris HCL, pH 6.8), loaded onto a 10% or 7.5% SDS-PAGE gel, and electrotransferred onto polyvinylidene fluoride (PVDF) membrane. Filters were blocked in PBS containing 5% skim milk, incubated with 0.2 Î¼g/ml primary antibody in PBS containing 0.1% Tween 20 (PBS-T), washed extensively with PBS-T, and incubated with 1:3000 dilution of the appropriate secondary antibody. After washing with PBS-T, detection was accomplished with the use of horseradish peroxidaseâ€“coupled secondary antibodies (Amersham) and enhanced chemiluminescence substrate (NEN) or by alkaline phosphotaseâ€“conjugated secondary antibodies and chemifluorescence ECF substrate (Amersham) or biotin-conjugated secondary antibodies (Sigma), streptavidin and 32P-3DNA dendrimer (Genisphere).  Quantification of Western Blots  Radioactive and fluorescent blots were scanned with the Molecular Dynamics STORM imager and quantitated by means of the ImageQuant software program (Molecular Dynamics). Luminescent blots were exposed to film, digitized with the Silverscan III flatbed scanner (La Cie), and quantitated with the National Institutes of Health Image Program, by means of a calibrated step tablet (Kodak).  Expression and Purification of GST Fusion Proteins  Logarithmically growing cultures of E. Coli BL21, transformed with the pGEX-5X-2 recombinant plasmids, were incubated overnight at room temperature, with 0.05 mM isopropyl-b-D-thiogalactoside. The cells were pelleted and were resuspended in 1/20 volume ice-cold PBS, containing 1% Triton X-100 and proteinase inhibitors, and were sonicated on ice for 30 s. Cellular debris was removed by centrifugation at 10,000 g for 15 min at 4Â°C. The supernatant was applied to a glutathione sepharose 4B column (Pharmacia Biotech) and the GST fusion proteins were eluted with 5 mM reduced glutathione in 50 mM Tris-HCL, pH 9.5. Purified proteins were analyzed by separation on a 10% SDS-PAGE gel stained with Commassie Blue and were quantified with the BioRad Protein Assay Reagent. Purified proteins were stored at âˆ’80Â°C.  In Vitro Protein Binding Assays  The merlin pcDNA3 plasmids were used as template for a T7-coupled transcription-translation system (Promega TnT kit) in the presence of 35S-methionine, and radiolabeled protein was made. Samples of the TnT reactions were boiled in 1X Laemmliâ€™s sample buffer and were separated on a 10% SDS-PAGE gel. The dried gel was exposed to film to determine the size, specificity, and quantity of the radiolabeled protein. Known amounts of radiolabeled protein (10â€“25 Î¼l of a 100-Î¼l TnT rxn) were incubated with equal amounts of GST or GSTâ€“merlin fusion proteins (5â€“25 Î¼g) and were immobilized on glutathione-sepharose beads in TEN buffer (10 mM Tris-HCL, pH7.5, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1 mg/ml BSA, and proteinase inhibitors) for 2â€“4 h at 4Â°C. The supernatant was removed, and the beads were washed four times with TEN buffer. Protein bound to the beads was eluted by boiling in 2X Laemmliâ€™s sample buffer for 5 min. Samples were separated on a 10% SDS-PAGE gel. The dried gel was analyzed by autoradiography and phosphoimagery, by means of the STORM imager and the ImageQuant software package.  In Vitro Microtubule Binding Assay  One hundred twenty-five micrograms of purified bovine tubulin (Molecular Probes) were assembled into microtubules in vitro with 50 Î¼l of 35S-labeled merlin protein in a total of 1 ml PGEM buffer (80 mM PIPES, 1 mM MgCl2, 1 mM EGTA, 1 mM GTP [Sigma], 30% glycerol, pH 6.8), with 20 M paclitaxel (Molecular Probes), for 30 min at 37Â°C. Prior to incubation, 50 Î¼l were removed and labeled as the â€œtotalâ€� fraction. After assembly, the polymerized microtubules were collected by centrifugation at 18,000 rpm in a Sorvall SS-34 rotor, for 30 min at 30Â°C. The supernatant was removed to a fresh tube and was labeled â€œsupernatant,â€� and the microtubule pellet was resuspended in 1 ml PGEM buffer and was labeled â€œpellet.â€� Fifty microliters of each fraction were separated on a 12% SDS-PAGE gel. The dried gel was analyzed with the use of the STORM imager and the ImageQuant software package.  Go to: Results Construction of Wild-Type and Mutant Merlin Proteins  To identify biological differences between mutant and wild-type merlin, we constructed GFP-tagged and -untagged expression plasmids for the two wild-type merlin isoforms; for the N-terminal domain, which is analogous to a common NF2-associated nonsense mutation Arg341X; for the unique C-terminal domain; and for five NF2-associated missense mutants (fig. 1). In addition, we designed mammalian expression plasmids for a â€œdominant-negativeâ€� and for an â€œactivatedâ€� form of merlin, Î”BB and Mer559, respectively, which have been characterized elsewhere (LaJeunesse et al. 1998) in the Drosophila homologue of merlin. The mammalian expression constructs were confirmed to produce stable proteins of the predicted size by in vitro transcription/translation (fig. 2A). As shown in figures figures33 and and4,4, western blot analysis revealed that the tagged and untagged wild-type merlin products migrate as a distinct doublet âˆ¼70 kD for the untagged protein (fig. 3A) and âˆ¼100 kD for the GFP-tagged protein (fig. 3A). This pattern of migration was demonstrated to be due to phosphorylation of merlin, with the lower migrating band corresponding to the dephosphorylated form (Shaw et al. 1998). We observed both migrating species for both the tagged and the untagged constructs containing the missense mutations and did not observe any difference in the phosphorylated/dephosphorylated ratio between the wild-type and missense proteins, which suggests that the mutant proteins produce phosphorylated and dephosphorylated products in vivo similar to the wild-type protein (fig. 3A). For all quantitative assays done in this study, we included both migrating species of merlin in all calculations.  Figure  1 Figure 1 Merlin structural domains and the different cDNA constructs used in the study. A, Predicted merlin structure. On the basis of the primary sequence and homology to the ERM proteins, merlin is predicted to consist of a globular amino terminus, an alpha-helical ... Figure  2 Figure 2 Analysis of NF2 mutations on merlin protein interactions in vitro. The ability of wild-type and mutant merlin proteins to form intermolecular complexes was quantitated by means of a GST-fusion binding assay. A, 35S-labeled wild-type and mutant merlin ... Figure  3 Figure 3 Analysis of mutant merlin expression on cell attachment. A, Immunoblot of attached and detached COS-7 cells transfected with wild-type and mutant cDNA constructs. Forty-eight hours after transfection the amount of transfected merlin protein expressed ... Figure  4 Figure 4 Analysis of NF2 mutations on protein solubility. A, Immunoblot of soluble (S) and insoluble (I) fractions of COS-7 cells transfected with untagged cDNA constructs. Transfected cell lysates were recovered 48 h after transfection, and equal amounts of soluble ... Subcellular Distribution of Wild-Type and Mutant Merlin  To investigate whether mutations in merlin affect proper subcellular distribution of the protein, we transiently transfected HeLa, 293, and COS-7 cells with the merlin expression constructs and observed the patterns of merlin localization in both fixed and live cells. Endogenous merlin in these cells was detected clearly by western blot (fig. 3A, vector lane) but was difficult to visualize by immunohistochemistry (fig. 5F), which suggests a low endogenous level of merlin expression. Polyclonal anti-Nterm, A-19, and anti-Cterm, C53, antibodies were used to stain for untagged merlin expression in fixed cells, and GFP autofluorescence was used to study protein localization in live cells. The results were similar for the tagged and untagged proteins and for the various cell types, and were consistent for multiple independent transfection experiments. The two wild-type isoforms localized to the plasma membrane and were particularly abundant in the submembranous regions of filopodia, microspikes, and ruffling membrane (figs. (figs.5A5A andand6B).6B). In addition to the membrane localization, in a large fraction of cells merlin also localized to punctate cytoplasmic granules (figs. (figs.5B5B andand6A).6A). The localization of the N-terminal and C-terminal truncations of merlin differed markedly from the full-length protein. The ERM homology domain Î”Cterm localized mainly to the nucleus, although some protein did localize to the plasma membrane and was never seen as cytoplasmic granules ((6D).6D). The C-terminal half of merlin Î”Nterm was localized diffusely in the cytoplasm and showed no localization to the dynamic regions of the membrane ((6C).6C). Of the five missense mutants, only two displayed an abnormal cellular distribution pattern. The K79E missense mutant was strongly localized to the perinuclear cytoplasm, with only minor staining at the plasma membrane ((6E).6E). The single aa deletion Î”118 protein showed diffuse cytoplasmic staining (figs. (figs.5E5E and and6F).6F). Of the remaining mutant proteins, the missense L535P mutant ((6J)6J) and the dominant-negative mutant Î”BB (fig. 5D) showed submembranous membrane localization but were rarely seen as cytoplasmic granules, which matched the localization pattern of the Î”BB mutant protein reported in Drosophila (LaJeunesse et al. 1998). Mutants N220Y (data not shown), T352M (fig. 5C), and Mer559 ((6I)6I) localized strongly to the submembranous regions in membrane extensions, in addition to cytoplasmic granules in some cells.  Figure  5 Figure 5 293 cells expressing untagged wild-type and mutant forms of merlin. Untagged wild-type merlin shows the same localization pattern as GFP-tagged merlin (A and B). The mutant T352M localizes to microspikes and filopodia and to cytoplasmic granules, similar ... Figure  6Figure  6 Figure 6 293 cells expressing GFP-tagged wild-type and mutant forms of merlin. Wild-type merlin (A and B) and the mutants Mer559 (I) and L535P (J) localize to submembranous regions, especially microspikes and filopodia (B, arrow), and wild-type merlin is sometimes ... Studies of the subcellular distribution of Drosophila merlin found the protein initially localized to the membrane but then internalized to form punctate cytoplasmic structures (LaJeunesse et al. 1998). We had observed merlin-rich punctate cytoplasmic structures in a subset of the transfected cells and wanted to determine if, over time, human merlin also moved from the membrane into cytoplasmic granules. Thus, we monitored the subcellular localization of the GFP-tagged merlin proteins in live cells during a period of 48 h, to determine if merlin localization altered with time. No time-dependent changes in protein localization were observed (data not shown). Since three of the five missense mutants are indistinguishable from wild-type in cellular localization, proper targeting of merlin to the plasma membrane may not be sufficient for tumor-suppressor activity, although it may be necessary.  Cell-Adhesion Properties of Merlin Proteins  Although morphology showed variability from cell to cell, we observed a general trend of altered morphology in merlin-transfected cells compared to cells transfected with vector alone (figs. (figs.5F5F and and6H).6H). Cells transfected with the wild-type isoforms and the mutants N220Y and T352M showed an increase in membrane spikes, long filopodia, and surface blebs, and some cells had extremely large surface areas (figs. (figs.5A,5A, ,5C,5C, and and6B).6B). In contrast, cells overexpressing full-length GFP-moesin did not display these morphological changes ((6G).6G). Cells expressing the activated mutant Mer559 often appeared as round cell bodies with multiple extremely long, thin cellular processes ((6I),6I), whereas cells expressing the dominant-negative mutant Î”BB were often completely round with no cellular extensions (fig. 5D). Cells expressing the mutants L535P and Î”Cterm showed an increase in microspikes but seldom had extremely long cellular processes (figs. (figs.6D6D and and6I).6I). Merlin constructs that mainly localized to the cytoplasm led to no noticeable morphological changes; cells expressing the missense protein Î”118 (figs. (figs.5E5E and and6F)6F) or Î”Nterm ((6C)6C) were similar in cell shape to vector-transfected cells (figs. (figs.5F5F and and6H6H).  These qualitative morphological changes suggested to us that merlin may be involved in cell-matrix interactions. To determine if NF2 mutant proteins could alter cell-matrix interactions, we assayed the adhesion properties of cells expressing the wild-type and mutant merlin proteins. COS-7 cells were transiently transfected with merlin expression constructs, and 48 h posttransfection detached and attached cell fractions were collected. Equal amounts of attached and detached cell lysates were analyzed by immunoblotting, to determine the percentage of total merlin protein found in the detached fraction. Cells expressing the mutant merlin proteins K79E, N220Y, T352M, L535P, Î”Nterm, and Î”Cterm showed an increased tendency to detach from the plate surface compared to cells expressing either wild-type merlin isoforms, which were seldom found in the detached fraction (fig. 3A). Interestingly, the mutant proteins Î”BB and Mer559, which correspond to the Drosophila dominant-negative mutation and to the activating mutation, respectively, showed opposite effects on the adhesion property of the cell. The activating mutation behaved similarly to the NF2-associated mutant proteins by decreasing cell adhesion, whereas the dominant-negative mutation had no effect on adhesion (fig. 3A). To test for reproducibility of this assay, the experiment was performed four separate times with both the tagged and untagged proteins. Although the absolute percentage of detached cells was variable between the experiments, the general trends were consistent, and differences between the wild-type and the mutant proteins were statistically significant with the student t-test (fig. 3B). Interestingly, only the lower migrating merlin band was found in the detached fraction for wild-type protein, which suggests that only dephosphorylated wild-type merlin is present in the detached cells (fig. 3A). In contrast, the upper migrating band was present in the detached fraction of some of the mutant proteins, such as L535P (fig. 3A), which implies that the phosphorylated form is no longer restricted from the detached cells. However, these results were not consistent among the four experiments.  To test for the possibility that the increase in detachment for the mutant-expressing cells was due to increased cell death, detached cells were examined for viability by staining with propidium iodide. More than 80% of the detached cells were viable by this assay, and there was no distinguishable difference in viability between the cells expressing mutant merlin and the wild-type (data not shown).  Cytoskeletal Interactions of Wild-Type and Mutant Merlin  It is possible that the effect on cell adhesion and morphology by merlin proteins is mediated through interactions with the actin cytoskeleton. The ERM proteins bind F-actin through a highly conserved region in the C-terminal domain (Turunen et al. 1994), and overexpression of this domain in transfected cells disrupts actin-based cytoskeleton organization (Edwards et al. 1994). Although merlin lacks this conserved actin-binding domain, studies have demonstrated that merlin colocalizes with cortical actin and that chemical disruption of the actin cytoskeleton leads to a redistribution of merlin in the cell (den Bakker et al. 1995b; Deguen et al. 1998). To investigate whether mutant merlin protein could disrupt actin cytoskeleton organization through aberrant merlin-cytoskeletal interactions, we studied the distribution of actin in 293 and CHO cells transfected with GFP-tagged wild-type and mutant merlin proteins by immunostaining with Texas Redâ€“conjugated phalloidin. Wild-type and mutant merlin, which showed normal subcellular distribution, colocalized with actin at the motile regions of the plasma membrane-filopodia, ruffling edges, and microspikes, but showed no colocalization with actin stress fibers (data not shown). The merlin mutations that decreased cell adhesion had no effect on organization or distribution of the actin cytoskeleton (data not shown).  To further our studies of possible effects on merlin-cytoskeletal interactions by NF2 mutations, we performed cell fractionation assays on merlin-transfected cells. It is well established that nonionic detergent extraction procedures preserve the cytoskeleton and isolate tightly linked cytoskeletal proteins in the insoluble fraction (Algrain et al. 1993). After mild nonionic detergent extraction, cells expressing the different merlin constructs were stained with the antimerlin antibodies A-19 and C53, to determine the solubility of the wild-type and mutant proteins. The wild-type isoforms and mutants N220Y, T352M, Î”BB, and Mer559 displayed no noticeable change in overall protein subcellular localization or intensity of staining after detergent extraction, which suggests that these proteins are linked to cytoskeletal elements. In contrast, the Î”118 and Î”Nterm mutant proteins display an altered staining pattern after mild detergent extraction, changing from a diffuse cytoplasmic to a strong punctate perinuclear localization, after detergent extraction (data not shown). The K79E mutant protein shows a change in cellular localization after extraction similar to but less pronounced than the Î”118 mutant protein. Furthermore, the Î”Cterm and the L535P mutant proteins display an overall decrease in intensity of staining, which implies that these mutations increased the solubility of the protein (data not shown). To confirm these observations, quantitative immunoblot analysis of equal amounts of soluble and insoluble fractions from the transfected cells were performed. The immunoblotting confirmed that the missense mutations K79E, Î”118, and L535P and the deletion of the N- or C-terminal domains increased the solubility of the protein, which suggests that these mutations decrease the stability of merlin-cytoskeletal interactions (fig. 4A). Since detergent extraction experiments can be difficult to reproduce, the experiment was performed several times, and the differences in solubility from wild-type were statistically significant for the mutants K79E, Î”118, L535P, and Î”Cterm (fig. 4B). It is interesting to note that the main species of merlin recovered in the soluble fraction is the dephosphorylated form.  Last, we performed in vitro microtubule binding assays with radiolabeled wild-type and mutant merlin proteins. Xu and Gutmann (1998) reported a microtubule-binding region in the N-terminal domain of merlin, which was normally masked in the wild-type protein but was exposed in NF2 mutant proteins containing C-terminal truncations, exon deletions, and an L64P missense mutation. They hypothesized that merlin protein that exists in an â€œopenâ€� conformation would be defective in growth suppression. We wanted to investigate whether the majority of missense mutations in merlin would alter the folding of the full-length molecule such that normally â€œmaskedâ€� binding domains would be revealed in the mutant molecule. Purified bovine tubulin was polymerized in the presence of in vitro transcribed and translated radiolabeled merlin protein. Polymerized microtubules and tightly linked proteins were pelleted by high-speed centrifugation, and proteins left in the supernatant were unassociated with microtubules. Equal amounts of each fraction were loaded on an SDS-PAGE gel, and the amount of radiolabeled merlin found in each fraction was determined by phosphoimage analysis. No significant differences in microtubule binding were seen between the wild-type isoforms 1 and 2 (14% and 15% bound, respectively) and the missense mutants K79E, N220Y, T352M, and L535P (18%, 18%, 14%, and 10% bound, respectively). In fact, contrary to other reports, the N-terminal domain (aa 1â€“341) did not display significant microtubule binding (8% bound), whereas the C-terminal domain (aa 342â€“595) showed no microtubule binding activity (0.9% bound). Furthermore, immunofluorescence staining of cells transiently transfected with GFP-merlin fusion constructs with antitubulin antibody showed no colocalization of merlin and microtubules (data not shown).  Merlin-Merlin Interactions  It has been demonstrated by the two-hybrid system and in vitro binding assays that merlin could form homodimers, and it was hypothesized that self-association could be a form of functional regulation (Gutmann et al. 1998; Scoles et al. 1998). To determine if NF2 mutations could disrupt merlin self-interactions, we used an in vitro affinity precipitation method to quantitate the binding of wild-type merlin to itself and missense forms of merlin. In a set of experiments, radiolabeled wild-type merlin was generated in vitro and equal amounts of radiolabeled product were incubated with equal amounts of immobilized, bacterially expressed GST-merlin proteins, with or without missense mutations. The GST moiety showed little or no binding of radiolabeled merlin (fig. 2B). The strength of the merlin interactions was quantitated by measuring the percentage of total radiolabeled protein that remained bound to the GST fusion proteins after extensive washing. The reciprocal experiment of measuring the amount of in vitro generated radiolabeled mutant merlin bound to immobilized GSTâ€“wild-type merlin was also performed (fig. 2A). The different radiolabeled merlin constructs all showed little or no binding to the GST moiety (fig. 2A shows the result for Mer559). Because the amount of in vitro generated radiolabeled product differed between the merlin constructs, the total amount of radiolabeled protein input for each incubation was determined by quantification on a phosphoimager (fig. 2). The amount of bound radiolabeled protein was calculated as a percentage of the total radiolabeled input for each separate incubation, thereby normalizing the results to allow direct quantitative comparison of the strength of binding among the different merlin constructs. The experiments were performed three times, and the results were consistent for all constructs except K79E and Î”Cterm, rendering the results for these two proteins inconclusive (fig. 2A and and2B).2B). In addition, the GST-isoform 1 displayed greatly increased binding of radiolabeled isoform 2 compared to isoform 1 (fig. 2A); however, the reciprocal binding experiment has not yet been performed to confirm this result. Five of the remaining seven mutant merlin proteins showed aberrant homodimerization. One missense construct, L535P, displayed a threefold increase in binding to wild-type merlin in vitro (table 1), which suggests that this aa substitution increased merlin dimerization. In contrast, the Î”118 mutant protein gave a fivefold decrease in binding to wild-type merlin, and Î”Nterm showed a complete inability to bind full-length merlin, which implicates the amino terminus as an essential domain for homodimerization (table 1). The dominant-negative Î”BB mutation in merlin and the activated mutant Mer559 both demonstrate an increased ability to dimerize with wild-type merlin (table 1), which suggests that homodimers may be an active form of the protein. The differences in binding ability in vitro are not likely to be due to gross differences in protein translation and stability among the GST fusion constructs or in vitro translated products, since by SDS-PAGE analysis, all merlin constructs displayed the expected-size protein products and showed similar protein stability over time (data not shown). Therefore, missense-containing mutations in merlin can have opposite effects on merlin homodimerization. Interestingly, we observed that full-length merlin binds more strongly to another full-length molecule than to either the amino- or carboxyl-terminal domain alone, which is opposite to that seen for the ERM proteins (Magendantz et al. 1995; Bhartur and Goldenring 1998), thereby demonstrating that merlin may be functionally regulated in a different manner from the ERM proteins. In addition, we observed that native merlin did not bind the closely related, full-length moesin protein (table 1).  Table 1 Table 1 Summary of Merlin Dimerization In Vitro Merlin-EBP50 Interactions  From a two-hybrid screen for merlin interactors and an affinity precipitation experiment for ERM binding partners, two groups independently identified a phosphoprotein, EBP50, which associated strongly with ERM and merlin through the highly conserved amino-terminal domain (Reczek et al. 1997; Murthy et al. 1998). Murthy et al. also reported that merlin containing the missense mutation N220Y showed reduced binding to EBP50, which suggests that this protein interaction may be important for merlin function. To determine if other NF2-associated mutations also affected merlin-EBP50 interactions, we used an affinity precipitation assay to quantitate the ability of mutant forms of merlin to bind EBP50. In vitro translated, radiolabeled EBP50 was incubated with wild-type and mutant merlin GST-fusion proteins immobilized on GSH beads. The amount of EBP50 bound to the GST-merlin proteins was quantitated by phosphoimage analysis of SDS-PAGE gels. In vitro translated EBP50 produced a distinct doublet âˆ¼50 kD (fig. 7A), which matches a report (Reczek et al. 1997) that stated that endogenous placental EBP50 produces three species âˆ¼50â€“53 kD because of differential phosphorylation. Therefore, in vitro generated EBP50 seems to undergo posttranslational modification similar to the endogenous protein. Binding of both EBP50 bands to merlin was quantified, and no differences in merlin binding between the two EBP50 species were detectable (fig. 7A). We confirmed the ability of EBP50 to bind wild-type merlin and moesin and found that four of five NF2-associated missense mutations of merlin decreased EBP50 binding by 35%â€“65% (fig. 7B). In addition, we confirmed that the ERM homology domain Î”Cterm was sufficient for binding EBP50, as has been reported elsewhere (Murthy et al. 1998). We also found that a missense mutation in the extreme carboxyl terminus at position 535 of merlin reduced binding by 50% compared to wild-type, a region which was not thought to be necessary for EBP50 interaction (fig. 7B). To confirm our results, the binding experiment was repeated. Although the overall amount of binding of EBP50-merlin was too low to allow sensitive quantification, the results were consistent in that only wild-type merlin, moesin, and the mutants T352M, Î”Cterm, and Î”Nterm gave detectable binding to EBP50, whereas the mutants K79E, Î”118, N220Y, L535P, and Î”BB displayed no detectable binding of EBP50 (data not shown). It is worth noting that the effect of NF2 mutations on merlin-EBP50 binding does not correlate with their effect on merlin-merlin interactions (table 2).  Figure  7 Figure 7 NF2 mutations decrease binding of merlin to EBP50 in vitro. A, Binding of mutant merlin proteins to EBP50, as was determined by means of a GST fusion binding assay. In vitro 35S-labeled full-length EBP50 (10 Î¼l) was incubated with equal amounts ... Table 2 Table 2 Summary of Molecular and Cellular Differences between Mutant and Wild-Type Merlin Proteins[Note] Go to: Discussion In this study, we used five NF2-associated missense mutations and one truncating mutation to identify cellular and molecular activities of the protein that are likely to be necessary for merlin tumor-suppressor action. Of all the cellular assays we performed, the most striking result was the effect on cell adhesion due to mutant protein expression. The expression of five of six NF2 mutant proteins resulted in a significant decrease in cell adhesion, which was observed as an increase in transfected cells detaching from the substratum. In contrast, endogenous and transfected wild-type merlin was seldom seen in detached cells. In agreement with our results, Koga et al. (1998) reported that human fibroblasts microinjected with mutant merlin constructs, containing either NF2-causing truncating mutations or exon deletions, would round up and detach from the substratum. Furthermore, it has been shown that STS26T cells transfected with antisense merlin oligonucleotides to give complete loss of merlin protein also detached from the substratum, in addition to displaying an increase in cell proliferation (Huynh and Pulst 1996). Together, these experimental results suggest that tumorigenesis may result from disruption of cell-matrix attachment because of a complete loss of merlin protein or because of the expression of a mutant merlin protein defective for the cell-adhesion function of wild-type merlin protein. It is well known that cell adhesion in adherent cells has an important function for normal cell growth; in fact, anchorage-independent growth is a criterion for cell transformation (Hynes 1992; Nur et al. 1992). Cultured NF2 Schwann cells, containing either truncating or missense NF2 alleles, lack contact inhibition of growth and display anchorage-independent growth and increased cell proliferation (Rosenbaum et al. 1998), whereas overexpression of full-length merlin in Ras-transformed fibroblast suppresses anchorage-independent growth and restores contact inhibition of cell growth (Tikoo et al. 1994). Therefore, we hypothesize that merlin acts as a positive regulator of cell-matrix attachment and that disruption of this activity is an initial step in tumor progression.  We investigated several possible molecular mechanisms by which merlin could regulate cell attachment. The various mutant merlin proteins were analyzed for their interaction with the cytoskeleton, since endogenous merlin has been shown to colocalize with several cytoskeletal elements, including F-actin, keratohyalin granules, and intermediate filaments (den Bakker et al. 1995a; Gonzalez-Agosti et al. 1996), and such interactions are likely to be involved in cell-matrix signaling pathways. Consistent with a protein associated with the cytoskeleton, we and others have demonstrated that wild-type merlin is mainly detergent insoluble (Deguen et al. 1998). We observed no change in merlin subcellular localization or intensity of staining in cells extracted with nonionic detergent, and western blot analysis of detergent soluble and insoluble fractions showed that >90% of merlin is retained in the insoluble fraction. In contrast, 55% of the NF2 mutant proteins displayed a significant increase in detergent extractability, indicating a relaxed association with the cytoskeleton. Furthermore, the mutant proteins K79E, Î”118, Î”Cterm, and Î”Nterm, which fail to localize properly to the plasma membrane and thus do not colocalize with cortical actin, all demonstrated a significant increase in protein solubility, further supporting the contention that these mutant proteins do not form stable interactions with the cytoskeleton. However, merlin protein solubility did not correlate with the proteinâ€™s effect on cell adhesion, since two NF2 mutant proteins that decreased cell adhesionâ€”N220Y and T352Mâ€”displayed no increase in detergent solubility and/or difference in subcellular localization compared to wild-type (table 2). Thus, merlin regulation of cell adhesion is not likely to be mediated simply through interaction with the actin cytoskeleton.  One possible mechanism that may account for the differences we observed between wild-type and mutant merlin proteins is differential phosphorylation. Evidence from several in vitro and in vivo studies of the closely related ERM proteins suggests a model where inactive ERM proteins in the cytoplasm are activated by phosphorylation of a conserved threonine in the carboxyl terminus, causing translocation of the activated form to the plasma membrane (Nakamura et al. 1995; Hirao et al. 1996; Serrador et al. 1997; Matsui et al. 1998; Hayashi 1999). Merlin also contains this conserved threonine at position 576, and, likewise, in vivo merlin exhibits both phosphorylated and dephosphorylated forms due to phosphorylation of serine and/or threonine residues (Takeshima et al. 1994; Shaw et al. 1998). The ratio of the phosphorylated and dephosphorylated forms of merlin in cultured cells are affected by cell adhesion. Loss of adhesion results in a complete dephosphorylation of merlin, whereas reattachment of cells to a substrate leads to a rapid increase in the phosphorylated species (Shaw et al. 1998). In this study we found, by western analysis, that the five missense mutants produced both the phosphorylated and dephosphorylated species and that detached cells only express the dephosphorylated form of wild-type merlin. However, we sometimes observed, by western analysis, the presence of the phosphorylated form of the missense mutants K79E, T352M, and L535P in the detached fraction, a condition we never saw for the two wild-type isoforms. Since the expression of these mutant proteins in cells causes loss of adhesion, and since the phosphorylated form of these mutants is abnormally retained in the detached cells, these results suggest that the phosphorylation of these mutant proteins may no longer be responsive to environmental cues, such as changes in cell spreading and attachment, which may lead to improper regulation of tumor-suppressor function. It will be interesting to determine if the addition of phosphatase inhibitors to cell cultures modulates merlinâ€™s effect on cell adhesion. In a recent study, the presence of phosphatase inhibitors in homogenized cells was demonstrated to increase the percentage of merlin recovered in the insoluble fraction, which suggests that merlin is translocated from the insoluble to the soluble fraction by dephosphorylation (Maeda et al. 1999). Under this model, we would expect to see a decrease in the ratio of phosphorylated to dephosphorylated merlin for mutants that showed increased solubility. We did not observe any significant difference in the ratio of total phosphorylated/dephosphorylated forms between the wild-type and the missense mutants.  Intriguingly, four of the five disease-causing missense mutants, as well as the dominant-negative Drosophila mutant Î”BB, displayed decreased binding to EBP50, a protein that binds all the MERM proteins (Murthy et al. 1998; Reczek and Bretscher 1998) (table 2). EBP50 is the human homologue of rabbit NHE-RF, a cofactor that has been shown to mediate protein kinase A inhibition of the renal Na+-H+ exchanger NHE3 in cultured cells (Yun et al. 1997). The physiological importance of merlin-EBP50 interaction remains highly speculative, but it is interesting to note that it has been well documented that stimulation of Na+-H+ exchangers is associated with increased cell proliferation and differentiation in response to growth factors and mitogenic agents (Ritter et al. 1997). We found no direct correlation between the strength of EBP50-merlin interactions and any of the cellular phenotypes we assayed; however, our finding that 63% of the mutant proteins studied reduced merlin-EBP50 binding merits further investigation into the possibility that this interaction is a necessary but not sufficient component of merlin tumor-suppressor function.  Another merlin-protein interaction that may be a contributing factor in merlin regulation of cell growth is merlin homodimerization. This hypothesis was suggested by Sherman et al. (1997), who demonstrated that alterations in the C-terminus that abolished merlin growth suppression also resulted in no merlin self-association. However, to date, no single aa NF2 mutations have been shown to alter merlin self-association. In this report, we demonstrated that two NF2-associated missense mutationsâ€”Î”118 and L535Pâ€”significantly altered the ability of the full-length mutant molecule to dimerize with wild-type merlin (table 2). Surprisingly, the two missense mutations had opposite effects on merlin interaction. Although the Î”118 mutation almost abolished merlin dimerization, the missense L535P greatly increased dimerization, implicating regulation of merlin self-association as an important component of merlin function. In support of this, the Î”BB mutation in merlin and the merlin mutant Mer559, genetically defined as a dominant-negative allele and a â€œgain-of-functionâ€� allele in Drosophila, respectively (LaJeunesse et al. 1998), both demonstrate an increased ability to dimerize with wild-type merlin, which suggests that homodimers may be an active form of the protein. In this model, functionally defective merlin that can form homodimers with remaining wild-type molecules and mutant merlin that is unable to dimerize could both lead to a decrease in merlin activity. Overall, all of the merlin-protein interactions we assayedâ€”cytoskeletal, EBP50, and homodimerizationâ€”were disrupted by NF2 mutations, but none of the changes was correlated with another or with the cell-adhesion phenotype. Thus, it is likely that merlin acts within a complex of molecules and that disruption of any of several interactions by NF2 mutations leads to abnormal cell growth.  In light of the observation that mutations in merlin can greatly alter cell adhesion, a potentially fruitful area of investigation may be in merlin direct interaction with adhesion transmembrane proteins. Recently, merlin was shown to partially colocalize and coimmunoprecipitate with the Î²1-integrin transmembrane receptor in differentiating Schwann/neuron cell cultures (Obremski et al. 1998). Î²1-integrin binding to the basal lamina and the actin cytoskeleton have been implicated as part of a signal transduction complex necessary for Schwann cell myelination (Fernandez-Valle et al. 1994). Like merlin, overexpression of integrins can suppress anchorage-independent growth and prevent abnormal cell growth (Giancotti and Ruoslahti 1990). Thus, NF2 mutant proteins may have aberrant interactions with Î²1-integrins, thereby altering the transduction of signals from the extracellular matrix necessary for Schwann cell differentiation and growth. This model could easily be tested by determining the ability of NF2 mutant merlin to coimmunoprecipitate with Î²1-integrin from cells and investigating for aberrant localization and responses of Î²1-integrin in NF2 Schwann cells.  Last, our demonstration of cellular phenotypes associated with exogenous expression of NF2 mutant alleles shows that these missense mutations may act in a dominant manner. We found that the decrease in cellular adhesion by mutant NF2 proteins could be a dominant effect, since COS-7 cells contain two wild-type NF2 alleles and have low levels of endogenous merlin expression detectable by western blotting. However, the mutant alleles may be acting as loss-of-function mutations in the adhesion phenotype. If overexpression of wild-type merlin causes greatly increased cell attachment, whereas mutant merlin has no effect on cell attachment, the results would be similar to what we observed in this study. In agreement with a dominant mode of action for mutant NF2 alleles, Koga et al. (1998) reported that loss of cell attachment still occurred when NF2 deletion mutants and wild-type merlin were coexpressed in fibroblasts. Experimental evidence in a mouse NF2 model supports a dominant mode of action for some NF2 mutant alleles. Recently, a report by Giovannini et al. (1999) showed that NF2 +/+ transgenic mice expressing an NF2-associated mutant allele, lacking exons 2 and 3, under control of a Schwann cell-specific promoter, had a high prevalence of Schwann-cellâ€“derived tumors and schwannosis. Furthermore, the tumorigenic activity of the NF2 mutant allele was modulated by the number of NF2 wild-type alleles in vivo, giving rise to the possibility that the mutant allele may act as in a dominant-negative manner (Giovannini et al. 1999). Providing some results to directly address this possibility, we observed that in the cell-adhesion assay, the expression of the Drosophila dominant-negative mutant Î”BB had no effect on cell attachment, whereas expression of the Drosophila gain-of-function mutant Mer559 in cells led to a significant increase in cell detachment. Our findings suggest that some NF2-associated missense mutations, which account for 10% of naturally occurring mutations and a subset of truncating mutations, may act as dominant gain-of-function alleles. It is possible that our findings and the findings in the mouse and Drosophila models are artifacts of overexpression of inherently unstable proteins or of the model system. In support of the stability of the missense proteins in vivo, the half-life of two missense proteinsâ€”L64P and L535Pâ€”in stable rat schwannoma cell lines was highly similar to the half-life of isoform 1 (Gutmann et al. 1998), and a meningioma expressing only a missense NF2 transcriptâ€”C300Yâ€”still produced full-length protein detectable by western analysis (Takeshima et al. 1998). For most of the missense alleles used in this studyâ€”Î”118, N220Y, T352M, and L535Pâ€”the status of the second NF2 allele in the tumors was not reported, and the mutation K79E was found in a sporadic schwannoma with deletion of the second NF2 allele (Sainz et al. 1994). Thus, no direct genetic evidence for dominance of missense alleles in human tumors is available. However, western analysis of 22 vestibular schwannoma for merlin expression found that three tumors (14%) expressed both full-length merlin and a truncated protein containing the N-terminal domain of merlin (Harwalkar et al. 1998), which supports the possibility of a dominant mode of action for a small fraction of NF2 truncating alleles. This mode of action could partially explain the conflicting finding that complete deletions of the gene are found in mildly affected patients (Evans et al. 1998; Zucman-Rossi et al. 1998), whereas it would be predicted that if merlin acts as a traditional tumor-suppressor gene, complete loss of the entire NF2 gene would be associated with a more-severe disease course. Since several recurring mutations have been described in patients with varying degrees of disease severity, it is also likely that additional genetic and environmental factors influence the course of the disease. Further detailed characterization of NF2 alleles and merlin expression in naturally occurring tumors is necessary to determine the mechanism by which specific NF2 mutant alleles disrupt merlin tumor-suppressor function.  Neurofibromatosis 2 (NF2) is a tumor predisposition syndrome in which affected individuals develop nervous system tumors at an increased frequency. The most common tumor in individuals with NF2 is the schwannoma, which is composed of neoplastic Schwann cells lacking NF2 gene expression. Moreover, inactivation of the NF2 gene is observed in nearly all sporadic schwannomas, suggesting that the NF2 gene is a critical growth regulator for Schwann cells. In an effort to gain insights into the function of the NF2 gene product, merlin or schwannomin, we performed a detailed functional analysis of eight naturally occurring non-conservative missense mutations in the NF2 gene. Using a regulatable expression system in rat schwannoma cells, we analyzed proliferation, actin cytoskeleton-mediated events and merlin folding. In this report, we demonstrate that mutations clustered in the predicted alpha-helical region did not impair the function of merlin whereas those in either the N- or C-terminus of the protein rendered merlin inactive as a negative growth regulator. These results suggest that the key functional domains of merlin lie within the highly conserved FERM domain and the unique C-terminus of the protein.\""
      ]
     },
     "execution_count": 276,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train_df.iloc[2900].Text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 290,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ID</th>\n",
       "      <th>Gene</th>\n",
       "      <th>Variation</th>\n",
       "      <th>Class</th>\n",
       "      <th>Variation_Alt</th>\n",
       "      <th>Text</th>\n",
       "      <th>num_words</th>\n",
       "      <th>num_chars</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2901</th>\n",
       "      <td>2901</td>\n",
       "      <td>NF2</td>\n",
       "      <td>K413E</td>\n",
       "      <td>6</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Neurofibromatosis type 2 (NF2) is a multiple n...</td>\n",
       "      <td>3863</td>\n",
       "      <td>27293</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        ID Gene Variation  Class Variation_Alt  \\\n",
       "2901  2901  NF2     K413E      6   ProteinSwap   \n",
       "\n",
       "                                                   Text  num_words  num_chars  \n",
       "2901  Neurofibromatosis type 2 (NF2) is a multiple n...       3863      27293  "
      ]
     },
     "execution_count": 290,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train_df[train_df['Variation'].str.match('K413E')]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ID</th>\n",
       "      <th>Gene</th>\n",
       "      <th>Variation</th>\n",
       "      <th>Class</th>\n",
       "      <th>Variation_Alt</th>\n",
       "      <th>Text</th>\n",
       "      <th>num_words</th>\n",
       "      <th>num_chars</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>140</th>\n",
       "      <td>140</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>I491M</td>\n",
       "      <td>5</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>The accurate determination of perfluoroalkyl s...</td>\n",
       "      <td>430</td>\n",
       "      <td>2925</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>145</th>\n",
       "      <td>145</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>K467T</td>\n",
       "      <td>2</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>The accurate determination of perfluoroalkyl s...</td>\n",
       "      <td>430</td>\n",
       "      <td>2925</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>259</th>\n",
       "      <td>259</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>S464L</td>\n",
       "      <td>2</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>The accurate determination of perfluoroalkyl s...</td>\n",
       "      <td>430</td>\n",
       "      <td>2925</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>344</th>\n",
       "      <td>344</td>\n",
       "      <td>CDH1</td>\n",
       "      <td>A617T</td>\n",
       "      <td>4</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>E-cadherin is involved in the formation of cel...</td>\n",
       "      <td>187</td>\n",
       "      <td>1315</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>346</th>\n",
       "      <td>346</td>\n",
       "      <td>CDH1</td>\n",
       "      <td>A634V</td>\n",
       "      <td>4</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>E-cadherin is involved in the formation of cel...</td>\n",
       "      <td>187</td>\n",
       "      <td>1315</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>348</th>\n",
       "      <td>348</td>\n",
       "      <td>CDH1</td>\n",
       "      <td>T340A</td>\n",
       "      <td>4</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>E-cadherin is involved in the formation of cel...</td>\n",
       "      <td>187</td>\n",
       "      <td>1315</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>648</th>\n",
       "      <td>648</td>\n",
       "      <td>CDKN2A</td>\n",
       "      <td>Q50*</td>\n",
       "      <td>4</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>The p16 gene is located in chromosome 9p21, a ...</td>\n",
       "      <td>103</td>\n",
       "      <td>706</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>688</th>\n",
       "      <td>688</td>\n",
       "      <td>CDKN2A</td>\n",
       "      <td>R79P</td>\n",
       "      <td>4</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Cell division is controlled by a series of pos...</td>\n",
       "      <td>228</td>\n",
       "      <td>1540</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>692</th>\n",
       "      <td>692</td>\n",
       "      <td>CDKN2A</td>\n",
       "      <td>G93W</td>\n",
       "      <td>4</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Cell division is controlled by a series of pos...</td>\n",
       "      <td>228</td>\n",
       "      <td>1540</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>693</th>\n",
       "      <td>693</td>\n",
       "      <td>CDKN2A</td>\n",
       "      <td>V118D</td>\n",
       "      <td>4</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Cell division is controlled by a series of pos...</td>\n",
       "      <td>228</td>\n",
       "      <td>1540</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>868</th>\n",
       "      <td>868</td>\n",
       "      <td>HLA-A</td>\n",
       "      <td>596_619splice</td>\n",
       "      <td>1</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>A new variant of the HLA-A*010101 allele desig...</td>\n",
       "      <td>184</td>\n",
       "      <td>1219</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>941</th>\n",
       "      <td>941</td>\n",
       "      <td>PDGFRB</td>\n",
       "      <td>ATF7IP-PDGFRB Fusion</td>\n",
       "      <td>2</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Chronic myelomonocytic leukemia (CMML) is a my...</td>\n",
       "      <td>116</td>\n",
       "      <td>776</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1057</th>\n",
       "      <td>1057</td>\n",
       "      <td>EWSR1</td>\n",
       "      <td>EWSR1-FEV Fusion</td>\n",
       "      <td>2</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>As a result of chromosome translocations, the ...</td>\n",
       "      <td>207</td>\n",
       "      <td>1215</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1154</th>\n",
       "      <td>1154</td>\n",
       "      <td>KMT2C</td>\n",
       "      <td>S3660L</td>\n",
       "      <td>5</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Several studies indicated that the expression ...</td>\n",
       "      <td>341</td>\n",
       "      <td>2176</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1286</th>\n",
       "      <td>1286</td>\n",
       "      <td>HRAS</td>\n",
       "      <td>A146V</td>\n",
       "      <td>2</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Costello syndrome is a rare congenital disorde...</td>\n",
       "      <td>244</td>\n",
       "      <td>1692</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1290</th>\n",
       "      <td>1290</td>\n",
       "      <td>HRAS</td>\n",
       "      <td>T58I</td>\n",
       "      <td>2</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>We report a 10-year-old girl presenting with s...</td>\n",
       "      <td>231</td>\n",
       "      <td>1668</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1368</th>\n",
       "      <td>1368</td>\n",
       "      <td>AKT2</td>\n",
       "      <td>D32H</td>\n",
       "      <td>7</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>The activating E17K mutations recently discove...</td>\n",
       "      <td>448</td>\n",
       "      <td>2864</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1378</th>\n",
       "      <td>1378</td>\n",
       "      <td>AKT2</td>\n",
       "      <td>D399N</td>\n",
       "      <td>7</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>The activating E17K mutations recently discove...</td>\n",
       "      <td>448</td>\n",
       "      <td>2864</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1583</th>\n",
       "      <td>1583</td>\n",
       "      <td>PMS1</td>\n",
       "      <td>Q233*</td>\n",
       "      <td>4</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>HEREDITARY nonpolyposis colorectal cancer (HNP...</td>\n",
       "      <td>114</td>\n",
       "      <td>742</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1613</th>\n",
       "      <td>1613</td>\n",
       "      <td>VHL</td>\n",
       "      <td>L158Q</td>\n",
       "      <td>4</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>The case of a 40-year-old woman with severe ed...</td>\n",
       "      <td>53</td>\n",
       "      <td>337</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1620</th>\n",
       "      <td>1620</td>\n",
       "      <td>VHL</td>\n",
       "      <td>P25L</td>\n",
       "      <td>5</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Background: von Hippel-Lindau (VHL) disease is...</td>\n",
       "      <td>431</td>\n",
       "      <td>2643</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2146</th>\n",
       "      <td>2146</td>\n",
       "      <td>PTCH1</td>\n",
       "      <td>Truncating Mutations</td>\n",
       "      <td>1</td>\n",
       "      <td>Truncating Mutations</td>\n",
       "      <td>Basal cell carcinoma (BCC) is the most common ...</td>\n",
       "      <td>212</td>\n",
       "      <td>1407</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2504</th>\n",
       "      <td>2504</td>\n",
       "      <td>BRCA1</td>\n",
       "      <td>V11A</td>\n",
       "      <td>6</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Identification of protein-protein interaction...</td>\n",
       "      <td>230</td>\n",
       "      <td>1632</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2900</th>\n",
       "      <td>2900</td>\n",
       "      <td>NF2</td>\n",
       "      <td>E106G</td>\n",
       "      <td>1</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Neurofibromatosis 2 (NF2) is a tumor predispos...</td>\n",
       "      <td>183</td>\n",
       "      <td>1219</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2906</th>\n",
       "      <td>2906</td>\n",
       "      <td>NF2</td>\n",
       "      <td>Q538P</td>\n",
       "      <td>1</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Neurofibromatosis 2 (NF2) is a tumor predispos...</td>\n",
       "      <td>183</td>\n",
       "      <td>1219</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2908</th>\n",
       "      <td>2908</td>\n",
       "      <td>NF2</td>\n",
       "      <td>Q324L</td>\n",
       "      <td>5</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>Neurofibromatosis 2 (NF2) is a tumor predispos...</td>\n",
       "      <td>183</td>\n",
       "      <td>1219</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2980</th>\n",
       "      <td>2980</td>\n",
       "      <td>KIT</td>\n",
       "      <td>N655K</td>\n",
       "      <td>2</td>\n",
       "      <td>ProteinSwap</td>\n",
       "      <td>TO THE EDITOR: I commend Drs. Freeman and Bank...</td>\n",
       "      <td>362</td>\n",
       "      <td>2689</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        ID    Gene             Variation  Class         Variation_Alt  \\\n",
       "140    140    EGFR                 I491M      5           ProteinSwap   \n",
       "145    145    EGFR                 K467T      2           ProteinSwap   \n",
       "259    259    EGFR                 S464L      2           ProteinSwap   \n",
       "344    344    CDH1                 A617T      4           ProteinSwap   \n",
       "346    346    CDH1                 A634V      4           ProteinSwap   \n",
       "348    348    CDH1                 T340A      4           ProteinSwap   \n",
       "648    648  CDKN2A                  Q50*      4           ProteinSwap   \n",
       "688    688  CDKN2A                  R79P      4           ProteinSwap   \n",
       "692    692  CDKN2A                  G93W      4           ProteinSwap   \n",
       "693    693  CDKN2A                 V118D      4           ProteinSwap   \n",
       "868    868   HLA-A         596_619splice      1           ProteinSwap   \n",
       "941    941  PDGFRB  ATF7IP-PDGFRB Fusion      2           ProteinSwap   \n",
       "1057  1057   EWSR1      EWSR1-FEV Fusion      2           ProteinSwap   \n",
       "1154  1154   KMT2C                S3660L      5           ProteinSwap   \n",
       "1286  1286    HRAS                 A146V      2           ProteinSwap   \n",
       "1290  1290    HRAS                  T58I      2           ProteinSwap   \n",
       "1368  1368    AKT2                  D32H      7           ProteinSwap   \n",
       "1378  1378    AKT2                 D399N      7           ProteinSwap   \n",
       "1583  1583    PMS1                 Q233*      4           ProteinSwap   \n",
       "1613  1613     VHL                 L158Q      4           ProteinSwap   \n",
       "1620  1620     VHL                  P25L      5           ProteinSwap   \n",
       "2146  2146   PTCH1  Truncating Mutations      1  Truncating Mutations   \n",
       "2504  2504   BRCA1                  V11A      6           ProteinSwap   \n",
       "2900  2900     NF2                 E106G      1           ProteinSwap   \n",
       "2906  2906     NF2                 Q538P      1           ProteinSwap   \n",
       "2908  2908     NF2                 Q324L      5           ProteinSwap   \n",
       "2980  2980     KIT                 N655K      2           ProteinSwap   \n",
       "\n",
       "                                                   Text  num_words  num_chars  \n",
       "140   The accurate determination of perfluoroalkyl s...        430       2925  \n",
       "145   The accurate determination of perfluoroalkyl s...        430       2925  \n",
       "259   The accurate determination of perfluoroalkyl s...        430       2925  \n",
       "344   E-cadherin is involved in the formation of cel...        187       1315  \n",
       "346   E-cadherin is involved in the formation of cel...        187       1315  \n",
       "348   E-cadherin is involved in the formation of cel...        187       1315  \n",
       "648   The p16 gene is located in chromosome 9p21, a ...        103        706  \n",
       "688   Cell division is controlled by a series of pos...        228       1540  \n",
       "692   Cell division is controlled by a series of pos...        228       1540  \n",
       "693   Cell division is controlled by a series of pos...        228       1540  \n",
       "868   A new variant of the HLA-A*010101 allele desig...        184       1219  \n",
       "941   Chronic myelomonocytic leukemia (CMML) is a my...        116        776  \n",
       "1057  As a result of chromosome translocations, the ...        207       1215  \n",
       "1154  Several studies indicated that the expression ...        341       2176  \n",
       "1286  Costello syndrome is a rare congenital disorde...        244       1692  \n",
       "1290  We report a 10-year-old girl presenting with s...        231       1668  \n",
       "1368  The activating E17K mutations recently discove...        448       2864  \n",
       "1378  The activating E17K mutations recently discove...        448       2864  \n",
       "1583  HEREDITARY nonpolyposis colorectal cancer (HNP...        114        742  \n",
       "1613  The case of a 40-year-old woman with severe ed...         53        337  \n",
       "1620  Background: von Hippel-Lindau (VHL) disease is...        431       2643  \n",
       "2146  Basal cell carcinoma (BCC) is the most common ...        212       1407  \n",
       "2504   Identification of protein-protein interaction...        230       1632  \n",
       "2900  Neurofibromatosis 2 (NF2) is a tumor predispos...        183       1219  \n",
       "2906  Neurofibromatosis 2 (NF2) is a tumor predispos...        183       1219  \n",
       "2908  Neurofibromatosis 2 (NF2) is a tumor predispos...        183       1219  \n",
       "2980  TO THE EDITOR: I commend Drs. Freeman and Bank...        362       2689  "
      ]
     },
     "execution_count": 91,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# remove rows with NaN\n",
    "train_df = train_df[train_df['Text'].notna()]\n",
    "test_df = test_df[test_df['Text'].notna()]\n",
    "\n",
    "train_df[train_df[\"num_words\"]<500]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Some variations have the same text descriptor, and belong to the same class. Some variations have the same text descriptor, but belongs to a separate class (see IDs [140,145,259], and [2906,2908]). This will definitely give us trouble later on...\n",
    "\n",
    "Let's take a look at the test data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ID</th>\n",
       "      <th>Gene</th>\n",
       "      <th>Variation</th>\n",
       "      <th>Text</th>\n",
       "      <th>num_words</th>\n",
       "      <th>num_chars</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>206</th>\n",
       "      <td>206</td>\n",
       "      <td>AR</td>\n",
       "      <td>H690P</td>\n",
       "      <td>The estrogen receptor complex is a known trans...</td>\n",
       "      <td>341</td>\n",
       "      <td>2419</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>527</th>\n",
       "      <td>527</td>\n",
       "      <td>MCFD2</td>\n",
       "      <td>D129E</td>\n",
       "      <td>THE critical pathways through which protein-ty...</td>\n",
       "      <td>487</td>\n",
       "      <td>3272</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>859</th>\n",
       "      <td>859</td>\n",
       "      <td>MSH2</td>\n",
       "      <td>R621*</td>\n",
       "      <td>Hereditary nonpolyposis colon cancer (HN-PCC) ...</td>\n",
       "      <td>134</td>\n",
       "      <td>882</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1193</th>\n",
       "      <td>1193</td>\n",
       "      <td>TYR</td>\n",
       "      <td>C55Y</td>\n",
       "      <td>Familial adenomatous polyposis (FAP) is an aut...</td>\n",
       "      <td>299</td>\n",
       "      <td>2009</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1309</th>\n",
       "      <td>1309</td>\n",
       "      <td>LDLR</td>\n",
       "      <td>D175N</td>\n",
       "      <td>It has previously been shown that, in the hete...</td>\n",
       "      <td>339</td>\n",
       "      <td>2219</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1575</th>\n",
       "      <td>1575</td>\n",
       "      <td>NCF1</td>\n",
       "      <td>R42Q</td>\n",
       "      <td>Glioblastoma multiforme (GBM) is the most comm...</td>\n",
       "      <td>401</td>\n",
       "      <td>2803</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2765</th>\n",
       "      <td>2765</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>Q25H</td>\n",
       "      <td>Gallbladder cancer (GBC) is more prevalent tha...</td>\n",
       "      <td>272</td>\n",
       "      <td>1688</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3299</th>\n",
       "      <td>3299</td>\n",
       "      <td>ARSA</td>\n",
       "      <td>P233T</td>\n",
       "      <td>A 44-year-old male presented with a violaceous...</td>\n",
       "      <td>378</td>\n",
       "      <td>2673</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3322</th>\n",
       "      <td>3322</td>\n",
       "      <td>CDKN2A</td>\n",
       "      <td>P73L</td>\n",
       "      <td>Cell division is controlled by a series of pos...</td>\n",
       "      <td>228</td>\n",
       "      <td>1540</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3996</th>\n",
       "      <td>3996</td>\n",
       "      <td>BRCA1</td>\n",
       "      <td>A1752G</td>\n",
       "      <td>Abstract Germline mutations in the tumor supp...</td>\n",
       "      <td>165</td>\n",
       "      <td>1127</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4061</th>\n",
       "      <td>4061</td>\n",
       "      <td>XRCC2</td>\n",
       "      <td>R188H</td>\n",
       "      <td>An acquired genetic instability, resulting fro...</td>\n",
       "      <td>217</td>\n",
       "      <td>1394</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5010</th>\n",
       "      <td>5010</td>\n",
       "      <td>ACADM</td>\n",
       "      <td>G195R</td>\n",
       "      <td>A single missense mutation in the human erbB-2...</td>\n",
       "      <td>463</td>\n",
       "      <td>3173</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        ID    Gene Variation  \\\n",
       "206    206      AR     H690P   \n",
       "527    527   MCFD2     D129E   \n",
       "859    859    MSH2     R621*   \n",
       "1193  1193     TYR      C55Y   \n",
       "1309  1309    LDLR     D175N   \n",
       "1575  1575    NCF1      R42Q   \n",
       "2765  2765    KRAS      Q25H   \n",
       "3299  3299    ARSA     P233T   \n",
       "3322  3322  CDKN2A      P73L   \n",
       "3996  3996   BRCA1    A1752G   \n",
       "4061  4061   XRCC2     R188H   \n",
       "5010  5010   ACADM     G195R   \n",
       "\n",
       "                                                   Text  num_words  num_chars  \n",
       "206   The estrogen receptor complex is a known trans...        341       2419  \n",
       "527   THE critical pathways through which protein-ty...        487       3272  \n",
       "859   Hereditary nonpolyposis colon cancer (HN-PCC) ...        134        882  \n",
       "1193  Familial adenomatous polyposis (FAP) is an aut...        299       2009  \n",
       "1309  It has previously been shown that, in the hete...        339       2219  \n",
       "1575  Glioblastoma multiforme (GBM) is the most comm...        401       2803  \n",
       "2765  Gallbladder cancer (GBC) is more prevalent tha...        272       1688  \n",
       "3299  A 44-year-old male presented with a violaceous...        378       2673  \n",
       "3322  Cell division is controlled by a series of pos...        228       1540  \n",
       "3996   Abstract Germline mutations in the tumor supp...        165       1127  \n",
       "4061  An acquired genetic instability, resulting fro...        217       1394  \n",
       "5010  A single missense mutation in the human erbB-2...        463       3173  "
      ]
     },
     "execution_count": 92,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test_df[test_df[\"num_words\"]<500]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Clean text data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [],
   "source": [
    "import string\n",
    "import re #regular expressions\n",
    "from nltk.corpus import stopwords\n",
    "# note: to use stopwords, first do nltk.download() to download the various corpi in nltk.\n",
    "\n",
    "# TO DO:\n",
    "# we should remove the references from the text field!! e.g., if there are references like (1,2) or [5][6]\n",
    "# use regex expression to clean these up!\n",
    "\n",
    "def textClean(text):\n",
    "    text = re.sub(r\"[^A-Za-z0-9^,!.\\/'+-=]\", \" \", text)\n",
    "    text = text.lower().split()\n",
    "    stops = set(stopwords.words(\"english\"))\n",
    "    text = [w for w in text if not w in stops]    \n",
    "    text = \" \".join(text)\n",
    "    return(text)\n",
    "\n",
    "def cleanup(text):\n",
    "    text = textClean(text)\n",
    "    text= text.translate(str.maketrans(\"\",\"\", string.punctuation))\n",
    "    return text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {},
   "outputs": [],
   "source": [
    "allText_train = train_df['Text'].apply(cleanup)\n",
    "allText_test = test_df['Text'].apply(cleanup)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'molecular mechanisms underlying STAR syndrome.Cyclin-dependent kinases (CDKs) play a pivotal role in the control of a number of fundamental cellular processes (1). The human genome contains 21 genes encoding proteins that can be considered as members of the CDK family owing to their sequence similarity with bona fide CDKs, those known to be activated by cyclins (2). Although discovered almost 20 y ago (3, 4), CDK10 remains one of the two CDKs without an identified cyclin partner. This knowledge gap has largely impeded the exploration of its biological functions. CDK10 can act as a positive cell cycle regulator in some cells (5, 6) or as a tumor suppressor in others (7, 8). CDK10 interacts with the ETS2 (v-ets erythroblastosis virus E26 oncogene homolog 2) transcription factor and inhibits its transcriptional activity through an unknown mechanism (9). CDK10 knockdown derepresses ETS2, which increases the expression of the c-Raf protein kinase, activates the MAPK pathway, and induces res'"
      ]
     },
     "execution_count": 80,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# before\n",
    "train_df['Text'][0][1500:2500]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "' 20 ago 3 4  cdk10 remains one two cdks without identified cyclin partner knowledge gap largely impeded exploration biological functions cdk10 act positive cell cycle regulator cells 5 6 tumor suppressor others 7 8  cdk10 interacts ets2 vets erythroblastosis virus e26 oncogene homolog 2 transcription factor inhibits transcriptional activity unknown mechanism 9  cdk10 knockdown derepresses ets2 increases expression craf protein kinase activates mapk pathway induces resistance mcf7 cells tamoxifen 6 here deorphanize cdk10 identifying cyclin m product fam58a binding partner mutations gene predict absence truncation cyclin associated star syndrome whose features include toe syndactyly telecanthus anogenital renal malformations heterozygous females 10  however functions cyclin pathogenesis star syndrome remain unknown show recombinant cdk10cyclin heterodimer active protein kinase phosphorylates ets2 vitro cyclin silencing phenocopies cdk10 silencing increasing craf phosphoerk expression lev'"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# after\n",
    "allText[0][1500:2500]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [],
   "source": [
    "from gensim.models.doc2vec import LabeledSentence\n",
    "from gensim import utils\n",
    "\n",
    "def constructLabeledSentences(data):\n",
    "    sentences=[]\n",
    "    for index, row in data.iteritems():\n",
    "        sentences.append(LabeledSentence(utils.to_unicode(row).split(), ['Text' + '_%s' % str(index)]))\n",
    "    return sentences"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 94,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\Kenny\\Anaconda3\\lib\\site-packages\\ipykernel_launcher.py:7: DeprecationWarning: Call to deprecated `LabeledSentence` (Class will be removed in 4.0.0, use TaggedDocument instead).\n",
      "  import sys\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "LabeledSentence(words=['cyclindependent', 'kinases', 'cdks', 'regulate', 'variety', 'fundamental', 'cellular', 'processes', 'cdk10', 'stands', 'one', 'last', 'orphan', 'cdks', 'activating', 'cyclin', 'identified', 'kinase', 'activity', 'revealed', 'previous', 'work', 'shown', 'cdk10', 'silencing', 'increases', 'ets2', 'vets', 'erythroblastosis', 'virus', 'e26', 'oncogene', 'homolog', '2', 'driven', 'activation', 'mapk', 'pathway', 'confers', 'tamoxifen', 'resistance', 'breast', 'cancer', 'cells', 'precise', 'mechanisms', 'cdk10', 'modulates', 'ets2', 'activity', 'generally', 'functions', 'cdk10', 'remain', 'elusive', 'demonstrate', 'cdk10', 'cyclindependent', 'kinase', 'identifying', 'cyclin', 'activating', 'cyclin', 'cyclin', 'm', 'orphan', 'cyclin', 'product', 'fam58a', 'whose', 'mutations', 'cause', 'star', 'syndrome', 'human', 'developmental', 'anomaly', 'whose', 'features', 'include', 'toe', 'syndactyly', 'telecanthus', 'anogenital', 'renal', 'malformations', 'show', 'star', 'syndromeassociated', 'cyclin', 'mutants', 'unable', 'interact', 'cdk10', 'cyclin', 'silencing', 'phenocopies', 'cdk10', 'silencing', 'increasing', 'craf', 'conferring', 'tamoxifen', 'resistance', 'breast', 'cancer', 'cells', 'cdk10cyclin', 'phosphorylates', 'ets2', 'vitro', 'cells', 'positively', 'controls', 'ets2', 'degradation', 'proteasome', 'ets2', 'protein', 'levels', 'increased', 'cells', 'derived', 'star', 'patient', 'increase', 'attributable', 'decreased', 'cyclin', 'levels', 'altogether', 'results', 'reveal', 'additional', 'regulatory', 'mechanism', 'ets2', 'plays', 'key', 'roles', 'cancer', 'development', 'also', 'shed', 'light', 'molecular', 'mechanisms', 'underlying', 'star', 'syndromecyclindependent', 'kinases', 'cdks', 'play', 'pivotal', 'role', 'control', 'number', 'fundamental', 'cellular', 'processes', '1', 'human', 'genome', 'contains', '21', 'genes', 'encoding', 'proteins', 'considered', 'members', 'cdk', 'family', 'owing', 'sequence', 'similarity', 'bona', 'fide', 'cdks', 'known', 'activated', 'cyclins', '2', 'although', 'discovered', 'almost', '20', 'ago', '3', '4', 'cdk10', 'remains', 'one', 'two', 'cdks', 'without', 'identified', 'cyclin', 'partner', 'knowledge', 'gap', 'largely', 'impeded', 'exploration', 'biological', 'functions', 'cdk10', 'act', 'positive', 'cell', 'cycle', 'regulator', 'cells', '5', '6', 'tumor', 'suppressor', 'others', '7', '8', 'cdk10', 'interacts', 'ets2', 'vets', 'erythroblastosis', 'virus', 'e26', 'oncogene', 'homolog', '2', 'transcription', 'factor', 'inhibits', 'transcriptional', 'activity', 'unknown', 'mechanism', '9', 'cdk10', 'knockdown', 'derepresses', 'ets2', 'increases', 'expression', 'craf', 'protein', 'kinase', 'activates', 'mapk', 'pathway', 'induces', 'resistance', 'mcf7', 'cells', 'tamoxifen', '6', 'here', 'deorphanize', 'cdk10', 'identifying', 'cyclin', 'm', 'product', 'fam58a', 'binding', 'partner', 'mutations', 'gene', 'predict', 'absence', 'truncation', 'cyclin', 'associated', 'star', 'syndrome', 'whose', 'features', 'include', 'toe', 'syndactyly', 'telecanthus', 'anogenital', 'renal', 'malformations', 'heterozygous', 'females', '10', 'however', 'functions', 'cyclin', 'pathogenesis', 'star', 'syndrome', 'remain', 'unknown', 'show', 'recombinant', 'cdk10cyclin', 'heterodimer', 'active', 'protein', 'kinase', 'phosphorylates', 'ets2', 'vitro', 'cyclin', 'silencing', 'phenocopies', 'cdk10', 'silencing', 'increasing', 'craf', 'phosphoerk', 'expression', 'levels', 'inducing', 'tamoxifen', 'resistance', 'estrogen', 'receptor', 'er', 'breast', 'cancer', 'cells', 'show', 'cdk10cyclin', 'positively', 'controls', 'ets2', 'degradation', 'proteasome', 'phosphorylation', 'two', 'neighboring', 'serines', 'finally', 'detect', 'increased', 'ets2', 'expression', 'level', 'cells', 'derived', 'star', 'patient', 'demonstrate', 'attributable', 'decreased', 'cyclin', 'expression', 'level', 'observed', 'cellsprevious', 'sectionnext', 'sectionresultsa', 'yeast', 'twohybrid', 'y2h', 'screen', 'unveiled', 'interaction', 'signal', 'cdk10', 'mouse', 'protein', 'whose', 'cterminal', 'half', 'presents', 'strong', 'sequence', 'homology', 'human', 'fam58a', 'gene', 'product', 'whose', 'proposed', 'name', 'cyclin', '11', 'thus', 'performed', 'y2h', 'mating', 'assays', 'determine', 'whether', 'human', 'cdk10', 'interacts', 'human', 'cyclin', 'fig', '1', 'c', 'longest', 'cdk10', 'isoform', 'p1', 'expressed', 'bait', 'protein', 'produced', 'strong', 'interaction', 'phenotype', 'fulllength', 'cyclin', 'expressed', 'prey', 'protein', 'detectable', 'phenotype', 'cyclin', 'd1', 'p21', 'cip1', 'cdi1', 'kap', 'known', 'binding', 'partners', 'cdks', 'fig', '1b', 'cdk1', 'cdk3', 'also', 'produced', 'y2h', 'signals', 'cyclin', 'm', 'albeit', 'notably', 'weaker', 'observed', 'cdk10', 'fig', '1b', 'interaction', 'phenotype', 'also', 'observed', 'fulllength', 'cyclin', 'cdk10', 'proteins', 'expressed', 'bait', 'prey', 'respectively', 'fig', 's1a', 'tested', 'different', 'isoforms', 'cdk10', 'cyclin', 'originating', 'alternative', 'gene', 'splicing', 'two', 'truncated', 'cyclin', 'proteins', 'corresponding', 'hypothetical', 'products', 'two', 'mutated', 'fam58a', 'genes', 'found', 'star', 'syndrome', 'patients', '10', 'none', 'shorter', 'isoforms', 'produced', 'interaction', 'phenotypes', 'fig', '1', 'c', 'fig', 's1a', 'fig', '1in', 'new', 'window', 'download', 'pptfig', '1cdk10', 'cyclin', 'form', 'interaction', 'complex', 'schematic', 'representation', 'different', 'protein', 'isoforms', 'analyzed', 'y2h', 'assays', 'amino', 'acid', 'numbers', 'indicated', 'black', 'boxes', 'indicate', 'internal', 'deletions', 'red', 'box', 'indicates', 'differing', 'amino', 'acid', 'sequence', 'compared', 'cdk10', 'p1', 'b', 'y2h', 'assay', 'set', 'cdk', 'proteins', 'expressed', 'baits', 'fusion', 'lexa', 'dna', 'binding', 'domain', 'cdk', 'interacting', 'proteins', 'expressed', 'preys', 'fusion', 'b42', 'transcriptional', 'activator', 'peg202', 'pjg45', 'empty', 'bait', 'prey', 'plasmids', 'expressing', 'lexa', 'b42', 'respectively', 'lacz', 'used', 'reporter', 'gene', 'blue', 'yeast', 'indicative', 'y2h', 'interaction', 'phenotype', 'c', 'y2h', 'assay', 'different', 'cdk10', 'cyclin', 'isoforms', 'aminoterminal', 'region', 'ets2', 'known', 'interact', 'cdk10', '9', 'also', 'assayed', 'western', 'blot', 'analysis', 'myccdk10', 'wt', 'kd', 'cycmv56his', 'expression', 'levels', 'transfected', 'hek293', 'cells', 'e', 'western', 'blot', 'analysis', 'myccdk10', 'wt', 'kd', 'immunoprecipitates', 'obtained', 'using', 'antimyc', 'antibody', 'inputs', 'correspond', '10', 'g', 'total', 'lysates', 'obtained', 'hek293', 'cells', 'coexpressing', 'myccdk10', 'wt', 'kd', 'cycmv56his', 'f', 'western', 'blot', 'analysis', 'immunoprecipitates', 'obtained', 'using', 'anticdk10', 'antibody', 'control', 'goat', 'antibody', 'human', 'breast', 'cancer', 'mcf7', 'cells', 'input', 'corresponds', '30', 'g', 'mcf7', 'total', 'cell', 'lysates', 'lower', 'band', 'doublet', 'observed', 'upper', 'panel', 'comigrates', 'exogenously', 'expressed', 'untagged', 'cdk10', 'thus', 'corresponds', 'endogenous', 'cdk10', 'upper', 'band', 'doublet', 'corresponds', 'nonspecific', 'signal', 'demonstrated', 'insensitivity', 'either', 'overexpression', 'cdk10', 'seen', 'left', 'lane', 'silencing', 'cdk10', 'fig', 's2b', 'another', 'experiment', 'longer', 'gel', 'migration', 'shown', 'fig', 's1dnext', 'examined', 'ability', 'cdk10', 'cyclin', 'interact', 'expressed', 'human', 'cells', 'fig', '1', 'e', 'tested', 'wildtype', 'cdk10', 'wt', 'kinase', 'dead', 'kd', 'mutant', 'bearing', 'd181a', 'amino', 'acid', 'substitution', 'abolishes', 'atp', 'binding', '12', 'expressed', 'cyclin', 'mv56his', 'andor', 'myccdk10', 'wt', 'kd', 'human', 'embryonic', 'kidney', 'cell', 'line', 'hek293', 'expression', 'level', 'cyclin', 'mv56his', 'significantly', 'increased', 'upon', 'coexpression', 'myccdk10', 'wt', 'kd', 'and', 'lesser', 'extent', 'myccdk10', 'wt', 'kd', 'increased', 'upon', 'coexpression', 'cyclin', 'mv56his', 'fig', '1d', 'immunoprecipitated', 'myccdk10', 'proteins', 'detected', 'presence', 'cyclin', 'cdk10', 'wt', 'kd', 'immunoprecipitates', 'proteins', 'coexpressed', 'pairwise', 'fig', '1e', 'confirmed', 'observations', 'detecting', 'presence', 'myccdk10', 'cyclin', 'mv56his', 'immunoprecipitates', 'fig', 's1b', 'experiments', 'confirmed', 'lack', 'robust', 'interaction', 'cdk10p2', 'isoform', 'cyclin', 'fig', 's1c', 'detect', 'interaction', 'endogenous', 'proteins', 'performed', 'immunoprecipitations', 'nontransfected', 'mcf7', 'cells', 'derived', 'human', 'breast', 'cancer', 'cdk10', 'cyclin', 'antibodies', 'detected', 'cognate', 'endogenous', 'proteins', 'western', 'blotting', 'readily', 'detected', 'cyclin', 'immunoprecipitates', 'obtained', 'cdk10', 'antibody', 'control', 'antibody', 'fig', '1f', 'results', 'confirm', 'physical', 'interaction', 'cdk10', 'cyclin', 'human', 'cellsto', 'unveil', 'hypothesized', 'cdk10cyclin', 'protein', 'kinase', 'activity', 'produced', 'gstcdk10', 'strepiicyclin', 'fusion', 'proteins', 'insect', 'cells', 'either', 'individually', 'combination', 'observed', 'gstcdk10', 'strepiicyclin', 'copurified', 'thus', 'confirming', 'interaction', 'yet', 'another', 'cellular', 'model', 'fig', '2a', 'performed', 'vitro', 'kinase', 'assays', 'purified', 'proteins', 'using', 'histone', 'h1', 'generic', 'substrate', 'histone', 'h1', 'phosphorylation', 'detected', 'lysates', 'cells', 'coexpressing', 'gstcdk10', 'strepiicyclin', 'm', 'phosphorylation', 'detected', 'gstcdk10', 'strepiicyclin', 'expressed', 'alone', 'strepiicyclin', 'coexpressed', 'gstcdk10', 'kd', 'fig', '2a', 'next', 'investigated', 'whether', 'ets2', 'known', 'interact', 'cdk10', '9', 'fig', '1c', 'phosphorylation', 'substrate', 'cdk10cyclin', 'm', 'detected', 'strong', 'phosphorylation', 'ets2', 'gstcdk10strepiicyclin', 'purified', 'heterodimer', 'whereas', 'phosphorylation', 'detected', 'using', 'gstcdk10', 'alone', 'gstcdk10', 'kd', 'strepiicyclin', 'heterodimer', 'fig', '2b', 'fig', '2in', 'new', 'window', 'download', 'pptfig', '2cdk10', 'cyclin', 'mdependent', 'protein', 'kinase', 'vitro', 'protein', 'kinase', 'assay', 'histone', 'h1', 'lysates', 'insect', 'cells', 'expressing', 'different', 'proteins', 'purified', 'glutathione', 'sepharose', 'matrix', 'capture', 'gstcdk10', 'wt', 'kd', 'fusion', 'proteins', 'alone', 'complex', 'strcycm', 'fusion', 'protein', 'purified', 'protein', 'expression', 'levels', 'analyzed', 'western', 'blots', 'top', 'upper', 'middle', 'kinase', 'activity', 'determined', 'autoradiography', 'histone', 'h1', 'whose', 'added', 'amounts', 'visualized', 'coomassie', 'staining', 'lower', 'middle', 'bottom', 'b', 'a', 'using', 'purified', 'recombinant', '6hisets2', 'substratecdk10', 'silencing', 'shown', 'increase', 'ets2driven', 'craf', 'transcription', 'activate', 'mapk', 'pathway', '6', 'investigated', 'whether', 'cyclin', 'also', 'involved', 'regulatory', 'pathway', 'aim', 'highly', 'specific', 'silencing', 'used', 'sirna', 'pools', 'mix', 'four', 'different', 'sirnas', 'low', 'final', 'concentration', '10', 'nm', 'cdk10', 'cyclin', 'sirna', 'pools', 'silenced', 'expression', 'cognate', 'targets', 'fig', '3', 'c', 'fig', 's2', 'and', 'interestingly', 'cyclin', 'sirna', 'pool', 'also', 'caused', 'marked', 'decrease', 'cdk10', 'protein', 'level', 'fig', '3a', 'fig', 's2b', 'results', 'shown', 'fig', '1d', 'suggest', 'cyclin', 'binding', 'stabilizes', 'cdk10', 'cyclin', 'silencing', 'induced', 'increase', 'craf', 'protein', 'mrna', 'levels', 'fig', '3', 'b', 'c', 'phosphorylated', 'erk1', 'erk2', 'protein', 'levels', 'fig', 's3b', 'similarly', 'cdk10', 'silencing', 'expected', 'effects', '6', 'cdk10', 'cyclin', 'silencing', 'decreased', 'sensitivity', 'er', 'mcf7', 'cells', 'tamoxifen', 'similar', 'extent', 'combined', 'silencing', 'genes', 'result', 'higher', 'resistance', 'drug', 'fig', 's3c', 'altogether', 'observations', 'demonstrate', 'functional', 'interaction', 'cyclin', 'cdk10', 'negatively', 'controls', 'ets2fig', '3in', 'new', 'window', 'download', 'pptfig', '3cyclin', 'silencing', 'upregulates', 'craf', 'expression', 'western', 'blot', 'analysis', 'endogenous', 'cdk10', 'cyclin', 'expression', 'levels', 'mcf7', 'cells', 'response', 'sirnamediated', 'gene', 'silencing', 'b', 'western', 'blot', 'analysis', 'endogenous', 'craf', 'expression', 'levels', 'mcf7', 'cells', 'response', 'cdk10', 'cyclin', 'silencing', 'quantification', 'shown', 'fig', 's3a', 'c', 'quantitative', 'rtpcr', 'analysis', 'cdk10', 'cyclin', 'm', 'craf', 'mrna', 'levels', 'response', 'cdk10', 'upper', 'cyclin', 'lower', 'silencing', 'p', '001', 'p', '0001we', 'wished', 'explore', 'mechanism', 'cdk10cyclin', 'controls', 'ets2', 'ets2', 'shortlived', 'protein', 'degraded', 'proteasome', '13', 'straightforward', 'hypothesis', 'cdk10cyclin', 'positively', 'controls', 'ets2', 'degradation', 'thus', 'examined', 'impact', 'cdk10', 'cyclin', 'silencing', 'ets2', 'expression', 'levels', 'silencing', 'cdk10', 'cyclin', 'caused', 'increase', 'expression', 'levels', 'exogenously', 'expressed', 'flagets2', 'protein', 'fig', 's4a', 'well', 'endogenous', 'ets2', 'protein', 'fig', '4a', 'increase', 'attributable', 'increased', 'ets2', 'mrna', 'levels', 'marginally', 'fluctuated', 'response', 'cdk10', 'cyclin', 'silencing', 'fig', 's4b', 'examined', 'expression', 'levels', 'flagtagged', 'ets2', 'protein', 'expressed', 'alone', 'combination', 'myccdk10', 'cdk10', 'kd', 'without', 'cyclin', 'mv56his', 'flagets2', 'readily', 'detected', 'expressed', 'alone', 'or', 'lesser', 'extent', 'coexpressed', 'cdk10', 'kd', 'however', 'expression', 'level', 'dramatically', 'decreased', 'coexpressed', 'cdk10', 'alone', 'cdk10', 'cyclin', 'fig', '4b', 'observations', 'suggest', 'endogenous', 'cyclin', 'levels', 'excess', 'compared', 'cdk10', 'mcf7', 'cells', 'show', 'major', 'decrease', 'ets2', 'levels', 'observed', 'upon', 'cdk10', 'coexpression', 'involves', 'cdk10', 'kinase', 'activity', 'treatment', 'cells', 'coexpressing', 'flagets2', 'cdk10', 'cyclin', 'proteasome', 'inhibitor', 'mg132', 'largely', 'rescued', 'flagets2', 'expression', 'levels', 'fig', '4b', 'fig', '4in', 'new', 'window', 'download', 'pptfig', '4cdk10cyclin', 'controls', 'ets2', 'stability', 'human', 'cancer', 'derived', 'cells', 'western', 'blot', 'analysis', 'endogenous', 'ets2', 'expression', 'levels', 'mcf7', 'cells', 'response', 'sirnamediated', 'cdk10', 'andor', 'cyclin', 'silencing', 'quantification', 'shown', 'fig', 's4b', 'b', 'western', 'blot', 'analysis', 'exogenously', 'expressed', 'flagets2', 'protein', 'levels', 'mcf7', 'cells', 'cotransfected', 'empty', 'vectors', 'coexpressing', 'myccdk10', 'wt', 'kd', 'myccdk10cycmv56his', 'latter', 'cells', 'treated', '16', 'h', 'mg132', 'proteasome', 'inhibitor', 'proper', 'expression', 'cdk10', 'cyclin', 'tagged', 'proteins', 'verified', 'western', 'blot', 'analysis', 'c', 'western', 'blot', 'analysis', 'expression', 'levels', 'exogenously', 'expressed', 'flagets2', 'wildtype', 'mutant', 'proteins', 'mcf7', 'cells', 'absence', 'c', 'response', 'myccdk10cycmv56his', 'expression', 'quantifications', 'shown', 'fig', 's4', 'c', 'da', 'mass', 'spectrometry', 'analysis', 'recombinant', 'ets2', 'phosphorylated', 'cdk10cyclin', 'vitro', 'revealed', 'existence', 'multiple', 'phosphorylated', 'residues', 'among', 'two', 'neighboring', 'phosphoserines', 'positions', '220', '225', 'may', 'form', 'phosphodegron', '14', 'figs', 's5', 's8', 'confirm', 'finding', 'compared', 'phosphorylation', 'level', 'recombinant', 'ets2wt', 'ets2sasa', 'protein', 'mutant', 'bearing', 'alanine', 'substitutions', 'two', 'serines', 'expected', 'existence', 'multiple', 'phosphorylation', 'sites', 'detected', 'small', 'reproducible', 'significant', 'decrease', 'phosphorylation', 'level', 'ets2sasa', 'compared', 'ets2wt', 'fig', 's9', 'thus', 'confirming', 'ser220ser225', 'phosphorylated', 'cdk10cyclin', 'm', 'establish', 'direct', 'link', 'ets2', 'phosphorylation', 'cdk10cyclin', 'degradation', 'examined', 'expression', 'levels', 'flagets2sasa', 'absence', 'cdk10cyclin', 'coexpression', 'differ', 'significantly', 'flagets2', 'contrary', 'flagets2dbm', 'bearing', 'deletion', 'nterminal', 'destruction', 'd', 'box', 'previously', 'shown', 'involved', 'apccdh1', 'mediated', 'degradation', 'ets2', '13', 'fig', '4c', 'however', 'contrary', 'flagets2', 'wild', 'type', 'expression', 'level', 'flagets2sasa', 'remained', 'insensitive', 'cdk10cyclin', 'coexpression', 'fig', '4d', 'altogether', 'results', 'suggest', 'cdk10cyclin', 'directly', 'controls', 'ets2', 'degradation', 'phosphorylation', 'two', 'serinesfinally', 'studied', 'lymphoblastoid', 'cell', 'line', 'derived', 'patient', 'star', 'syndrome', 'bearing', 'fam58a', 'mutation', 'c5551g', 'a', 'predicted', 'result', 'aberrant', 'splicing', '10', 'accordance', 'incomplete', 'skewing', 'x', 'chromosome', 'inactivation', 'previously', 'found', 'patient', 'detected', 'decreased', 'expression', 'level', 'cyclin', 'protein', 'star', 'cell', 'line', 'compared', 'control', 'lymphoblastoid', 'cell', 'line', 'line', 'preceding', 'observations', 'detected', 'increased', 'expression', 'level', 'ets2', 'protein', 'star', 'cell', 'line', 'compared', 'control', 'fig', '5a', 'fig', 's10a', 'examined', 'quantitative', 'rtpcr', 'mrna', 'expression', 'levels', 'corresponding', 'genes', 'star', 'cell', 'line', 'showed', 'decreased', 'expression', 'level', 'cyclin', 'mrna', 'expression', 'level', 'ets2', 'mrna', 'similar', 'control', 'cell', 'line', 'fig', '5b', 'demonstrate', 'increase', 'ets2', 'protein', 'expression', 'indeed', 'result', 'decreased', 'cyclin', 'expression', 'observed', 'star', 'patientderived', 'cell', 'line', 'expressed', 'cyclin', 'mv56his', 'cell', 'line', 'expression', 'caused', 'decrease', 'ets2', 'protein', 'levels', 'fig', '5c', 'fig', '5in', 'new', 'window', 'download', 'pptfig', '5decreased', 'cyclin', 'expression', 'star', 'patientderived', 'cells', 'results', 'increased', 'ets2', 'protein', 'level', 'western', 'blot', 'analysis', 'cyclin', 'ets2', 'protein', 'levels', 'star', 'patientderived', 'lymphoblastoid', 'cell', 'line', 'control', 'lymphoblastoid', 'cell', 'line', 'derived', 'healthy', 'individual', 'quantification', 'shown', 'fig', 's10a', 'b', 'quantitative', 'rtpcr', 'analysis', 'cyclin', 'ets2', 'mrna', 'levels', 'cells', 'p', '0001', 'c', 'western', 'blot', 'analysis', 'ets2', 'protein', 'levels', 'star', 'patientderived', 'lymphoblastoid', 'cell', 'line', 'transfected', 'empty', 'vector', 'vector', 'directing', 'expression', 'cyclin', 'mv56his', 'another', 'western', 'blot', 'revealing', 'endogenously', 'exogenously', 'expressed', 'cyclin', 'levels', 'shown', 'fig', 's10b', 'quantification', 'ets2', 'protein', 'levels', 'shown', 'fig', 's10cprevious', 'sectionnext', 'sectiondiscussionin', 'work', 'unveil', 'interaction', 'cdk10', 'last', 'orphan', 'cdk', 'discovered', 'pregenomic', 'era', '2', 'cyclin', 'm', 'cyclin', 'associated', 'human', 'genetic', 'disease', 'far', 'whose', 'functions', 'remain', 'unknown', '10', 'closest', 'paralogs', 'cdk10', 'within', 'cdk', 'family', 'cdk11', 'proteins', 'interact', 'ltype', 'cyclins', '15', 'interestingly', 'closest', 'paralog', 'cyclins', 'within', 'cyclin', 'family', 'cyclin', 'fig', 's11', 'fact', 'none', 'shorter', 'cdk10', 'isoforms', 'interact', 'robustly', 'cyclin', 'suggests', 'alternative', 'splicing', 'cdk10', 'gene', '16', '17', 'plays', 'important', 'role', 'regulating', 'cdk10', 'functionsthe', 'functional', 'relevance', 'interaction', 'cdk10', 'cyclin', 'supported', 'different', 'observations', 'proteins', 'seem', 'enhance', 'stability', 'judged', 'increased', 'expression', 'levels', 'partner', 'exogenously', 'coexpressed', 'fig', '1d', 'much', 'reduced', 'endogenous', 'cdk10', 'expression', 'level', 'observed', 'response', 'cyclin', 'silencing', 'fig', '3a', 'fig', 's2b', 'cdk10', 'subject', 'ubiquitinmediated', 'degradation', '18', 'observations', 'suggest', 'cyclin', 'protects', 'cdk10', 'degradation', 'cyclin', 'partner', 'cdk10', 'least', 'mcf7', 'cells', 'also', 'suggest', 'cyclin', 'stability', 'enhanced', 'upon', 'binding', 'cdk10', 'independently', 'kinase', 'activity', 'seen', 'cyclin', 'c', 'cdk8', '19', 'uncover', 'cyclin', 'mdependent', 'cdk10', 'protein', 'kinase', 'activity', 'vitro', 'thus', 'demonstrating', 'protein', 'named', 'cdk', 'sole', 'basis', 'amino', 'acid', 'sequence', 'indeed', 'genuine', 'cyclindependent', 'kinase', 'y2h', 'assays', 'reveal', 'truncated', 'cyclin', 'proteins', 'corresponding', 'hypothetical', 'products', 'two', 'star', 'syndromeassociated', 'fam58a', 'mutations', 'produce', 'interaction', 'phenotype', 'cdk10', 'hence', 'regardless', 'whether', 'mutated', 'mrnas', 'undergo', 'nonsensemediated', 'decay', 'suggested', 'decreased', 'cyclin', 'mrna', 'levels', 'star', 'cells', 'shown', 'fig', '5b', 'give', 'rise', 'truncated', 'cyclin', 'proteins', 'females', 'affected', 'star', 'syndrome', 'must', 'exhibit', 'compromised', 'cdk10cyclin', 'kinase', 'activity', 'least', 'tissues', 'specific', 'developmental', 'stageswe', 'show', 'ets2', 'known', 'interactor', 'cdk10', 'phosphorylation', 'substrate', 'cdk10cyclin', 'vitro', 'cdk10cyclin', 'kinase', 'activity', 'positively', 'controls', 'ets2', 'degradation', 'proteasome', 'control', 'seems', 'exerted', 'fine', 'mechanism', 'judged', 'sensitivity', 'ets2', 'levels', 'partially', 'decreased', 'cdk10', 'cyclin', 'levels', 'achieved', 'mcf7', 'cells', 'observed', 'star', 'cells', 'respectively', 'findings', 'offer', 'straightforward', 'explanation', 'already', 'reported', 'upregulation', 'ets2driven', 'transcription', 'craf', 'response', 'cdk10', 'silencing', '6', 'bring', 'evidence', 'cdk10cyclin', 'directly', 'controls', 'ets2', 'degradation', 'phosphorylation', 'two', 'neighboring', 'serines', 'may', 'form', 'noncanonical', 'trcp', 'phosphodegron', 'dsmcpas', '14', 'none', 'two', 'serines', 'precede', 'proline', 'conform', 'usual', 'cdk', 'phosphorylation', 'sites', 'however', 'multiple', 'socalled', 'transcriptional', 'cdks', 'cdk7', '8', '9', '11', 'cdk10', 'may', 'belong', 'fig', 's11', 'shown', 'phosphorylate', 'variety', 'motifs', 'non', 'prolinedirected', 'fashion', 'especially', 'context', 'molecular', 'docking', 'substrate', '20', 'here', 'hypothesized', 'highaffinity', 'interaction', 'cdk10', 'pointed', 'domain', 'ets2', '6', '9', 'fig', '1c', 'would', 'allow', 'dockingmediated', 'phosphorylation', 'atypical', 'sites', 'control', 'ets2', 'degradation', 'involves', 'number', 'players', 'including', 'apccdh1', '13', 'cullinring', 'ligase', 'crl4', '21', 'formal', 'identification', 'ubiquitin', 'ligase', 'involved', 'cdk10cyclin', 'pathway', 'elucidation', 'concerted', 'action', 'ubiquitin', 'ligases', 'regulate', 'ets2', 'degradation', 'require', 'studiesour', 'results', 'present', 'number', 'significant', 'biological', 'medical', 'implications', 'first', 'shed', 'light', 'regulation', 'ets2', 'plays', 'important', 'role', 'development', '22', 'frequently', 'deregulated', 'many', 'cancers', '23', 'second', 'results', 'contribute', 'understanding', 'molecular', 'mechanisms', 'causing', 'tamoxifen', 'resistance', 'associated', 'reduced', 'cdk10', 'expression', 'levels', 'suggest', 'that', 'like', 'cdk10', '6', 'cyclin', 'could', 'also', 'predictive', 'clinical', 'marker', 'hormone', 'therapy', 'response', 'er', 'positive', 'breast', 'cancer', 'patients', 'third', 'findings', 'offer', 'interesting', 'hypothesis', 'molecular', 'mechanisms', 'underlying', 'star', 'syndrome', 'ets2', 'transgenic', 'mice', 'showing', 'less', 'twofold', 'overexpression', 'ets2', 'present', 'severe', 'cranial', 'abnormalities', '24', 'observed', 'star', 'patients', 'could', 'thus', 'caused', 'least', 'part', 'increased', 'ets2', 'protein', 'levels', 'another', 'expected', 'consequence', 'enhanced', 'ets2', 'expression', 'levels', 'would', 'decreased', 'risk', 'develop', 'certain', 'types', 'cancers', 'increased', 'risk', 'develop', 'others', 'studies', 'various', 'mouse', 'models', 'including', 'models', 'syndrome', 'three', 'copies', 'ets2', 'exist', 'revealed', 'ets2', 'dosage', 'repress', 'promote', 'tumor', 'growth', 'and', 'hence', 'ets2', 'exerts', 'noncell', 'autonomous', 'functions', 'cancer', '25', 'intringuingly', 'one', 'star', 'patients', 'identified', 'far', 'diagnosed', 'nephroblastoma', '26', 'finally', 'findings', 'facilitate', 'general', 'exploration', 'biological', 'functions', 'cdk10', 'and', 'particular', 'role', 'control', 'cell', 'division', 'previous', 'studies', 'suggested', 'either', 'positive', 'role', 'cell', 'cycle', 'control', '5', '6', 'tumorsuppressive', 'activity', 'cancers', '7', '8', 'severe', 'growth', 'retardation', 'exhibited', 'star', 'patients', 'strongly', 'suggests', 'cdk10cyclin', 'plays', 'important', 'role', 'control', 'cell', 'proliferationprevious', 'sectionnext', 'sectionmaterials', 'methodscloning', 'cdk10', 'cyclin', 'cdnas', 'plasmid', 'constructions', 'tamoxifen', 'response', 'analysis', 'quantitative', 'rtpcr', 'mass', 'spectrometry', 'experiments', 'antibody', 'production', 'detailed', 'si', 'materials', 'methodsyeast', 'twohybrid', 'interaction', 'assays', 'performed', 'yeast', 'interaction', 'mating', 'assays', 'previously', 'described', '27', 'mammalian', 'cell', 'cultures', 'transfections', 'grew', 'human', 'hek293', 'mcf7', 'cells', 'dmem', 'supplemented', '10', 'volvol', 'fbs', 'invitrogen', 'grew', 'lymphoblastoid', 'cells', 'rpmi', '1640', 'glutamax', 'supplemented', '15', 'volvol', 'fbs', 'transfected', 'hek293', 'mcf7', 'cells', 'using', 'lipofectamine', '2000', 'invitrogen', 'plasmids', 'lipofectamine', 'rnaimax', 'invitrogen', 'sirnas', 'jetprime', 'polyplus', 'plasmidssirnas', 'combinations', 'according', 'manufacturers', 'instructions', 'transfected', 'lymphoblastoid', 'cells', 'electroporation', 'neon', 'invitrogen', 'ets2', 'stability', 'studies', 'treated', 'mcf7', 'cells', '32', 'h', 'transfection', '10', 'mg132', 'fisher', 'scientific', '16', 'hcoimmunoprecipitation', 'western', 'blot', 'experiments', 'collected', 'cells', 'scraping', 'pbs', 'centrifugation', 'lymphoblastoid', 'cells', 'lysed', 'sonication', 'lysis', 'buffer', 'containing', '60', 'mm', 'glycerophosphate', '15', 'mm', 'pnitrophenylphosphate', '25', 'mm', '3', 'nmorpholino', 'propanesulfonic', 'acid', 'mops', 'ph', '72', '15', 'mm', 'egta', '15', 'mm', 'mgcl2', '1', 'mm', 'na', 'vanadate', '1', 'mm', 'naf', '1mm', 'phenylphosphate', '01', 'nonidet', 'p40', 'protease', 'inhibitor', 'mixture', 'roche', 'spun', 'lysates', '15', 'min', '20000', 'g', '4', 'c', 'collected', 'supernatants', 'determined', 'protein', 'content', 'using', 'bradford', 'assay', 'performed', 'immunoprecipitation', 'experiments', '500', 'g', 'total', 'proteins', 'lysis', 'buffer', 'precleared', 'lysates', '20', 'l', 'protein', 'gagarose', 'beads', 'incubated', '1', 'h', '4', 'c', 'rotating', 'wheel', 'added', '5', 'g', 'antibody', 'supernatants', 'incubated', '1', 'h', '4', 'c', 'rotating', 'wheel', 'added', '20', 'l', 'protein', 'gagarose', 'beads', 'incubated', '1', 'h', '4', 'c', 'rotating', 'wheel', 'collected', 'beads', 'centrifugation', '30', '18000', 'g', '4', 'c', 'washed', 'three', 'times', 'bead', 'buffer', 'containing', '50', 'mm', 'tris', 'ph', '74', '5', 'mm', 'naf', '250', 'mm', 'nacl', '5', 'mm', 'edta', '5', 'mm', 'egta', '01', 'nonidet', 'p40', 'protease', 'inhibitor', 'coktail', 'roche', 'directly', 'added', 'sample', 'buffer', 'washed', 'pellets', 'heatdenatured', 'proteins', 'ran', 'samples', '10', 'bistris', 'sdspage', 'transferred', 'proteins', 'onto', 'hybond', 'nitrocellulose', 'membranes', 'processed', 'blots', 'according', 'standard', 'procedures', 'western', 'blot', 'experiments', 'used', 'following', 'primary', 'antibodies', 'antimyc', 'abcam', 'ab9106', '12000', 'antiv5', 'invitrogen', 'r960', '15000', 'antitubulin', 'santa', 'cruz', 'biotechnology', 'b7', '1500', 'anticdk10', 'covalab', 'pab0847p', '1500', 'santa', 'cruz', 'biotechnology', 'c19', '1500', 'anticycm', 'homemade', 'dilution', '1500', 'covalab', 'pab0882p', 'dilution', '1500', 'antiraf1', 'santa', 'cruz', 'biotechnology', 'c20', '11000', 'antiets2', 'santa', 'cruz', 'biotechnology', 'c20', '11000', 'antiflag', 'sigma', 'f7425', '11000', 'antiactin', 'sigma', 'a5060', '15000', 'used', 'hrpcoupled', 'antigoat', 'santa', 'cruz', 'biotechnology', 'sc2033', 'dilution', '12000', 'antimouse', 'biorad', '170', '6516', 'dilution', '13000', 'antirabbit', 'biorad', '172', '1019', '15000', 'secondary', 'antibodies', 'revealed', 'blots', 'enhanced', 'chemiluminescence', 'supersignal', 'west', 'femto', 'thermo', 'scientific', 'production', 'purification', 'recombinant', 'proteinsgstcdk10', 'kd', 'strepiicycm', 'generated', 'recombinant', 'bacmids', 'dh10bac', 'escherichia', 'coli', 'baculoviruses', 'sf9', 'cells', 'using', 'bactobac', 'system', 'described', 'provider', 'invitrogen', 'infected', 'sf9', 'cells', 'gstcdk10', 'gstcdk10kd', 'producing', 'viruses', 'coinfected', 'cells', 'strepiicycm', 'producing', 'viruses', 'collected', 'cells', '72', 'h', 'infection', 'purify', 'gstfusion', 'proteins', 'spun', '250', 'ml', 'cells', 'resuspended', 'pellet', '40', 'ml', 'lysis', 'buffer', 'pbs', '250', 'mm', 'nacl', '05', 'nonidet', 'p40', '50', 'mm', 'naf', '10', 'mm', 'glycerophosphate', '03', 'mm', 'navanadate', 'containing', 'protease', 'inhibitor', 'mixture', 'roche', 'lysed', 'cells', 'sonication', 'spun', 'lysate', '30', 'min', '15000', 'g', 'collected', 'soluble', 'fraction', 'added', '1ml', 'glutathionesepharose', 'matrix', 'incubated', '1', 'h', '4', 'c', 'washed', 'four', 'times', 'lysis', 'buffer', 'one', 'time', 'kinase', 'buffer', 'see', 'finally', 'resuspended', 'beads', '100', 'l', 'kinase', 'buffer', 'containing', '10', 'volvol', 'glycerol', 'storage6hisets2', 'transformed', 'origami2', 'de3', 'novagen', '6hisets2', 'expression', 'vector', 'induced', 'expression', '02', 'mm', 'isopropyl', 'd1thiogalactopyranoside', '3', 'h', '22', 'c', 'purify', '6hisets2', 'spun', '50', 'ml', 'cells', 'resuspended', 'pellet', '2', 'ml', 'lysis', 'buffer', 'pbs', '300', 'mm', 'nacl', '10', 'mm', 'imidazole', '1', 'mm', 'dtt', '01', 'nonidet', 'p40', 'containing', 'protease', 'inhibitor', 'mixture', 'without', 'edta', 'roche', 'lysed', 'cells', '16', 'bar', 'using', 'cell', 'disruptor', 'spun', 'lysate', '10', 'min', '20000', 'g', 'collected', 'soluble', 'fraction', 'added', '200', 'l', 'cobalt', 'beads', 'thermo', 'scientific', '1', 'h', 'incubation', '4', 'c', 'rotating', 'wheel', 'washed', 'four', 'times', 'lysis', 'buffer', 'elute', 'incubated', 'beads', '30', 'min', 'elution', 'buffer', 'pbs', '250', 'mm', 'imidazole', 'ph', '76', 'containing', 'protease', 'inhibitor', 'mixture', 'spun', '30', '10000', 'g', 'collected', 'eluted', 'proteinprotein', 'kinase', 'assays', 'mixed', 'glutathionesepharose', 'beads', 'harboring', 'gstcdk10', 'wt', 'kd', 'either', 'monomeric', 'complexed', 'strepiicycm', '227', 'bsa', '15', 'mm', 'dtt', '100', 'atp', '5', 'ci', 'atp', '32p', '775', 'histone', 'h1', '1', '6hisets2', 'added', 'kinase', 'buffer', '25', 'mm', 'tris', 'hcl', '10', 'mm', 'mgcl2', '1', 'mm', 'egta', '1', 'mm', 'dtt', '37', 'heparin', 'ph', '75', 'total', 'volume', '30', 'l', 'incubated', 'reactions', '30', 'min', '30', 'c', 'added', 'laemli', 'sample', 'buffer', 'heatdenatured', 'samples', 'ran', '10', 'bistris', 'sdspage', 'cut', 'gel', 'slices', 'detect', 'gstcdk10', 'strepiicycm', 'western', 'blotting', 'stained', 'gel', 'slices', 'containing', 'substrate', 'coomassie', 'r250', 'biorad', 'dried', 'them', 'detected', 'incorporated', 'radioactivity', 'autoradiography', 'identified', 'four', 'unrelated', 'girls', 'anogenital', 'renal', 'malformations', 'dysmorphic', 'facial', 'features', 'normal', 'intellect', 'syndactyly', 'toes', 'similar', 'combination', 'features', 'reported', 'previously', 'mother', 'daughter', 'pair1', 'table', '1', 'supplementary', 'note', 'online', 'authors', 'noted', 'clinical', 'overlap', 'townesbrocks', 'syndrome', 'suggested', 'phenotype', 'represented', 'separate', 'autosomal', 'dominant', 'entity', 'mim601446', 'define', 'cardinal', 'features', 'syndrome', 'characteristic', 'facial', 'appearance', 'apparent', 'telecanthus', 'broad', 'tripartite', 'nasal', 'tip', 'variable', 'syndactyly', 'toes', '2', '5', 'hypoplastic', 'labia', 'anal', 'atresia', 'urogenital', 'malformations', 'fig', '1a', 'h', 'also', 'observed', 'variety', 'features', 'table', '1', 'figure', '1', 'clinical', 'molecular', 'characterization', 'star', 'syndrome', 'figure', '1', 'clinical', 'molecular', 'characterization', 'star', 'syndrome', 'f', 'facial', 'appearances', 'cases', '1', '3', 'apparent', 'telecanthus', 'dysplastic', 'ears', 'thin', 'upper', 'lips', 'ace', 'toe', 'syndactyly', '2', '5', '3', '5', '4', '5', 'bdf', 'cases', 'illustrate', 'recognizable', 'features', 'star', 'syndrome', 'specific', 'parental', 'consent', 'obtained', 'publication', 'photographs', 'anal', 'atresia', 'hypoplastic', 'labia', 'shown', 'gh', 'xray', 'films', 'feet', 'case', '2', 'showing', 'four', 'rays', 'left', 'deltashaped', '4th', '5th', 'metatarsals', 'right', 'h', 'compare', 'clinical', 'picture', 'arraycgh', 'data', 'log2', 'ratio', 'represents', 'copy', 'number', 'loss', 'six', 'probes', 'spanning', '379', '507', 'kb', 'one', 'probe', 'positioned', 'within', 'fam58a', 'deletion', 'remove', 'parts', 'functional', 'genes', 'j', 'schematic', 'structure', 'fam58a', 'position', 'mutations', 'fam58a', 'five', 'coding', 'exons', 'boxes', 'cyclin', 'domain', 'green', 'encoded', 'exons', '2', '4', 'horizontal', 'arrow', 'indicates', 'deletion', 'extending', '5', 'case', '1', 'includes', 'exons', '1', '2', 'whereas', 'horizontal', 'line', 'exon', '5', 'indicates', 'deletion', 'found', 'case', '3', 'removes', 'exon', '5', '3', 'sequence', 'pink', 'horizontal', 'bars', 'boxes', 'indicate', 'amplicons', 'used', 'qpcr', 'sequencing', 'one', 'alternative', 'exon', '5', 'amplicon', 'indicated', 'space', 'constraints', 'mutation', '201dupt', 'case', '4', 'results', 'immediate', 'stop', 'codon', '5551g', '5551g', 'splice', 'mutations', 'cases', '2', '5', '6', 'predicted', 'deleterious', 'alter', 'conserved', 'splice', 'donor', 'acceptor', 'site', 'intron', '4', 'respectively', 'full', 'size', 'image', '97', 'kb', 'table', '1', 'clinical', 'features', 'star', 'syndrome', 'cases', 'table', '1', 'clinical', 'features', 'star', 'syndrome', 'cases', 'full', 'table', 'basis', 'phenotypic', 'overlap', 'townesbrocks', 'okihiro', 'feingold', 'syndromes', 'analyzed', 'sall1', 'ref', '2', 'sall4', 'ref', '3', 'mycn4', 'found', 'mutations', 'genes', 'supplementary', 'methods', 'online', 'next', 'carried', 'genomewide', 'highresolution', 'oligonucleotide', 'array', 'comparative', 'genomic', 'hybridization', 'cgh', '5', 'analysis', 'supplementary', 'methods', 'genomic', 'dna', 'severely', 'affected', 'individual', 'case', '1', 'lower', 'lid', 'coloboma', 'epilepsy', 'syringomyelia', 'identified', 'heterozygous', 'deletion', '379', '507', 'kb', 'xq28', 'removed', 'exons', '1', '2', 'fam58a', 'fig', '1ij', 'using', 'realtime', 'pcr', 'confirmed', 'deletion', 'child', 'excluded', 'unaffected', 'parents', 'supplementary', 'fig', '1a', 'online', 'supplementary', 'methods', 'supplementary', 'table', '1', 'online', 'cgh', 'customized', 'oligonucleotide', 'array', 'enriched', 'probes', 'xq28', 'followed', 'breakpoint', 'cloning', 'defined', 'exact', 'deletion', 'size', '40068', 'bp', 'g152514164', '152554231del', 'chromosome', 'x', 'ncbi', 'build', '362', 'fig', '1j', 'supplementary', 'figs', '23', 'online', 'deletion', 'removes', 'coding', 'regions', 'exons', '1', '2', 'well', 'intron', '1', '2774', 'bp', '492', 'bp', 'intron', '2', '36608', 'bp', '5', 'sequence', 'including', '5', 'utr', 'entire', 'krt18p48', 'pseudogene', 'ncbi', 'gene', 'id', '340598', 'paternity', 'proven', 'using', 'routine', 'methods', 'find', 'deletions', 'overlapping', 'fam58a', 'available', 'copy', 'number', 'variation', 'cnv', 'databases', 'subsequently', 'carried', 'qpcr', 'analysis', 'three', 'affected', 'individuals', 'cases', '2', '3', '4', 'motherdaughter', 'pair', 'literature', 'cases', '5', '6', 'case', '3', 'detected', 'de', 'novo', 'heterozygous', 'deletion', '11', '103', 'kb', 'overlapping', 'exon', '5', 'supplementary', 'fig', '1b', 'online', 'using', 'xq28targeted', 'array', 'cgh', 'breakpoint', 'cloning', 'identified', 'deletion', '4249', 'bp', 'g152504123', '152508371del', 'chromosome', 'x', 'ncbi', 'build', '362', 'fig', '1j', 'supplementary', 'figs', '23', 'removed', '1265', 'bp', 'intron', '4', 'exon', '5', 'including', '3', 'utr', '2454', 'bp', '3', 'sequence', 'found', 'heterozygous', 'fam58a', 'point', 'mutations', 'remaining', 'cases', 'fig', '1j', 'supplementary', 'fig', '2', 'supplementary', 'methods', 'supplementary', 'table', '1', 'case', '2', 'identified', 'mutation', '5551g', 'a', 'affecting', 'splice', 'donor', 'site', 'intron', '4', 'case', '4', 'identified', 'frameshift', 'mutation', '201dupt', 'immediately', 'results', 'premature', 'stop', 'codon', 'n68xfsx1', 'cases', '5', '6', 'detected', 'mutation', '5561g', 'a', 'alters', 'splice', 'acceptor', 'site', 'intron', '4', 'validated', 'point', 'mutations', 'deletions', 'independent', 'rounds', 'pcr', 'sequencing', 'qpcr', 'confirmed', 'paternity', 'de', 'novo', 'status', 'point', 'mutations', 'deletions', 'sporadic', 'cases', 'none', 'mutations', 'seen', 'dna', '60', 'unaffected', 'female', 'controls', 'larger', 'deletions', 'involving', 'fam58a', 'found', '93', 'unrelated', 'arraycgh', 'investigations', 'analyzing', 'xchromosome', 'inactivation', 'supplementary', 'methods', 'supplementary', 'fig', '4', 'online', 'found', 'complete', 'skewing', 'x', 'inactivation', 'cases', '1', '3', '6', 'almost', 'complete', 'skewing', 'case', '2', 'suggesting', 'cells', 'carrying', 'mutation', 'active', 'x', 'chromosome', 'growth', 'disadvantage', 'fetal', 'development', 'using', 'rtpcr', 'rna', 'lymphoblastoid', 'cells', 'case', '2', 'supplementary', 'fig', '2', 'find', 'aberrant', 'splice', 'products', 'additional', 'evidence', 'mutated', 'allele', 'inactivated', 'furthermore', 'fam58a', 'subjected', 'x', 'inactivation6', 'cases', '1', '3', 'parental', 'origin', 'deletions', 'could', 'determined', 'result', 'lack', 'informative', 'snps', 'case', '5', 'mother', 'case', '6', 'gave', 'birth', 'two', 'boys', 'clinically', 'unaffected', 'samples', 'available', 'cannot', 'exclude', 'condition', 'lethal', 'males', 'fetal', 'losses', 'reported', 'families', 'function', 'fam58a', 'unknown', 'gene', 'consists', 'five', 'coding', 'exons', '642bp', 'coding', 'region', 'encodes', 'protein', '214', 'amino', 'acids', 'genbank', 'lists', 'mrna', 'length', '1257', 'bp', 'reference', 'sequence', 'nm', '1522742', 'expression', 'gene', 'est', 'data', 'found', '27', '48', 'adult', 'tissues', 'including', 'kidney', 'colon', 'cervix', 'uterus', 'heart', 'ncbi', 'expression', 'viewer', 'unigene', 'hs496943', 'expression', 'also', 'noted', '24', '26', 'listed', 'tumor', 'tissues', 'well', 'embryo', 'fetus', 'genes', 'homologous', 'fam58a', 'ncbi', 'homologene', '13362', 'found', 'x', 'chromosome', 'chimpanzee', 'dog', 'zebrafish', 'similar', 'gene', 'chromosome', '23', 'however', 'mouse', 'rat', 'true', 'homologs', 'species', 'similar', 'intronless', 'genes', 'chromosomes', '11', 'mouse', '10', 'rat', 'likely', 'arising', 'retrotransposon', 'insertion', 'event', 'murine', 'x', 'chromosome', 'flanking', 'genes', 'atp2b3', 'dusp9', 'conserved', 'remnants', 'fam58a', 'sequence', 'detected', 'fam58a', 'contains', 'cyclinboxfold', 'domain', 'proteinbinding', 'domain', 'found', 'cyclins', 'role', 'cell', 'cycle', 'transcription', 'control', 'human', 'phenotype', 'resulting', 'cyclin', 'gene', 'mutation', 'yet', 'reported', 'homozygous', 'knockout', 'mice', 'ccnd1', 'encoding', 'cyclin', 'd1', 'viable', 'small', 'reduced', 'lifespan', 'also', 'dystrophic', 'changes', 'retina', 'likely', 'result', 'decreased', 'cell', 'proliferation', 'degeneration', 'photoreceptor', 'cells', 'embryogenesis7', '8', 'cyclin', 'd1', 'colocalizes', 'sall4', 'nucleus', 'proteins', 'cooperatively', 'mediate', 'transcriptional', 'repression9', 'phenotype', 'cases', 'overlaps', 'considerably', 'townesbrocks', 'syndrome', 'caused', 'sall1', 'mutations1', 'carried', 'coimmunoprecipitation', 'find', 'sall1', 'sall4', 'would', 'interact', 'fam58a', 'manner', 'similar', 'observed', 'sall4', 'cyclin', 'd1', 'found', 'fam58a', 'interacts', 'sall1', 'sall4', 'supplementary', 'fig', '5', 'online', 'supporting', 'hypothesis', 'fam58a', 'sall1', 'participate', 'developmental', 'pathway', 'fam58a', 'mutations', 'lead', 'star', 'syndrome', 'growth', 'retardation', 'cases', 'table', '1', 'retinal', 'abnormalities', 'three', 'cases', 'reminiscent', 'reduced', 'body', 'size', 'retinal', 'anomalies', 'cyclin', 'd1', 'knockout', 'mice7', '8', 'therefore', 'proliferation', 'defect', 'might', 'partly', 'responsible', 'star', 'syndrome', 'address', 'question', 'carried', 'knockdown', 'fam58a', 'mrna', 'followed', 'proliferation', 'assay', 'transfection', 'hek293', 'cells', 'three', 'different', 'fam58aspecific', 'rnai', 'oligonucleotides', 'resulted', 'significant', 'reduction', 'fam58a', 'mrna', 'expression', 'proliferation', 'transfected', 'cells', 'supplementary', 'methods', 'supplementary', 'fig', '6', 'online', 'supporting', 'link', 'fam58a', 'cell', 'proliferation', 'found', 'lossoffunction', 'mutations', 'fam58a', 'result', 'rather', 'homogeneous', 'clinical', 'phenotype', 'additional', 'anomalies', 'case', '1', 'likely', 'result', 'effect', '40kb', 'deletion', 'expression', 'neighboring', 'gene', 'possibly', 'atp2b3', 'dusp9', 'however', 'cannot', 'exclude', 'homogeneous', 'phenotype', 'results', 'ascertainment', 'bias', 'fam58a', 'mutations', 'including', 'missense', 'changes', 'could', 'result', 'broader', 'spectrum', 'malformations', 'genes', 'causing', 'overlapping', 'phenotypes', 'star', 'syndrome', 'townesbrocks', 'syndrome', 'seem', 'act', 'pathway', 'note', 'mycn', 'gene', 'mutated', 'feingold', 'syndrome', 'direct', 'regulator', 'cyclin', 'd2', 'refs', '1011', 'thus', 'worth', 'exploring', 'whether', 'phenotypic', 'similarities', 'feingold', 'star', 'syndrome', 'might', 'explained', 'direct', 'regulation', 'fam58a', 'mycn', 'fam58a', 'located', 'approximately', '056', 'mb', 'centromeric', 'mecp2', 'xq28', 'duplications', 'overlapping', 'mecp2', 'fam58a', 'described', 'associated', 'clinical', 'phenotype', 'females12', 'deletions', 'overlapping', 'mecp2', 'fam58a', 'observed', 'date13', 'although', 'genes', 'fam58a', 'mecp2', 'implicated', 'brain', 'development', 'fam58a', 'mecp2', 'genes', 'region', 'known', 'result', 'xlinked', 'dominant', 'phenotypes', 'thus', 'deletion', 'genes', 'allele', 'might', 'lethal', 'males', 'females'], tags=['Text_0'])"
      ]
     },
     "execution_count": 94,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sentences_train = constructLabeledSentences(allText_train)\n",
    "sentences_test = constructLabeledSentences(allText_test)\n",
    "sentences_train[0]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Classification w/ Doc2Vec\n",
    "https://radimrehurek.com/gensim_3.8.3/auto_examples/tutorials/run_doc2vec_lee.html\n",
    "\n",
    "## Q for TA\n",
    "original author contatenates train & test sets in order to vectorize them together - this is cheating isn't  it.\n",
    "what should be the strategy for vectorizing words?\n",
    "vectorize train only -> then use that model to vectorize test set\n",
    "then perform classification somehow"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [],
   "source": [
    "from gensim.models import Doc2Vec\n",
    "\n",
    "Text_INPUT_DIM=300\n",
    "filename='docEmbeddings_5_clean.d2v'\n",
    "\n",
    "if os.path.isfile(filename):\n",
    "    text_model = Doc2Vec.load(filename)\n",
    "else:\n",
    "    text_model = Doc2Vec(min_count=1, window=5, size=Text_INPUT_DIM, sample=1e-4, negative=5, workers=4, iter=5,seed=1)\n",
    "    text_model.build_vocab(sentences_train)\n",
    "    text_model.train(sentences_train, total_examples=text_model.corpus_count, epochs=text_model.iter)\n",
    "    text_model.save(filename)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([[ 0.6941397 , -0.25972953, -0.38372758, ...,  0.20565027,\n",
       "        -0.17740808, -0.38016596],\n",
       "       [-0.5085135 , -0.08632835,  0.84247404, ..., -0.10618666,\n",
       "        -0.21201849, -0.99569863],\n",
       "       [-0.6995477 ,  0.2326269 ,  0.8145231 , ..., -0.4212626 ,\n",
       "        -0.34836587, -0.9586505 ],\n",
       "       ...,\n",
       "       [ 1.1577262 , -1.1070532 ,  0.30936334, ...,  0.3388028 ,\n",
       "        -0.6622645 , -0.576919  ],\n",
       "       [-0.7001159 ,  0.291759  ,  0.18138885, ...,  0.04804012,\n",
       "        -0.01955466, -1.067801  ],\n",
       "       [-0.85409915,  0.6074473 ,  0.23229153, ...,  0.26017228,\n",
       "         0.34098622, -1.2710245 ]], dtype=float32)"
      ]
     },
     "execution_count": 66,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# grab the training data vectors learned by Dov2Vec\n",
    "text_train_arrays = text_model.docvecs.vectors_docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 109,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "ename": "IndexError",
     "evalue": "list index out of range",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mIndexError\u001b[0m                                Traceback (most recent call last)",
      "\u001b[1;32m<ipython-input-109-0da3d790936e>\u001b[0m in \u001b[0;36m<module>\u001b[1;34m\u001b[0m\n\u001b[0;32m      3\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m      4\u001b[0m \u001b[1;32mfor\u001b[0m \u001b[0mi\u001b[0m \u001b[1;32min\u001b[0m \u001b[0mrange\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mtest_size\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m----> 5\u001b[1;33m     \u001b[0mtext_test_arrays\u001b[0m\u001b[1;33m[\u001b[0m\u001b[0mi\u001b[0m\u001b[1;33m]\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mtext_model\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0minfer_vector\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0msentences_test\u001b[0m\u001b[1;33m[\u001b[0m\u001b[0mi\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;36m0\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[1;31mIndexError\u001b[0m: list index out of range"
     ]
    }
   ],
   "source": [
    "# turn the test set into embedded vectors based on text_model\n",
    "test_size = len(test_df)\n",
    "text_test_arrays = np.zeros((test_size, Text_INPUT_DIM))\n",
    "\n",
    "for i in range(test_size):\n",
    "    text_test_arrays[i] = text_model.infer_vector(sentences_test[i][0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 256,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# Find the class and ID of the document most similar to each of the test examples\n",
    "\n",
    "#print(u'SIMILAR/DISSIMILAR DOCS PER MODEL %s:\\n' % text_model)\n",
    "#for label, index in [('MOST', 0), ('MEDIAN', len(sims)//2), ('LEAST', len(sims) - 1)]:\n",
    "#    print(u'%s %s: «%s»\\n' % (label, sims[index], ' '.join(train_df.iloc[int(sims[index][0].split('_')[1])].Text)))\n",
    "#train_df.iloc[most_similar_index].Text\n",
    "test_size = len(test_df)\n",
    "pred_class = np.zeros((test_size, 1))\n",
    "pred_ID = np.zeros((test_size, 1))\n",
    "\n",
    "for i in range(test_size):\n",
    "    sims = text_model.docvecs.most_similar([text_test_arrays[i]], topn=len(text_model.docvecs))\n",
    "    most_similar_index = int(sims[0][0].split('_')[1])\n",
    "    j = 1\n",
    "    while most_similar_index > len(train_df):\n",
    "        most_similar_index = int(sims[j][0].split('_')[1])\n",
    "        j = j+1\n",
    "    pred_class[i] = train_df.iloc[most_similar_index].Class\n",
    "    pred_ID[i] = test_df.iloc[i].ID\n",
    "   \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 259,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([[0.000e+00],\n",
       "       [1.000e+00],\n",
       "       [2.000e+00],\n",
       "       ...,\n",
       "       [5.665e+03],\n",
       "       [5.666e+03],\n",
       "       [5.667e+03]])"
      ]
     },
     "execution_count": 259,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pred_ID"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 220,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([ 2.73529917e-01, -7.67974198e-01,  3.38040516e-02,  5.10134101e-01,\n",
       "        1.87989354e-01,  5.15650451e-01, -1.10088922e-01, -2.69527525e-01,\n",
       "       -8.84564817e-02, -4.88153517e-01, -6.51699066e-01,  8.48728597e-01,\n",
       "       -1.10977888e+00, -1.00720495e-01, -8.06569993e-01,  8.78672361e-01,\n",
       "       -5.48517168e-01, -2.25258380e-01, -3.09274308e-02,  7.92165041e-01,\n",
       "       -9.13630366e-01,  3.66611600e-01,  5.03295302e-01, -2.40026772e-01,\n",
       "       -5.10182440e-01, -1.94001749e-01,  4.58730370e-01, -1.34616995e+00,\n",
       "       -1.73575982e-01, -8.18157077e-01, -3.94942522e-01, -1.29859552e-01,\n",
       "       -3.42161298e-01, -2.40033627e-01, -1.67181313e-01, -3.77275348e-01,\n",
       "       -2.96776235e-01, -4.25613433e-01, -6.34822130e-01, -3.23024243e-02,\n",
       "        2.49526829e-01, -5.60754776e-01, -1.17049001e-01,  5.72463274e-01,\n",
       "        1.97480559e-01, -9.73346457e-02,  7.02669322e-02, -3.31470817e-01,\n",
       "       -5.79605345e-03, -2.12137923e-01,  5.79481900e-01,  6.16508663e-01,\n",
       "        1.86752903e+00, -7.36853302e-01,  2.52869546e-01,  1.38826296e-01,\n",
       "       -3.71918291e-01, -1.74850082e+00, -1.13108605e-01, -2.05506489e-01,\n",
       "       -8.80601048e-01,  8.17869082e-02, -4.02516395e-01, -5.00740826e-01,\n",
       "       -4.96893257e-01, -3.10382038e-01,  8.53606910e-02,  4.58413422e-01,\n",
       "       -2.88448036e-01,  1.32141209e+00, -1.29970536e-01, -6.21096380e-02,\n",
       "       -2.10428819e-01,  5.42540073e-01, -3.61826420e-01,  7.95573890e-02,\n",
       "       -7.46150196e-01, -8.79700959e-01, -6.57944083e-01,  9.00970042e-01,\n",
       "       -2.96124339e-01,  4.35783044e-02,  1.18330598e+00,  1.07937324e+00,\n",
       "       -9.83146280e-02, -3.15023422e-01,  7.94440746e-01,  4.46457386e-01,\n",
       "        1.69557482e-01, -2.82471955e-01, -2.28481784e-01, -1.52772114e-01,\n",
       "       -5.81431150e-01,  5.89399219e-01, -8.61698329e-01,  2.19650362e-02,\n",
       "        8.71130675e-02, -9.50696826e-01, -2.10328668e-01,  1.94893226e-01,\n",
       "       -8.73515546e-01,  3.23617220e-01,  6.13792419e-01, -5.48406363e-01,\n",
       "       -5.73560774e-01, -2.80718952e-01, -7.26478875e-01,  1.12229340e-01,\n",
       "        1.88027725e-01, -1.84099689e-01,  5.93513012e-01, -4.98340786e-01,\n",
       "       -9.90580767e-02, -1.48524940e+00, -6.16448760e-01, -4.37155634e-01,\n",
       "       -2.29774937e-01,  6.22754097e-01,  4.14105467e-02, -4.16401923e-01,\n",
       "       -3.04789513e-01, -4.78250384e-01,  9.82008696e-01,  2.43470162e-01,\n",
       "        1.70793802e-01,  1.73921287e-01, -5.82290113e-01, -1.84410468e-01,\n",
       "        6.33800030e-01,  8.54649246e-01, -1.25204325e+00, -7.24284530e-01,\n",
       "        1.77890942e-01,  1.90168753e-01,  8.12426686e-01,  5.71794808e-01,\n",
       "       -1.87054789e+00,  3.17977481e-02,  1.90988585e-01, -1.13263273e+00,\n",
       "        2.00008944e-01, -4.66489971e-01, -3.58873129e-01, -7.14579821e-01,\n",
       "        2.52774775e-01,  7.84987152e-01,  8.09501827e-01, -6.68194890e-01,\n",
       "        5.06001234e-01, -5.85440457e-01,  9.18297023e-02,  1.52936786e-01,\n",
       "       -3.44201922e-01,  2.71694567e-02,  4.50949669e-01, -3.55912566e-01,\n",
       "       -6.86457038e-01,  7.60642409e-01, -8.18162680e-01, -1.37265161e-01,\n",
       "        2.48559430e-01,  3.85922492e-01, -9.73272845e-02, -2.75139343e-02,\n",
       "        4.50640947e-01,  3.96807969e-01,  3.08196098e-01, -4.10848111e-01,\n",
       "        1.80636153e-01,  3.66713703e-01, -9.83718395e-01,  5.16224988e-02,\n",
       "       -3.35488409e-01, -6.27601087e-01, -9.98389900e-01,  1.51597416e+00,\n",
       "        5.08552253e-01, -8.09640139e-02,  1.47079557e-01, -3.19492668e-01,\n",
       "        6.65514290e-01,  6.62801508e-03, -1.15048960e-01,  7.18839705e-01,\n",
       "        1.96955815e-01,  3.72240037e-01, -1.58775598e-01,  2.90437460e-01,\n",
       "        2.95613557e-01,  1.31106234e+00, -2.92572100e-02, -6.12528861e-01,\n",
       "       -9.14918244e-01, -5.01243956e-02, -6.31329000e-01,  9.16671038e-01,\n",
       "        1.63310513e-01, -3.91635776e-01, -1.60712451e-01, -1.03519164e-01,\n",
       "        3.83175522e-01, -4.08973992e-01, -6.64384127e-01, -1.85622752e-01,\n",
       "       -4.37925845e-01,  2.31043175e-01,  2.54388005e-01, -8.77865925e-02,\n",
       "       -4.80041206e-01, -6.78483963e-01, -9.12606478e-01, -3.94067727e-03,\n",
       "        3.91771924e-03, -4.15606976e-01, -5.92401445e-01, -7.54619062e-01,\n",
       "        3.29529077e-01,  9.29851457e-02, -6.93540871e-01, -1.75536856e-01,\n",
       "        6.80689454e-01, -6.61150932e-01, -3.18821251e-01, -2.60233104e-01,\n",
       "       -3.00011575e-01, -6.47364020e-01, -1.97033182e-01, -2.22862214e-01,\n",
       "       -1.22361398e+00,  6.81303680e-01, -8.44180584e-01, -3.28978151e-01,\n",
       "       -8.41510355e-01,  1.30981579e-01, -1.47178113e-01,  1.26328838e+00,\n",
       "       -1.49790978e+00,  4.58211869e-01, -2.35948354e-01, -5.77016294e-01,\n",
       "       -1.41328946e-01, -1.27978468e+00,  2.66173333e-01, -4.82114136e-01,\n",
       "       -5.43358564e-01, -1.55418053e-01, -6.73571229e-02, -3.57136354e-02,\n",
       "       -4.86933917e-01,  1.93300433e-02, -1.56095848e-04,  6.38286412e-01,\n",
       "       -5.56044094e-02,  1.09879650e-01, -1.77813247e-01,  6.33211657e-02,\n",
       "        7.65745938e-01,  6.98317289e-01, -1.67350978e-01,  7.02492833e-01,\n",
       "        4.93886411e-01,  4.29654717e-01, -7.46336639e-01, -7.48739183e-01,\n",
       "        5.61156809e-01,  2.59459734e-01, -7.97287405e-01,  3.64960134e-02,\n",
       "        4.03777137e-02,  1.04322910e+00,  2.58066803e-01, -2.75991201e-01,\n",
       "       -2.71410912e-01, -4.76513624e-01, -8.62601474e-02, -1.14111617e-01,\n",
       "       -3.06398183e-01,  8.29886079e-01,  5.23131303e-02,  2.88029343e-01,\n",
       "       -3.91108751e-01,  7.51606464e-01,  2.11995408e-01,  1.15452379e-01,\n",
       "        2.85235554e-01, -1.58862486e-01,  4.00908053e-01, -6.49077058e-01,\n",
       "        1.62598416e-01, -2.08251148e-01, -3.37031260e-02, -4.44096684e-01,\n",
       "       -1.11900933e-01, -8.77883554e-01, -1.58256829e-01,  7.53494322e-01,\n",
       "        1.11194217e+00, -1.02905214e-01, -9.28571820e-01,  1.54010952e-01])"
      ]
     },
     "execution_count": 220,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Assess using stage1 solution"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 171,
   "metadata": {},
   "outputs": [],
   "source": [
    "solution = pd.read_csv('stage1_solution_filtered.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 244,
   "metadata": {},
   "outputs": [],
   "source": [
    "# build solution class\n",
    "sol_size = len(solution)\n",
    "desired_class = np.zeros((sol_size,1))\n",
    "desired_ID = np.zeros((sol_size,1))\n",
    "\n",
    "for i in range(sol_size):\n",
    "    desired_class[i] = np.where(solution.iloc[i][1:] == 1)[0][0]+1\n",
    "    desired_ID[i] =  solution.iloc[i].ID"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 269,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "368 5667 368\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "0        12\n",
       "1        19\n",
       "2        21\n",
       "3        55\n",
       "4        64\n",
       "       ... \n",
       "363    5600\n",
       "364    5609\n",
       "365    5626\n",
       "366    5628\n",
       "367    5650\n",
       "Name: ID, Length: 368, dtype: int64"
      ]
     },
     "execution_count": 269,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "print(len(desired_ID), len(pred_ID), sol_size)\n",
    "solution.ID"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Classify data!\n",
    "https://keras.io/examples/nlp/text_classification_with_transformer/"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
